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Defining Cardiovascular Dysfunction in the Metabolic Syndrome: 
therapeutic and nutritional approaches to treatment 
 
Sara Brooks Fournier 
 
Metabolic syndrome (MetS) is a complex disease state defined by the 
manifestation of a cluster of cardiovascular (CV) risk factors including, abdominal 
obesity, dyslipidemia, hypertension, and hyperglycemia. Individuals afflicted with 
MetS have been demonstrated to assume the burden of a 3-fold increased risk of 
cardiovascular disease (CVD) mortality, myocardioal infarction, stroke, type II 
diabetes (T2DM) and all cause mortality. The national prevalence of 
hyperglycemia and abdominal obesity paralleled by a surge in sedentary lifestyle 
behavior underscore the importance of early identification and treatment of MetS.  
Deleterious adaptations to both vascular and myocardial structure and function 
have been demonstrated in MetS. Alterations in CV function associated with 
accelerated arterial aging have been implicated in the association between MetS 
and CVD. The underlying pathophysiology of MetS is not well understood and 
CV dysfunction has not been comprehensively examined in a MetS population 
free from confounding pathologies including T2DM and/or overt CVD. 
Furthermore, the effects of therapeutic lifestyle interventions for targeting 
subclinical CV dysfunction in MetS without T2DM and/or overt CVD require 
investigation. Therefore, the directive of the studies included in this dissertation 
was to perform a comprehensive assessment of CV function to validate the 
presence of CV dysfunction in MetS and to evaluate practical therapeutic 
strategies for improving cardiac and arterial dysfunction associated with MetS. 
Results from these studies identified subclinical left ventricular (LV) diastolic 
dysfunction at rest LV systolic dysfunction during exercise. Additionally, it was 
discovered that deleterious adaptations to large artery structure and function 
occur in individuals with MetS. Importantly, these alterations occurred in the 
absence of chronic disease including T2DM and clinical CVD. These results 
suggest for the first time that CV dysfunction does occur in individuals afflicted 
with MetS without T2DM and/or CVD. The investigation of exercise training as a 
therapeutic strategy for targeting arterial dysfunction revealed improvements in 
central arterial stiffness, central systolic blood pressure and aerobic capacity 
after 8 weeks of moderate/high intensity aerobic training. During peak exercise 
we have demonstrated improvements in arterial-ventricular coupling, LV 
contractility, peripheral vascular resistance, and aerobic capacity after 8 weeks of 
aerobic training in MetS. Exercise training was unable, however, to improve 
resting LV structure, LV diastolic function, or metabolic profile. Results from our 
investigation using a nutritional therapeutic approach to CV dysfunction in MetS 
demonstrate similar inconclusive findings. Single-dose supplementation with two 
doses of trans-resveratrol demonstrated no conclusive therapeutic potential for 
improving arterial stiffness or reducing central systolic blood pressure. These 
results would suggest that a greater understanding of the underlying pathology of 
  
MetS is required for identifying and optimizing therapeutic approaches to its 
treatment.  Taken together the results of these collective documents demonstrate 
an understanding of the synergistic effects of co-occurring risk factors on CV 
function in the absence of chronic clinical disease. Further, these results highlight 
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In 1988 Gerald M. Reaven established “Syndrome X” to identify high-risk 
patients with co-occurring metabolic risk factors predisposed to cardiovascular 
disease (CVD) and type II diabetes (T2DM). Today we refer to the manifestation 
of a cluster of co-morbidities as the metabolic syndrome (MetS). MetS as defined 
by the guidelines set forth by the US National Cholesterol Education Program 
Adult Treatment Panel III (NCEP) requires the manifestation of at least three of 
the following five risk factors: abdominal obesity, dyslipidemia (e.g. increased 
triglycerides, and decreased high density lipoprotein), hypertension, and 
hyperglycemia. The prevalence of MetS among U.S. adults (≥ 20 years of age) 
estimated from data collected using the National Health and Nutrition 
Examination Survey (NHANES) from 1999 to 2010 indicates a decreasing trend 
over the last decade from 25.5 percent to 22.9 percent [1]. The source of the 
descending shift in MetS reflects individual decreases in the prevalence of 
hypertriglyceridemia and in elevated blood pressure, both of which are correlated 
with increases in the use of anti-hypertensive and lipid-modifying drugs.  
Although this trend appears to reflect a favorable shift, the increasing trends in 
the prevalence of hyperglycemia and elevated waist circumference (abdominal 
obesity) and predictions based on the spread of the American obesity epidemic 
estimate that the future incidence of MetS in the US will continue to rise [2]. The 
American epidemic of obesity paralleled by a surge in sedentary lifestyle 
behavior underscore the importance of early identification, treatment, and 
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prevention of MetS.  Compared to healthy individuals, those who present with 
MetS assume the burden of a 3-fold increased risk of cardiovascular disease 
(CVD) mortality, myocardial infarction, stroke, and all-cause mortality [3-5] and 
T2DM. The pathophysiological mechanisms underlying these associations are 
incompletely understood, however. Existing literature has reported evidence of 
both vascular and myocardial abnormalities in MetS. Indeed our lab and others 
have shown that MetS is associated with the acceleration of arterial aging. 
Grouping of metabolic risk factors can also affect functional properties of the 
arterial system, promoting vascular endothelial dysfunction. Given that large 
elastic artery stiffness (AS) is a feature of MetS [6-7] and impaired endothelium-
dependent dilation of the brachial artery has been identified in the presence of 
MetS, pathophysiological changes to the arterial vasculature may represent an 
important link between MetS and increased CVD risk. 
 
Macrovascular Adaptations  
The large elastic arteries serve two important functions. First, they act as 
conduits to deliver oxygen-rich blood pumped from the left ventricle (LV) to 
peripheral arteries. Second, large distensible conduits (e.g. aorta) are 
responsible for the Windkessel effect, which helps to maintain a relatively 
constant arterial pressure despite the pulsatile nature of blood flow from the LV. 
During systole the elastic aorta expands to store a portion of the blood ejected 
from the LV. During diastole, potential energy created from the expansion and 
subsequent passive elastic recoil of the aorta helps to maintain blood pressure 
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and provide continuous steady blood flow to peripheral vessels. With aging and 
under pathological conditions, the Windkessel effect is diminished as a result of 
increases in AS and a loss of large elastic artery compliance [8]. 
 
Conduit Remodeling 
The large elastic arteries are comprised of three distinct structural layers: 
the tunica adventitia, the tunica media, and the tunica intima. Collagen and 
elastin filaments responsible for the elastic properties of large arteries reside 
within the tunic media, which is largely made up of smooth muscle cells and the 
extracellular matrix. Biomechanical properties (stiffness and viscoelasticity) of the 
aorta are determined primarily by the elastic matrix, which consists of elastic 
fibers, collagens, proteoglycans, and glycoaminoglycans.  Changes to conduit 
artery structure can occur with normative aging as well as in the presence of 
pathological stimuli in an effort to maintain arterial wall integrity. In individuals 
with MetS, changes occur to the structure and function of the arterial system that 
compromise the efficiency of the cardiovascular system and increase the risk for 
the development of CVD. Two key contributors to arterial dysfunction associated 
with MetS include arterial remodeling and large elastic artery stiffness (AS). 
 Arterial remodeling describes changes in vessel size; more specifically 
this term refers to changes in the cross-sectional area within the elastic lamina 
surrounding the vessel. Existing studies in healthy humans and nonhuman 
primate and rodent models of aging provide evidence of luminal dilation in the 
central elastic arteries with advancing age, leading to an increase in lumen size 
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[9]. In healthy humans, outward remodeling of elastic arteries is a homeostatic 
response to changes in blood flow in order to maintain optimal levels of shear 
stress and circumferential wall tension [10]. 
 MetS is regularly associated with thickening of the carotid wall, indexed as 
carotid intimal medial thickness (cIMT). IMT refers to the measurement of the 
thickness of the innermost layers of the arterial wall: the tunica intima and tunica 
media. IMT is most commonly used in clinical trials and in observational studies 
as an important endpoint for the evaluation of the progression or the regression 
of atherosclerotic CVD [11]. Although IMT is strongly associated with the 
identification of subclinical atherosclerosis, factors other than plaque formation 
have an influence on IMT. Indeed, IMT has been shown to increase linearly as 
much as 3-fold between the ages of 20 and 90 years in the absence of 
atherosclerosis [12].  Further, studies using animal models not known to develop 
atherosclerosis, including rodents and nonhuman primates, report thickening of 
the intima media with aging [13-14]. In MetS cIMT has been shown to increase 
between 0.08 mm and 0.11 mm vs. healthy controls [7, 15]. Specifically, when 
considering impact of specific clusters of MetS components, the presence of low 
HDL and abdominal obesity increases the probability of having an extreme 
common carotid artery (CCA) IMT (i.e. values >2 SD from the mean of CCA IMT) 
by 70 percent compared to those without reduced HDL or abdominal obesity [7]. 
A recent longitudinal study examining the temporal relationship between 
structural arterial remodeling and arterial function provides evidence to support 
the results from cross-sectional studies that suggest maladaptive arterial 
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remodeling in MetS. Ferreira et al. [16] report that baseline values of 
interadventitial diameter, lumen diameter (LD), circumferential wall tension 
(CWT), circumferential wall strain (CWS) but not IMT were significantly elevated 
in individuals with MetS vs. non-MetS. At follow-up MetS displayed significantly 
steeper increases in IMT vs. non-MetS (0.011 vs. 0.005 mm/year, respectively), 
and lumen diameter (0.055 vs. 0.023 mm/year, respectively). Importantly, despite 
arterial remodeling, changes in CWS tended to decrease over time but remained 
significantly elevated in MetS compared to non-MetS. These findings suggest 
that arterial thickening in MetS occurs in advance of changes in CWS to restore 
arterial wall integrity. Interestingly, those individuals who recovered from MetS at 
the 6-year follow-up and non-MetS displayed similar arterial properties, pointing 
to the reversible nature of an early pathological process.  
 
Large Elastic Artery Stiffening 
In addition to changes in arterial structure the large elastic arteries (i.e. 
aorta and carotid) are subject to age-related stiffening [17]. Large elastic AS is a 
strong independent predictor of CVD and mortality. AS has been shown to 
increase with advancing age [18-19] and in the presence of MetS [15, 20]. 
Central AS can be assessed non-invasively from carotid-to-femoral pulse wave 
velocity (PWV). Observational studies in healthy humans have demonstrated a 
modest increase in central PWV that occurs in midlife [21]. In MetS, increases in 
AS may have a detrimental impact on cardiac function; Increases in central 
systolic pressure that accompany AS promote cardiac hypertrophy leading to 
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decreases in diastolic pressure and impairment of coronary perfusion [22]. For 
individuals with MetS, the CVD risk associated with increased AS is of particular 
importance as a 1.0 m/sec increase in AS corresponds to a 15 percent increased 
risk of CV mortality after adjustment for age, sex and risk factors [23]. Evidence 
f rom exist ing l i terature indicates that changes in the expression and/or 
bioactivity of structural proteins in the arterial wall (and heart) lead to AS. AS is 
influenced by the composition of the extracellular matrix (elastin-collagen 
network) and by vascular smooth muscle cell function (VSMC) [24-25]. Further, 
increased collagen production and smooth muscle cell proliferation, as a 
consequence of endothelial dysfunction, can alter the structure and composition 
of the arterial wall and increase AS [26-30]. MMPs and TIMPs are key regulators 
of arterial and cardiac [26-27, 29-30] remodeling. In animal models, increased 
MMP9 activity, responsible for the degradation of elastin and collagen [31], was 
directly linked with AS [32] and cardiac stiffness [33]. In hypertensive patients, 
plasma MMP9 and TIMP1 were elevated vs. controls, and implicated in AS and 
an increased risk of CV events [34-36]. Notably, TIMP1 inhibits MMP1 activity 
that increases type 1 collagen (high tensile strength and rigidity) formation. While 
structural changes that contribute to AS take several months to develop, AS 
can also be altered acutely by changes in VSMC tone, which is regulated by 
endothelial cell function and sympathetic nervous system activity [37]. 
Sympathetic stimulation can alter AS through an indirect change in arterial 
pressure or through a direct increase in vascular tone, causing vasoconstriction 
and decreased arterial diameter [38-40]. Moreover, impaired endothelial 
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dysfunction, as a result of low-grade inflammation [28], enhances vasoconstrictor 
activity, altering large artery smooth muscle tone [41-43] which may contribute 
to acute changes in AS.  
 
Large Artery Endothelial Dysfunction 
Endothelial dysfunction (ED) is regarded as an early event in the initiation 
and progression of atherosclerosis, and as a trademark of vascular disease [44-
45]. Impaired endothelial function refers to an imbalance in the production of 
endothelial-derived mediators that regulate vascular permeability, coagulation, 
platelet aggregation, and vascular tone. Among the specialized functions of the 
endothelial monolayer in the regulation of vascular homeostasis, its role in 
controlling vascular tone is considered the most extensively studied and thus, the 
term ED refers to an imbalance in the relative contribution of endothelium-derived 
relaxing factors and contracting factors. Under normal physiological conditions, 
the vascular endothelium produces mediators of vascular hemodynamics in 
response to physical and chemical stimuli. ECs contribute to the regulation of 
blood pressure and blood flow through the production and release of vasodilators 
including nitric oxide (NO) [46] and prostacyclin (PGI2), as well as 
vasoconstrictors including endothelin-1, thromboxane A2 (TxA2), and angiotensin 
II (ANG II). The balance between endothelial-derived relaxing factors and 
contracting factors represents a major determinant of basal vascular smooth 
muscle tone [47].  
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 In a clinical setting, ED is quantified by an impaired endothelium-
dependent relaxation of the vascular smooth muscle in response to a chemical or 
physical stimulus. Impaired relaxation of the smooth muscle is associated with 
diminished production or availability of vasodilator substances, particularly NO, 
due to a decline in the production of NO by the endothelium, inactivation of NO 
by reactive oxygen species (ROS), or a decline in the availability of co-factors 
required for the synthesis of NO. In the presence of cardiovascular risk factors 
(e.g. hypertension, T2DM, hyperglycemia, etc.) the normal production of NO by 
eNOS (Figure 1) is altered such that eNOS favors the generation of ROS 
including superoxide, and hydrogen peroxide. This shift in eNOS function is 
termed “eNOS uncoupling” [48]. EC activation and ED initiate a change in the 
anti-proliferative, quiescent state of the healthy endothelium to one that promotes 
increased production of endothelial-derived constricting factors, increased EC 
permeability, increased expression of adhesion molecules, increased secretion of 
chemokines, VSMC proliferation, and platelet activation and thrombosis.  
  Endothelial-dysfunction in conduit arteries is most often quantified by the 
recording of endothelial-dependent dilation following pharmacological (e.g. 
nitroglycerin or sodium nitro-prusside) or physiological stimulation of endothelial-
mediated NO synthesis [49]. Clinical assessment and identification of ED has 
been shown to be an independent predictor of cardiovascular events [45]. 
Impaired endothelium-dependent dilation of the brachial artery has been 
identified in the presence of MetS, a finding that is expected, as each component 
of MetS is associated with ED [50-55]. Such findings suggest that ED may 
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mediate, in part, the mechanisms responsible for the increased CVD risk in 
MetS. The exact mechanism by which MetS causes ED remains unclear and it is 
likely that multiple pathways are involved; however, oxidative stress appears to 
be a primary mechanism contributing to loss of vascular homeostasis in MetS. 
 MetS is associated with a chronic state of low-grade inflammation [56]. 
The presence of inflammation and other co-morbidities of MetS including, 
hyperglycemia and insulin resistance leads to a decreased generation of NO and 
an increased production of ROS through eNOS uncoupling [48]. Elevated levels 
of ROS stimulate the continued production of ROS in a positive feedback loop, 
leading to chronic elevations in oxidative stress and a decrease in NO 
production, reduced EC sensitivity to NO, and an increase in NO 
inactivation/degradation [57].  Further, inflammation promotes the release of cell 
growth factors that contribute to adverse vascular remodeling observed in MetS 
through stimulation of VSMC proliferation and collagen formation [58]. 
 
Cardiac Dysfunction  
 
Existing studies have documented the adverse effects of individual MetS 
components including hypertension, T2DM, and obesity on cardiac structure and 
function. In individuals with the MetS, groupings of interrelated risk factors act 
synergistically to increase the risk of adverse cardiovascular events, such that 
MetS is associated with a 3-fold increased risk of mortality resulting from CVD, 
coronary heart disease, and all causes compared to those without MetS [59]. 
Recent literature has reported evidence of preclinical myocardial abnormalities in 
  
 11 
MetS. While it is unsurprising that each component of MetS is known to 
independently and adversely affect cardiac structure and function, the 
combination of risk factors has been shown to convey additional risk [60-61]. 
Consequently, the greater CVD burden associated with MetS may be mediated, 
in part, by asymptomatic abnormalities in left ventricular (LV) systolic function, 
which has been noted at rest in some studies [62-65], but not all [66-67].  
 
Left Ventricular Geometry 
General agreement exists in regards to adaptations of cardiac structure in 
the presence of MetS. The impact of MetS on changes in LV mass have been 
shown to be greater than the contributions of the individual components of MetS 
(e.g. blood pressure and body size) [68], emphasizing the importance of the 
synergistic effects of the component of MetS. Indeed, increases in LV mass and 
relative wall thickness have been reported in hypertensive subjects with MetS 
compared to hypertensive subjects without MetS [69] indicating an association of 
MetS with increased LV mass independent of hypertension. Studies comparing 
LV structure and function between individuals without MetS, pre-MetS, and MetS 
indicate progressive LV dysfunction and remodeling with an increasing burden of 
MetS [67]. Similarly, Aijaz et al. [70] identified an increase in LV mass index (91.7 
vs. 87.9 g/m2; P=0.04) and LV diastolic dysfunction in women (n=1058) with 
isolated MetS (i.e. excluding individuals with MetS and established hypertension 
and/or T2DM) compared to those without MetS. LV hypertrophy (LVH) promotes 
a decrease in coronary flow reserve (decreased capillary density per unit of 
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myocardium and increased resistance to flow [71]) and is often a precursor of 
diastolic dysfunction, however, impaired LV relaxation has been identified in 
MetS patients independent of LV mass [67]. The presence of LVH is a risk factor 
for CV morbidity and mortality, including the development of systolic and diastolic 
function and further progression to heart failure [72-73]. Thus, together with 
impairments in cardiac function, LVH may provide a modest explanation for the 
increased CV risk in individuals with MetS.  
 
Left Ventricular Function at Rest 
Although the LV structural differences in MetS are fairly well agreed upon, 
consensus is lacking with regard to changes in LV function. The prevalence of 
diastolic myocardial dysfunction in individuals aged 65 years and older is 
estimated to be 35 percent in individuals with MetS [74]. In MetS and in T2DM, 
diastolic dysfunction results from abnormal myocardial active relaxation and an 
increase in LV passive stiffness due to metabolic derangements and structural 
remodeling [74]. Previously, Chinali et al. [66] have shown alterations of LV 
diastolic dysfunction as characterized by early LV relaxation in American Indians. 
In agreement with this finding, echocardiographic evaluation of parameters 
related to LV diastolic function including E/A ratio, deceleration time (DT), and 
isovolumic relaxation time (IVRT) by Turhan et al. [75] provides evidence of early 
diastolic dysfunction in MetS vs. healthy control subjects. Using cardiac magnetic 
resonance imaging technology, Nyman et al. assessed cardiac fat compartments 
and LV function in men with MetS. These authors found that Mets was 
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associated with LV diastolic dysfunction and LV concentric remodeling. 
Furthermore, epicardial and pericardial fat correlated with the degree of LV 
diastolic dysfunction implicating a role for visceral obesity in the development of 
MetS-associated LV diastolic dysfunction [76].  
Some studies [62-64, 66-67, 77], but not all [66-67] have suggested that 
individuals with MetS present with LV systolic dysfunction at rest. It has been 
suggested that the elevated risk for CVD in MetS is mediated, in part, by 
impaired resting LV systolic function; however, conclusions regarding systolic 
dysfunction in MetS remain controversial with some studies reporting 
impairments in LV contractile function assessed using a doppler-derived index of 
myocardial performance [75]. Wong et al. [78] have identified LV systolic 
dysfunction in patients with Mets using global strain rate, strain, and regional 
systolic velocity and diastolic velocity. In an effort to explain the broad contrasting 
results from several human studies it is important to emphasize that many 
investigators rely on load-dependent measures to assess LV contractility 
including ejection fraction (EF). Despite its traditional application, EF is a poor 
prognostic measure of systolic function because it may be potentially influenced 
by common observations in MetS including loading conditions and chamber 
remodeling. Other common load-dependent indices used in the literature to 
evaluate myocardial contractility include fractional shortening, systolic time 
intervals and strain and strain rate deformation parameters. Using myocardial 
strain and strain rate imaging to assess intrinsic LV myocardial contractility, Gong 
et al. reported impaired global systolic strain and strain rate in the septum, 
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lateral, posterior, anterior, and inferior walls of the LV in patients with MetS. 
Importantly, subclinical abnormalities in LV systolic and diastolic function were 
observed in the presence of normal LV EF [79].  
 
Left Ventricular Function during Aerobic Exercise 
Exercise testing is a well-established procedure for physiological stress 
that can be used to elicit cardiovascular abnormalities not present at rest. 
Pathophysiologic irregularities may emerge when cardiac demands are 
increased during aerobic exercise. MetS patients often report a reduced quality 
of life as a consequence of exertional dyspnoea and reduced exercise capacity 
[74]. The deterioration of exercise capacity in MetS has been suggested to be a 
consequence of early diastolic myocardial dysfunction [74].  
While the assessment of cardiac function in MetS has been documented 
within the literature, this manuscript will attempt to add to the current 
understanding of cardiac dysfunction in MetS by addressing some important 
limitations of existing investigations. A general shortcoming observed in many 
studies includes the use of load-dependent measures of myocardial contractility. 
In individuals with MetS, loading conditions including resting heart rate (HR), and 
chamber geometry are often altered and therefore, may influence load-
dependent assessments. Further, the MetS populations considered in the 
existing literature often include individuals with T2DM and/or overt CVD [67, 78, 
80]. With the inclusion of individuals with symptomatic or clinical CVD, 
observations of CV structure and function may reflect a synergistic consequence 
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of the presence of MetS and other confounding pathologies rather than MetS 
alone. Notably, many studies examining CV structure and function in MetS are 
limited to resting situations when the CV system is attempting to optimize 
chamber pumping efficiency [81]. During aerobic exercise the CV system 
prioritizes cardiac efficacy over energetic efficiency to meet the body’s increasing 
demands [82]. Accordingly, maximal graded exercise testing may expose 
subclinical LV abnormalities undetectable at rest that may predispose this 




A comprehensive understanding of cardiac function requires an 
examination of the interactions between the left ventricle (LV) and the arterial 
system (arterial-ventricular coupling).  Arterial-ventricular coupling (Ea/Ees) is a 
key determinant of cardiovascular function and is most often assessed in the 
pressure-volume plane as the ratio of effective arterial elastance (Ea; a lumped 
parameter of the net arterial impedance to stroke flow [83-84]) to left ventricular 
end-systolic elastance (Ees; a load-independent index of the contractility and 
systolic stiffness of the LV [85-86]).  
 
Left Ventricular End-Systolic Elastance 
Early work by Suga and Sagawa [87-90] was the first to conceptualized 
and conceive a role for LV end-systolic elastance (Ees) in LV pump function and 
myocardial energetics. The end-systolic pressure-volume relation (ESPVR) can 
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be obtained using an excised canine heart preparation to generate a series of 
pressure-volume loops during acute alterations in preload or afterload at a 
constant contractile state. Ees is quantified as the slope of the ESPVR and is 
generally assumed to be linear (Figure 1). Ees represents an index of LV 
contractility and may be influenced by LV geometric remodeling and the 
biophysical properties of the myocardium [85-86]. Accordingly, caution must be 
applied when interpreting the significance of changes in Ees in the absence of 
abnormalities in other measures of LV systolic function [91].   Ees can be 
approximated as [(end-systolic pressure (ESP) / end-systolic volume (ESV)) – 
V0], where V0 represents the volume-axis intercept of the ESPVR obtained when 
the ESPVR is extrapolated to zero pressure, assuming a linear relationship. 
When calculating Ees some assumptions to consider are: 1) that the slope of the 
ESPVR is linear and is independent of loading conditions; 2) V0 represents a 
common intercept with the volume-axis for joining instantaneous pressure-
volume points at similar times during the cardiac cycle; 3) Ees is a function of 
time only, and is independent of instantaneous and past pressure and volume 
[87-90].  
 
 Effective Arterial Elastance  
Effective arterial elastance (Ea) is approximated as the ratio of LV end-
systolic pressure (ESP) and stroke volume (SV), and is often considered to be a 
lumped parameter of the net arterial load imposed on the LV [92-93]. Specifically, 
Ea is an index which integrates elements of arterial load including peripheral 
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vascular resistance (PVR), total arterial compliance (TAC), characteristic 
impedance, and systolic and diastolic time intervals [83]. Notably, a significant 
limitation of Ea is that while it provides information on the steady and pulsatile 
components of the arterial load, it is unable to provide information on their 
relative contribution [93]. Ea is determined from pressure-volume loops as the 
negative slope of the line joining the end-diastolic volume (EDV) and end-systolic 
pressure (ESP) points (Figure 1). Later work by Kelly et al. [94] showed 
agreement between Ea measured invasively as ESP/SV from pressure-volume 
data and Ea calculated from arterial impedance data in normal and hypertensive 
humans.  
 
Arterial-Ventricular Coupling Ratio 
Original efforts by Sunagawa et al. led the way for the conception of 
innovative methods to compare arterial load and LV performance as traditionally 
measured in the frequency domain and the time domain respectively [83]. 
Quantification of effective arterial elastance and LV end-systolic elastance using 
the same units (mm/mL) provided the first platform for the study of arterial and 
ventricular interactions. The ratio of Ea/Ees is a measure of the interaction 
between the LV and the arterial system [83]. Early experimental studies 
discovered that the heart is able to transfer maximal stroke work (SW; 
mechanical energy) when Ea/Ees = 1.0 while energetic efficiency (ratio of SW to 
pressure-volume area) is maximized at lower values of Ea/Ees [95]. In healthy 
men and women, in the resting state, mean ± SD values of EA/ELV, EA, and 
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ELV measured invasively are ≈1.0 ± 0.36, 2.2 ± 0.8 mmHg/ml, and 2.3 ± 1.0 
mmHg/ml, respectively [96]. Examination of Ea/Ees and its components using 
non-invasive methods offers the potential for a more comprehensive 
understanding of arterial and LV interactions under normal physiologic conditions 
and in various disease states.  
 
Arterial-Ventricular Coupling and Its Components During Exercise 
At rest, the LV and the arterial system are optimally coupled to produce 
SW. During exercise, small changes to HR, LV contractility, preload, and 
afterload ensure that the cardiovascular system adapts to meet the increased 
metabolic demands of the body. Using adult dogs, Little and Cheng [97] showed 
that submaximal exercise produced a left-shift in the LV pressure-volume relation 
with an increased slope (Ees) which caused a decrease in the ratio of Ea to Ees 
from rest to submaximal exercise. Notably, despite the decrease in Ea/Ees the 
coupling of the arterial system and the LV remained in the range to produce 
nearly optimal SW during steady state exercise. Studies in healthy human 
subjects show agreement with work performed using animal models. For 
example, Chantler et al. [92] examined Ea/Ees at rest and at peak exercise  in 
normotensive and hypertensive subjects and found that Ea/Ees decreased in 
both men and women due to a disproportionate increase in Ees vs. Ea during 
exercise. During exercise the increase in Ea parallels the observed increase in 




Arterial-Ventricular Coupling in the Metabolic Syndrome 
The following section will review the influence of some of the individual 
components of MetS on arterial-ventricular coupling and its components.  
 
Aging 
Normative aging is known to be associated with alterations in LV structure 
and function in both men and women. Notably, advancing age is accompanied by 
increases in LV wall thickness and collagen deposition [86]. Consequently, aging 
is also associated with an increase in resting Ees [96, 99-100]. A comparison of 
resting Ea/Ees in old (70 ± 8 yr, n = 15) and young (30 ± 5 yr, n = 17) subjects 
showed no significant differences due to comparable increase in both Ea and 
Ees (11 percent and 15 percent, respectively) in older subjects [101]. 
 
Hypertension 
Hypertension is diagnosed when systolic blood pressure and diastolic 
blood pressure reach and exceed values of 140 mmHg and 80 mmHg 
respectively. If left untreated, over time hypertension can have deleterious effects 
on arterial and LV structure and function. For example, patients with 
hypertension have been shown to have greater carotid wall thickness, central 
arterial stiffness and greater wave reflection compared to normotensive patients 
[102]. In addition, increased wall tension and wall tensile stress elicit pathological 
changes in LV structure [103]. General agreement exists in the literature 
regarding the impact of hypertension on arterial-ventricular coupling with 
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hypertensive subjects displaying significant increases in Ea and Ees compared to 
normotensive subjects [104-105]. Notably, these same studies report no 
differences in the ratio of Ea/Ees indicating matched increases in Ea and Ees in 
hypertensive subjects.  
 
Obesity 
Deleterious changes that occur with obesity have been well documented 
within the literature including reduced arterial distensibility [106] and increased 
AS [106-107]. Further, obesity in the absence of CVD has been shown to cause 
changes in cardiac geometry including increased LV mass and LV volumes 
[108]. In terms of how changes in arterial and cardiac structure and function due 
to obesity affect arterial-ventricular coupling and its components, recent evidence 
has shown that when Ea and Ees are scaled ratiometrically or allometrically to 
body surface area, there is a significant increase in Ea and Ees in obese vs. non-
obese controls [109]. The same study reported no change in the ratio of Ea/Ees 
between obese and non-obese controls, irrespective of body size [109].  
Arterial-ventricular coupling and its components are essential 
determinants of the interactions between the heart and arteries. However, to 
date, very few studies in humans have examined the impact of MetS, free from 
T2DM and/or overt CVD, on cardiac energetics at rest or during exercise. This 
manuscript will set out to examine how the presence of MetS will impact arterial-




Metabolic Syndrome and Exercise Training 
Recommendations from the American Heart Association (AHA) for the 
management of MetS encourage therapeutic lifestyle changes to target the 
negative effects of atherogenic diet, weight gain, and sedentary lifestyle 
behavior. Exercise training has been reported to prevent and/or partly reverse 
MetS, however the most optimal exercise (i.e. type, duration, frequency, and 
intensity) for the treatment of MetS remains unresolved [110]. The following 
section will focus on the role of exercise training in the prevention and treatment 
of MetS and its individual components.  
 
Obesity 
Significant excess body weight (BMI ≥ 30 kg/m2) may occur as a result of 
a long-term imbalance between energy intake and energy utilization. In the US 
the cholesterol-rich western diet and declining rates in physical activity in 
combination with long-term caloric excess have created an obesity epidemic. 
Evidence from scientific literature encourages the use of regular exercise to 
manage weight and decrease the long-term risk of obesity-related diseases 
including MetS and type II diabetes. Central adiposity or abdominal obesity, 
expressed as waist circumference (WC), is a key feature of MetS and is strongly 
associated with the risk of incident CVD events [111]. In a randomized, controlled 
study comparing diet-induced weight loss and exercise-induced weight loss, 
Ross et al. enrolled obese (BMI ≥27kg/m2 and WC >100cm), sedentary men 
(n=101) and reported a greater significant reduction in total body fat following 12 
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weeks of exercise-induced weight loss [112]. Further, exercise-without-weight-
loss showed a reduction in abdominal and visceral fat, which is closely related to 
WC and BMI [112]. Similarly, the authors of Studies of a Targeted Risk 
Reduction Intervention through Defined Exercise (STRRIDE-AT/RT) [113], a 
large randomized clinical trial of obese and overweight adults, found that WC 
was significantly reduced after combined aerobic/resistance exercise training vs. 
resistance training alone; Aerobic training alone produced a trend toward a 
significant decrease in WC. In a second publication from the STRRIDE study 
[114], all three eight-month aerobic exercise-training groups (high 
amount/vigorous intensity, low amount/vigorous intensity, and low 
amount/moderate intensity) displayed significant reductions in weight loss, fat 
loss, and waist and hip circumference measurements despite no significant 
changes in dietary intake for any group. These authors concluded that in non-
dieting, mildly obese individuals a modest amount of moderate-intensity exercise 
(e.g. 30 minutes per day) is necessary to reverse a positive caloric imbalance 
and maintain body weight. In a small pilot study [115], 32 patients with MetS 
were recruited to address the efficacy of two modes of exercise to reverse 
features of MetS. Participants were randomized to equal volumes of either 
continuous moderate exercise or aerobic interval training for 16 weeks. Following 
16 weeks of exercise training investigators reported exercise-induced reductions 
in WC and total body weight. Together with reported improvements in lipogenesis 
(the process by which simple sugars are converted to fatty acids) and increased 
circulating levels of adiponectin, these data suggest reductions in intraabdominal 
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visceral obesity and improvements in fat metabolism following 16 weeks of high 
intensity aerobic exercise training.  
 
Hypertension 
Long-term hypertension (HTN) (SBP ≥140mmHg and DBP ≥90mmHg) is 
recognized as a strong independent predictor of CVD [116]. It has been 
estimated that 40 percent of prehypertensive (SBP levels of 120 to 139 mmHg 
and/or DBP levels of 80 to 89 mm Hg) US adults will progress to HTN [117]. 
Studies based on the evaluation of physical activity using survey results support 
the idea that physical fitness may play a role in the attenuation of the progression 
to HTN [118-119].  Results from a recent study that followed 13,953 men (20-90 
yrs.) free from hypertension, CVD and cancer, over a 36-year period support the 
notion that cardiorespiratory fitness can delay the age-associted increase of BP 
over an adult lifespan [120]. These results underscore the potential for delaying 
age-associated changes in BP by improving physical fitness levels with regular 
exercise and are in agreement with national guidelines for the primary and 
secondary prevention of HTN [116]. Specifically, the American College of Sports 
Medicine and the AHA recommends at least 150 minutes of moderate intensity, 
75 minutes of high intensity exercise, or a combination of the two each week 
supplemented with at least 30 minutes of aerobic activity per day per week [121]. 
Importantly, the use of different exercise modalities as well as the parameters of 
frequency, duration, and intensity may have varying effects on BP. Historically 
regular endurance training has been the preferred physical activity for producing 
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favorable changes in BP [122-125]. Recent evidence from a meta-analysis of 
randomized controlled trials to compare the effects of various exercise modalities 
on the magnitude of changes in SBP and DBP in healthy adults found that 
endurance training, dynamic resistance training, and isometric resistance training 
significantly reduce BP and DBP [126]. Further, this analysis demonstrated that 
no significant differences in effect size were observed between endurance 
training and dynamic resistance training, however, the authors report that in 
hypertensive individuals, the greatest reductions in BP occurred after dynamic 
endurance training compared to other exercise modalities. A subgroup analysis 
of endurance training revealed that exercise-training programs of less than six 
months resulted in larger reductions in BP compared to programs of a longer 
duration. In terms of training intensity, low-intensity endurance training produced 
smaller BP reductions than those observed following moderate- or high-intensity 
endurance exercise [126].  
  
Dyslipidemia 
Dyslipidemia describes a disorder of lipoprotein metabolism. In MetS, 
dyslipidemia manifests as elevated total cholesterol, increased low-density 
lipoprotein cholesterol (LDL-C), decreased high-density lipoprotein (HDL-C), and 
elevations in plasma triglyceride (TG) concentrations. Studies focused on 
identifying the effects of exercise training and blood lipid profiles report dose-
dependent relationships between exercise training volume and favorable 
changes in blood lipids [127]. Specifically, data from cross-sectional studies have 
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identified increases (2-3 mg/dL) in HDL-C and decreases in TG (8-20 mg/dL) 
following exercise training designed to elicit between 1200 to 2200 kcal/week 
[127]. Moderate intensity walking or jogging approximately 15-20 miles per week 
would be an appropriate stimulus to meet weekly caloric expenditures required to 
elicit favorable change in blood lipids [127]. Data from a meta-analysis of 
randomized controlled trials examining the effects of aerobic exercise on lipid 
and lipoproteins in overweight and obese adults is less convincing with trending, 
but statistically nonsignificant beneficial increases (3%) in HDL-C [128]. In 
contrast, evidence from the same meta-analysis suggests that aerobic exercise 
training produces a statistically significant (11%, p < 0.05) reduction in TG which 
remained significant even after removal of studies in which changes in diet, 
smoking status, and use of drugs could produce changes in the blood lipid profile 
[128]. In contrast to these reports, data from the Health, Risk Factors, Exercise 
Training and Genetics (HERITAGE) Family Study [129], reveal a beneficial effect 
(+4.9%, p<0.005) of 20 weeks of aerobic exercise training on men with high 
TG/low HDL-C and visceral adipose tissue. In men with isolated low HDL-C and 
normolipidemia 20 weeks of aerobic exercise training was unable to produce a 
significant increase in HDL-C (+0.4%, P=NS) [129]. While the lack of an effect in 
men with isolated HDL-C may seem discouraging, the “HDL-raising” effect 
observed in men with unfavorable blood lipids and abdominal obesity highlight 
the potential for exercise training to produce favorable changes in individuals with 




Impaired Fasting Plasma Glucose 
 Under normal physiological conditions, the body responds to elevations in 
blood glucose concentrations by signaling the production and release of insulin 
by the pancreas.  After binding to cell-surface receptors in skeletal muscle, fat, 
and liver, insulin initiates the uptake and storage of glucose, thereby playing a 
key role in the regulation of glucose homeostasis. In MetS, insulin resistance can 
result in chronically elevated blood sugar and if left untreated, the development of 
T2DM. Exercise is often employed as a lifestyle-related intervention to reverse 
and/or control elevations in blood glucose through improvements in insulin 
sensitivity. Data from human studies suggest significant improvements in fasting 
plasma glucose and insulin sensitivity in individuals with impaired glucose 
tolerance following aerobic exercise training. A recent investigation examined 
adaptations in insulin sensitivity (HOMA) in response to continuous moderate 
exercise or high intensity aerobic interval training in individuals with MetS [115]. 
When compared to continuous moderate exercise, high intensity aerobic 
exercise training 3x/week for 16 weeks was shown to be superior at improving 
insulin sensitivity (HOMA) in MetS [115]. The observed benefits of high intensity 
exercise training above and beyond moderate intensity exercise training 
highlights the importance of exercise intensity for targeting improvements in 
insulin action and glucose homeostasis. Several human studies have 
demonstrated similar findings and suggest an important role for substrate 
utilization. For example, high intensity exercise contributes to the use of 
intramuscular glycogen as a reserve source of available glucose for fuel. The 
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post-exercise actions of insulin include stimulation of glucose uptake by the liver 
and muscle cells and subsequent glycogen synthesis to replenish depleted 
intramuscular glycogen. Evidence from animals studies using a rat model of 
MetS demonstrates that treadmill training for 1 hour/day, 5 days/week for 10 
weeks reduced blood pressure, improved insulin sensitivity, and increased 
glucose transporter Type 4 (GLUT4) content in the heart, white adipose tissue, 
and gastrocnemius muscle relative to untrained animals [130]. Exercise training-
induced improvements in insulin sensitivity are believed to be mediated from 
increases in GLUT4 gene expression [131] as well as from improved 
translocation of GLUT4 from the cytoplasm to the cell membrane [132-133]. 
 
Metabolic Syndrome 
When considering the efficacy of a therapeutic lifestyle change for the 
management of MetS, it is important to take into account not only the effects of 
exercise training on each individual risk factor but to focus on reversing multiple 
risk factors for the prevention and improvement of MetS.  Evidence from the 
STRRIDE study examining the effects of different volumes of exercise training on 
multiple components of MetS reveal that both shorter duration/moderate intensity 
and longer duration/vigorous intensity had significantly reductions in ATP III and 
MS z scores compared to inactive controls [134]. Compared to moderate-
intensity exercise, vigorous-intensity exercise produced a greater number of 
improved components of MetS [134]  however, a modest amount of moderate-
intensity exercise was adequate to obtain metabolic health benefits. 
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Comparatively, a second publication from the STRRIDE study addressed the 
comparison of cardiometabolic benefits of aerobic training, resistance training, 
and combined training in MetS [113]. Investigators reported significant 
improvements in the MS z score following combined exercise training and a trend 
toward improvement following aerobic training, while resistance training failed to 
have any effect on MS z score [113]. Despite the reported benefits of combined 
exercise training in MetS, the authors concluded that aerobic exercise training 
represented the most efficient mode of exercise training to address the 
cardiometabolic risk factors associated with MetS citing that the argument for 
combined exercise training was weak when considering the time commitment vs. 
cardiometabolic health benefits [113]. Similarly, findings from the HERITAGE 
Family Study to determine the efficacy of aerobic exercise training for treating 
MetS, provide evidence of the efficacy of physical activity in treating individuals 
with multiple cardiovascular risk factors [135]. The HERITAGE STUDY recruited 
288 men and 333 women who were evaluated for MetS to participate in a 20-
week ramp-style aerobic exercise-training program. Interestingly the overall 
prevalence of MetS decreased from 16.9 percent to 11.8 percent following 
exercise training. Of the total number of participants with MetS at the start of the 
study, 30.5 percent were no longer classified as meeting the NCEP diagnostic 
criteria for MetS following training. Even more encouraging is the fact that this 
study did not include individuals with overt cardiovascular disease or 
hypertension and thus, the observed benefits of aerobic exercise in the treatment 
of MetS may play an important role in the prevention of the progression of 
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subclinical metabolic disease to overt chronic disease [135]. The results of the 
HERITAGE Family Study and others strongly support the NCEP ATP III 
recommendations for the use of therapeutic lifestyle modifications (aerobic 
exercise training) for the treatment of individuals with MetS.  
While the benefits of exercise training on reversing and preventing the 
progression of MetS to overt CVD are well agreed upon, the mechanisms 
underlying exercise training-induced adaptations in MetS are unclear. Aerobic 
exercise training has been established as an effective intervention for improving 
arterial stiffness, increasing aerobic capacity, and improving peak LV 
performance and LV contractility in healthy persons as well as in older persons 
with overt CVD, including T2DM and coronary artery disease. However it is 
unknown whether aerobic exercise training can improve arterial stiffening and 
peak LV-arterial coupling and CV function in MetS, which would likely reflect a 
reduction in CVD risk. In this document we will demonstrate the benefits of 
aerobic exercise training on arterial stiffness and arterial-ventricular coupling and 
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Figure 1. Synthesis, activation, and signaling of NO for smooth muscle cell 
relaxation. 
 
Figure 2.  This figure was modified from Chantler et al. [136]. Pressure-volume 
relationships illustrating the slope of the end-systolic pressure volume 
relationship (Ees), and the slope of the line joining end-systolic pressure and 
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 Metabolic syndrome (MetS) is the manifestation of a cluster of 
cardiovascular (CV) risk factors and is associated with a three-fold increase risk 
of CV morbidity and mortality, which is suggested to be mediated, in part, by 
resting left ventricular (LV) systolic dysfunction. However, to what extent resting 
LV systolic function is impaired in MetS is controversial, and there are no data 
indicating whether LV systolic function is impaired during exercise. Accordingly, 
the objective of this study was to comprehensively examine LV and arterial 
responses to exercise in MetS individuals without diabetes and/or overt CVD 
compared to a healthy control population. CV function was characterized using 
Doppler echocardiography and gas exchange in MetS (n=27) vs. healthy controls 
(n=20) at rest and during peak exercise. At rest, MetS individuals displayed 
normal LV systolic function but reduced LV diastolic function vs. healthy controls. 
During peak exercise, individuals with MetS had impaired contractility; pump 
performance, and vasodilator reserve capacity vs. controls. A blunted contractile 
reserve response resulted in diminished arterial-ventricular coupling reserve and 
limited aerobic capacity in MetS vs. controls. These findings possess clinical 
importance as they provide insight to the pathophysiological changes in MetS 
that may predispose this population of individuals to an increased risk of CV 








 Individuals with the metabolic syndrome (MetS) are at a three-fold 
increased risk of cardiovascular disease (CVD) mortality than non-MetS 
individuals [1]. Alarmingly, the prevalence of MetS in US adults is 34 percent and 
is on the rise due, in part, to rising rates of obesity [2], which will likely lead to a 
further increase in CVD incidence. This increased CVD mortality in MetS may be 
mediated, in part, by impaired LV systolic function that has been noted at rest in 
some studies [3-6] but not all [7, 8]. However, many of the studies used load-
dependent measures of systolic function (endocardial or midwall fractional 
shortening) or ejection fraction, which is more representative of the interaction 
between the LV and arterial system [9], as measures of LV systolic function 
(Azevedo et al., 2007; Aijaz et al., 2008; Mahmud et al., 2009; de las Fuentes et 
al., 2007). Further, the populations examined in these studies were confounded 
by including MetS patients with diabetes and/or overt CVD [7, 10, 11], and/or 
comparing MetS individuals to a control group that contained individuals with 
CVD [3-7, 11]. Such confounding factors do not allow interpretations as to 
whether the severity of the changes in cardiovascular (CV) function is 
representative of MetS or other pathologies. 
 Importantly, existing evidence of LV dysfunction in MetS is limited to 
resting situations, where the CV system is attempting to optimize chamber 
pumping efficiency [12]. In contrast, during exercise the CV system is set to 
prioritize the output of the heart over energetic efficiency by coordinating 
changes in LV function, arterial tone, endothelial function, venous return, and 
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autonomic signaling. Thus, it could be expected that LV abnormalities, 
undetectable at rest, may appear with exertion to limit exercise capacity in MetS 
and contribute to an impaired quality of life [13]. However, to date, the 
pathophysiological alterations in LV function, and the degree to which these 
changes influence the interaction of the heart with the arterial system during 
exercise in MetS is unknown. Thus, examining the LV functional changes during 
exercise may further provide pathophysiological insights into the CVD risk in 
MetS patients. Accordingly, the aim of this study was to determine the severity of 
LV and arterial dysfunction during exercise in MetS individuals without diabetes 
and/or overt CVD compared to a healthy control population. Further, we will also 
examine resting LV systolic and diastolic function between MetS and healthy 
controls. We hypothesize that MetS individuals will have an impaired LV 
contractile response (peak end-systolic elastance and pre-load recruitable stroke 
work) to maximal exercise, leading to a blunted arterial-ventricular coupling 













Study Population  
 Twenty-seven subjects with MetS were recruited into the study. MetS was 
defined according to the updated National Cholesterol Education Program: Adult 
Treatment Panel III [14] comprised of three out of the following five components: 
1) obesity (waist men >102 cm, women >88 cm); 2) low HDL cholesterol 
(men<40 mg/dL; women<50 mg/dL); 3) hypertriglyceridemia (≥150 mg/dL); 4) 
elevated glucose (≥100 mg/dL), and; 5) elevated BP (130/85 mmHg or use of 
hypertensive medications). The MetS population was compared to twenty healthy 
controls free from CVD, as determined by a detailed history, physical 
examination, and a normal resting and exercise electrocardiogram. Exclusion 
criteria for MetS and healthy controls included abnormal resting and/or exercise 
electrocardiogram, diabetes mellitus (HbA1c ≥6.5 % or use of diabetic 
medications), pulmonary disease, angina, atrial fibrillation, aortic stenosis (or 
other types of valve disease), anemia, myocardial infarction, stroke, or coronary 
revascularization as assessed by a detailed medical history, and physical 
examination. No evidence of wall motion abnormalities was identified during the 
maximal exercise test. Subjects who participated in regular exercise, defined as 
greater than 30 minutes, three times/week were excluded to ensure similar 
physical activity levels between groups. All subjects provided written informed 





Study Design  
 Physiological assessments were performed between 7:00-10:00 AM, in a 
quiet, temperature-controlled room, after a 12-hour fast and abstinence from 
alcohol, caffeine, and vitamins. CV medications were withheld 24 hours prior to 
assessments. After a minimum 15 minutes of quiet rest subjects underwent 
supine, resting, non-invasive assessments of arterial and cardiac structure and 
function. Once supine assessments were completed, subjects moved to a 
modified monarch bike (Figure 1) where upright rest and exercise measures of 
CV function were obtained.  
 
Exercise Performance 
 Subjects underwent upright cycle maximal exercise testing. To optimize 
acquisition of the echo images, the back support of the cycle was set at 
approximately 130 degrees. Pedal speed was maintained at 50 rpm, and 
workloads increased by 25 W every 3 minutes until exhaustion. Oxygen 
consumed (VO2), carbon dioxide produced (VCO2), and the respiratory exchange 
ratio (RER=VCO2/VO2) were measured (ParvoMedics) throughout exercise. 
Subjective symptoms of fatigue (BORG score 6 to 20) [15], and BP’s (sphyg-
momanometry) were recorded at the end of each workload. Registered 
diagnostic cardiac sonographers acquired transthoracic echo-Doppler/tissue 
Doppler images during the final 1.5 minutes of each 3-minute exercise workload 





 Arterial Geometry and stiffness: In the supine position, ultrasound (GE 
Vivid i) 2-D images of the right common carotid artery were obtained 1-2 cm 
proximal to the carotid bifurcation to measure maximal lumen diameter, and 
intima-medial thickness (cIMT) following standard procedures [16]. Cross-
sectional area of the carotid artery was calculated as [(maximal lumen 
diameter/2)2 x π]-(maximal lumen diameter/2-cIMT)2 x π). Carotid circumferential 
stress was calculated as systolic BP x (carotid diameter in diastole/2). Carotid to 
femoral pulse wave velocity (cfPWV; central arterial stiffness) was measured by 
applanation tonometry (AtCor Medical, Sydney, Australia) [17]. ECG-gated 
waveforms were sequentially recorded. Aortic distance (D) was calculated as the 
difference in the distances from the carotid to the suprasternal notch and from 
the suprasternal notch to the femoral artery. Time delay was calculated using a 
foot-of-the-wave method. 
 
Left Ventricular Geometry and Remodeling: In the supine position, LV 
dimensions, wall thickness, and chamber volumes were determined in triplicate 
from 2-D, M-mode, and Doppler spectra echocardiography using standard 
methods [18]. Sex-specific LV hypertrophy (LVH) and geometry patterns based 
on LV mass index and relative wall thickness (RWT) was defined as LV mass 
index >95 g/m2 for women or >115 g/m2 for men, and LV geometry was classified 




Resting Diastolic Function: In the supine position, the medial mitral annular 
early diastolic velocity (e’) was determined by spectral tissue Doppler imaging 
(GE Vivid i) using standard methods. The e’ velocity is inversely related to the 
time constant of isovolumic relaxation (τ), derived from τ =(14.70-100e’)/0.15 
[19]. Early (E) and late (A) transmitral flow velocities, the isovolumetric relaxation 
time (IVRT), and the deceleration time of early filling velocity (Dec T) were 
measured by pulsed-wave Doppler (GE Vivid i). End-diastolic pressure was 
estimated as EDP =11.96+0.596 x E/e’ [19].  
 
Left Ventricular Volumes and Contractility: In the upright seated rest position 
and during exercise, LV end diastolic (EDV), and end-systolic (ESV) volumes, 
along with ejection fraction (EF) were determined from Simpson’s biplane 
method; the recommended method for measurement of volumes [18]. Cardiac 
index (Ci) was determined from the product of heart rate (HR) and stroke volume 
index. Load-independent measures of chamber contractility were examined as: 
1) pre-load recruitable stroke work (PRSW [calculated from product of peak 
volumetric ejection rate from LV outflow Doppler and systolic BP, divided by 
EDV]), determined from the validated single-beat technique [20] and; 2) LV end-
systolic elastance (Ees [calculated from BP, stroke volume, EF, and pre-ejection 
and systolic ejection time intervals from LV outflow Doppler]), determined by the 
validated single-beat technique [21]. The orientation of the LV outflow Doppler 
velocity was positioned 5 mm proximal to the aortic valve in the apical five 
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chamber view. The change in each parameter from upright seated rest to peak 
exercise was used to characterize contractile reserve. 
 
Arterial Function: Effective arterial elastance (Ea), a measure of the net arterial 
load, was calculated as end-systolic pressure (ESP)/stroke volume (SV), where 
ESP is approximated as 0.9 × systolic blood pressure (SBP) [9]. Systemic 
vascular resistance index (SVRi) was calculated as mean arterial pressure 
(MAP) x 80/Ci. The change in each parameter from upright seated rest to peak 
exercise was used to characterize global arterial reserve. 
 
Arterial-Ventricular Coupling: The LV and the central arteries have 
bidirectional interactions. These interactions were examined the depiction of the 
function of the LV and arterial system in terms of elastance i.e., LV chamber 
elastance (Ees) and arterial Elastance (Ea), and examining their ratio (arterial-
ventricular coupling ratio: Ea/Ees) [9]. 
 
Scaling for Body Size  
 Adequate scaling of physiological measures for body size is essential for 
correct interpretation, and often the relationship between body size and 
physiological function may not be linear, a major assumption for the ratiometric 
scaling approach [22]. The allometric scaling approach accounts for this potential 
nonlinear relationship by normalizing physiological measures using exponential 
powers that linearize the relationship. In our data set, the relationship between 
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body surface area (BSA) and cardiac volumes, cardiac output, and PRSW were 
adequately scaled for using the ratiometric scaling approach. No relationships 
were presented between BSA and Ees, or Ea. To account for differences in 
chamber size, Ees was normalized to end-diastolic volume (EDV). However, 
EDV was allometrically related to Ees and thus EDV to the power of 0.45 was 
used to scale Ees. Also, LVM was allometrically scaled to height to the power of 
2.7. The relationship between BSA and the CV parameters were examined using 
Pearson’s correlation. Initally, significant correlations were adjusted 
ratiometrically, y= a+bx+ ε, where b represents the slope of the line of best 
fit, a the intercept on the y-axis, and ε the additive residual error term. If 
significant correlations remained between the ratiometrically adjusted CV 
variable and BSA, then these data were adjusted allometrically, y=axbε, 
where y represents the CV variable, x represents BSA,  a represents the 
proportionality coefficient or constant multiplier, b is the power function exponent, 
and ε represents the multiplicative residual error term, as described in detail 
previously [22]. 
 
Sample Size and Statistical Analysis 
 Measurements of CV function were performed offline, by a single 
investigator who was blinded to group allocation. The intra-class correlation 
coefficient (ICC) for all echocardiographic variables was derived in a subset of 
subjects (n=8). At rest, the ICC for all variables, collected on two separate days, 
was >0.80. Similar results were obtained for echocardographic variables 
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evaluated during peak exercise with all variables having an ICC>0.80 with the 
exception of the arterial-ventricular coupling ratio (ICC=0.63).  
 Based on previous data identifying differences in peak exercise Ees (≈4 
mmHg/ml/m2) and the Ea/Ees ratio (≈0.10) between young and older healthy 
individuals [23-25] sample size was calculated as follows using G*Power 3.1: 
Assuming independence among subjects and a SD estimate of 6.5 mmHg/ml/m2 
for peak Ees and 0.11 for the Ea/Ees ratio at peak exercise, eighteen subjects 
per group would provide us with an 80 percent power (2-sided α=0.05), to detect 
a difference of 4 mmHg/ml/m2 for peak Ees and 0.10 for peak Ea/Ees between 
any two groups. 
 All analyses were performed using SPSS version 20 (SPSS Inc, Chicago, 
Illinois). A two-tailed p≤0.05 was required for significance. Data are reported as 
mean ± SEM unless otherwise stated. Normality was evaluated by the 
Kolmogorov-Smirnov test. Categorical variables were compared by the chi-
square test. Continuous variables were log transformed as necessary and 
compared between groups through ANCOVA adjusting for sex. The changes 
from rest to peak exercise in CV parameters were examined by: a) calculating 
their delta and comparing this variable between groups using ANCOVA adjusting 
for sex, and; b) by examining a time (seated rest to peak exercise) by group 
(MetS vs. healthy controls) interaction evaluated using a two-way repeated-
measures ANOVA. Further, to account for structural differences (LV Mass, 
cfPWV, cIMT) between groups we: c) examined the time by group interaction 
adjusting for LV Mass, cfPWV, and cIMT as covariates in the repeated-measures 
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ANCOVA; d) in a subset of the population, individuals (MetS vs. controls) were 
matched by age, LV Mass, cfPWV, cIMT, peak HR, and respiratory exchange 
ratio, and analyzed using a repeated-measures ANCOVA (time by group 
























 As expected, baseline CVD risk factors were significantly different 
between MetS and controls but not for age or sex as summarized in Table 1.  
 
Cardiovascular Differences at Rest 
Arterial Structure and Function 
 In MetS subjects, carotid diameter, carotid CSA and cIMT were larger 
(p<0.05) compared to controls. As such, carotid circumferential stress was larger 
in MetS (Table 2). Although net arterial load (Ea) and vascular resistance (SVRi) 
did not significantly differ between groups (Table 3), cfPWV was moderately 
increased (23%, p<0.01) in MetS vs. controls and remained significant after 
adjusting for MAP between groups (p=0.01), indicating an increase in arterial 
stiffness in MetS.  
 
Left Ventricular Structure and Function 
 LVmass was 37 percent larger in MetS, but RWT was similar compared to 
controls. Thus, LVH was 18 percent greater in MetS than controls, with 33 
percent of MetS presenting with concentric remodeling and 7 percent presenting 
with concentric and eccentric LVH (Table 2). In addition to these remodeling 
differences between groups; the MetS group tended to present with reduced 
supine LV diastolic function evident by a greater impaired LV relaxation (lower e’ 
and longer τ), a higher A-wave (thus the E/A ratio was reversed p<0.01), and a 
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higher E/e’ (a predictor of elevated LV filling pressure), and EDP vs. controls 
(Table 3).   
Comparisons of EDV, ESV, and SV were significantly elevated in MetS 
however, after adjusting to BSA, cardiac volume no longer differed between 
groups (Table 4). Cardiac index (Ci) and HR were also similar between groups. 
LV load-independent contractility as assessed by Ees, EesEDV0.45, and PRSW 
did not differ between MetS and controls at rest. The similarity between groups in 
Ees and Ea guaranteed that Ea/Ees (a measure of net cardiovascular 
performance) was also comparable between groups.  
 
Cardiovascular Responses to Upright Exercise 
Exercise Performance and Cardiac Function 
 Aerobic capacity adjusted to body weight (ml/min/kg) at peak exercise and 
at the ventilatory threshold were (p<0.001) lower in MetS than healthy controls, 
this was despite both MetS and controls achieving similar rates of perceived 
exercise exhaustion, exercise duration and peak workload (Table 5).  
 During exercise, there was no significant time by group interactions for 
components of LV diastolic function, namely, IVRT, E-wave, A-wave, and Dec T 
(Figure 2). The change from rest to peak exercise in EDVi (p>0.9) and SVi 
(p=0.3) did not significantly differ between MetS and controls. However, there 
was a significant time by group interaction for the reduction in ESVi during 
exercise with MetS individuals having a blunted decrease vs. healthy controls 
(Figure 3). MetS individuals also demonstrated a blunted increase in EF (6%, 
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p=0.02), and Ci (-24%, p<0.05) compared to controls, which were evident at 
submaximal workloads (Figure 3); whereas peak HR was lower at peak exercise 
in MetS. Importantly, LV contractility reserve (change from rest to peak exercise) 
was impaired in MetS compared to controls, evident by a blunted increase in Ees 
(-35%, p=0.01), and PRSWi (-26%, p=0.013) in MetS (Figure 4). Once again 
these differences were manifested at submaximal exercise workloads. Further, 
even after adjusting statistically the above parameters individually for either peak 
HR, LV Mass, cIMT, or cfPWV the results above did not differ significantly. 
Further, in a subcohort of this population matched for resting LV Mass, cIMT, 
cfPWV, peak exercise HR and respiratory exchange ratio, the results above did 
not differ significantly (see supplemental data). 
 
Arterial Function and AVC Reserve 
 During exercise the change in Ea did not differ between groups (p>0.2) 
(Figure 4B). The combination of an impaired contractile reserve in MetS, but a 
similar change in Ea between groups during exercise considerably limited the 
Ea/Ees response in MetS (25% impaired decrease, p<0.05) compared to controls 
(Figure 4A). Submaximal and peak SBP and DBP were higher in MetS than 
controls (Figure 5A), and a significant time by group interaction was noted for the 
change in SVRi during exercise. We further examined these data by statistically 
adjusting the above CV variables for LV Mass, cIMT, or cfPWV, and with the 
exception of SVRi (p=0.1 time by group interaction), the results above did not 
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differ significantly. Similarly, the results above did not differ significantly from the 
































 The present study provides the first comparison of LV and arterial 
structure and function responses to exercise in non-diabetic MetS individuals 
without overt CVD. This finding is of significant clinical interest, and a growing 
public health concern. Our study provides evidence of LV systolic dysfunction 
during exercise including limitations in peripheral vasodilation accumulating in a 
blunted arterial-ventricular coupling reserve and impaired peak aerobic capacity 
in MetS. These data demonstrate that pathophysiological CV alterations occur in 
the earliest stages of MetS development, prior to any evidence of chronic 
disease such as diabetes and/or overt CVD, and that impaired LV systolic 
function during exercise occurs prior to evidence of LV systolic dysfunction at 
rest.  
 
Resting LV and Arterial Structure and Function  
 Previous studies examining CV alterations in MetS patients (with or 
without diabetes) have been limited to characterizing differences in LV and 
arterial structure and function at rest. MetS patients are traditionally 
characterized as having increased cIMT (range 9-16%), and PWV (range 13-
32%) [26, 27]. The results of the present study are similar to previous findings 
with MetS individuals presenting with a 21 percent higher PWV, and an 18 
percent higher cIMT. They also confirm the presence of increased LV Mass in 




Although the LV structural differences in MetS are fairly well agreed upon, 
consensus is lacking with regard to changes in LV function. Some studies [3-8], 
but not all [7, 8], have suggested that MetS individuals have LV systolic 
dysfunction at rest [3-6]. However, many of these studies used EF as a measure 
of systolic function, which despite its conventional clinical application, is a rather 
poor prognostic measure of systolic function as it is potently influenced by 
loading conditions and chamber remodeling [28]. Further, the populations 
examined in these studies were confounded by the inclusion of MetS patients 
with diabetes [4, 7, 11] and moderate stenosis [5], conditions that would 
exacerbate symptoms of LV dysfunction. In addition, control subjects included 
people with hypertension [4-6], obesity [7], diabetes [3, 4, 11], and many were 
taking CV medications [5, 11]. Such confounding factors do not allow 
interpretation as to whether the changes in LV function are representative of 
MetS or of other existing pathologies. Using load-independent measures of 
contractility (Ees, or Ees•EDV, and PRSWi) we found no evidence of LV 
dysfunction in MetS. The present findings cannot exclude the possibility of 
cellular abnormalities in the cardiomyocytes of MetS individuals. However, we did 
identify differences in resting diastolic function in MetS versus healthy controls 
(Table 4), which has been previously reported in some [6, 8] but not all [29, 30] 
studies. It has been postulated that LV diastolic dysfunction is a pre-cursor of LV 
systolic dysfunction and heart failure with a preserved EF (HFpEF) [31-33]. In 
addition, abnormalities of LV relaxation, i.e. grade 1 diastolic dysfunction, confer 
a two-fold increase in all-cause and cardiac mortality [32]. This statistic highlights 
  
 69 
the clinical importance of recognizing the early, and/or subclinical, changes in 
diastolic function at rest in individuals with MetS. 
 
Aerobic Capacity and Cardiovascular Reserve Function 
 Exercise provides a powerful tool to examine the response of the LV and 
arterial systems to stress and to assess functional reserve. If LV function is 
impaired in MetS individuals it would likely be revealed during exercise, and to 
promote intolerance to exercise.  
Widely regarded as a load-independent measure of LV chamber 
performance, the change from rest to peak exercise in Ees is blunted with 
advancing age and may be limited further in the presence of disease [34]. 
Although at rest Ees is determined by geometric and biochemical properties that 
regulate LV end-systolic stiffness (i.e. structural changes from LV hypertrophy or 
fibrosis) [35], acute changes in Ees, such as those observed during exercise 
reflect inherent changes in LV contractile function [9]. Using load-independent 
measures of LV contractility, we identified a blunted Ees, and PRSWi reserve 
capacity in MetS that manifested at submaximal workloads (Figure 4). Ha et al. 
[36] noted a blunted increase in s’ in MetS during exercise; however the extent of 
the LV function impairment was limited by the load dependence of s’ and the lack 
of a healthy control for comparison. In the present study, impaired LV contractility 
was accompanied by altered cardiac pump performance, and an impaired 
vasodilator reserve capacity in MetS. Importantly, impaired contractile function 
and vasodilator capacity resulted in a blunted arterial-ventricular coupling 
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response to exercise. Ea/Ees is a key determinant of CV performance, cardiac 
energetics and exercise capacity [9]. At rest in healthy individuals, Ea/Ees varies 
from 0.5-1.0 to ensure maximal cardiac power and chamber efficiency [12]. 
During exercise, Ea/Ees decreases due to an acute mismatch between Ees and 
Ea to optimize cardiac performance [9]. While resting Ea/Ees did not differ 
between our groups, the Ea/Ees response to exercise was considerably blunted, 
which in part contributed to reduced peak aerobic capacity in MetS. Similar 
impairments in Ea/Ees have been reported during acute maximal exercise with 
advancing age and have been suggested to explain, in part, diminished CV 
functional capacity in the elderly [34].  
Mechanisms limiting CV reserve in MetS individuals remain speculative. 
But, it is likely that multiple factors are involved, including sympathetic nervous 
system activity, activation of the renin-angiotensin-aldosterone system, and 
cardiac metabolism during exercise [37-39]. Importantly, the blunted CV 
response is unlikely to be attributed to differences in exercise effort exercise 
duration, maximal workload, and peak BORG were similar between groups 
(Table 5). Further, the blunted CV responses in MetS remained evident even 
after: a) adjusting statistically for peak HR and the respiratory exchange ratio 
(which were higher in MetS vs. controls); and b) in the subgroup analyses in 
which subjects were matched for peak HR and the respiratory exchange ratio.  
Impairments in contractile reserve observed in the present study may be 
mediated in part by altered calcium handling, as the influx of calcium is a primary 
determinant of cardiac performance. Specifically, contractile dysfunction as a 
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result of alterations in sarcoplasmic reticulum calcium handling has been 
implicated in aging and type 2 diabetes [40, 41]. Although there was no sign of 
wall motion abnormalities during exercise in MetS, the use of upright 
echocardiography may have missed subtle wall motion abnormalities [42]. Thus 
this blunted systolic function in MetS could, in part, be a manifestation of early 
myocardial ischemia even in the presence of normal wall motion during exercise.  
An additional potential mechanism for the impaired CV response to 
exercise in MetS may be depressed systemic peripheral vasodilation in the 
resistance vessels. An impaired SVRi response to exercise is evident in HFpEF 
and is known to contribute to limited exercise capacity in systolic heart failure, 
and is thought to be a result of a reduction in NO generation [43, 44]. In 
accordance with these findings, we observed a blunted reduction in SVRi during 
exercise in MetS vs. controls. Indeed, endothelial dysfunction is a common 
denominator linking MetS, type 2 diabetes, and CVD [45] suggesting that therapy 
targeted to promoting the bioavailability and/or stimulating the generation of NO 
may effectively improve systemic vasodilatation during exercise in MetS.  
 The MetS is characterized by structural changes to the heart (increase LV 
Mass and remodeling) and conduit arteries (increased cIMT and cfPWV) [27, 46]. 
These structural changes are not only predictors of CV events (myocardial or 
cerebral infarction) [47, 48] and mortality [49, 50] but they are also predictors of 
poor aerobic capacity [51-54]. It is plausible that the LV and arterial structural 
differences noted between MetS and healthy controls could contribute to the 
blunted CV response during exercise. However, after adjusting for LV mass, 
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cIMT, or cfPWV in the statistical models, the blunted Ees, PRSWi, Ci and EF 
response from rest to peak exercise in MetS remained. We further examined 
these relationships by matching healthy controls and MetS by LV mass, cIMT, 
and cfPWV. Once again, MetS individuals demonstrated a blunted CV response 
to exercise compared to healthy controls in this subcohort. These results suggest 
that the structural CV differences between MetS and healthy controls do not fully 
account for the impaired exercise CV response in MetS. 
 Previous literature has suggested a link between LV diastolic dysfunction 
and exercise intolerance [7, 55]. Although the focus of this study was to examine 
the extent of LV systolic dysfunction during exercise (and thus echocardiographic 
views were optimized to examine systolic function), we were able to compare 
some components of LV diastolic function during exercise between MetS and 
controls. No differences in IVRT, and Dec T were evident between groups. 
Further, the early (E) and late (A) mitral inflow filling velocities, during 
submaximal workloads, did not differ between groups. At moderate exercise 
workloads there is a high incidence of fusion of the E and A-wave, thus from 50 
W onwards the A-wave dominated and no differences were noted between 
groups at peak exercise (Figure 2). Unfortunately the acquisition of LV diastolic 
parameters during exercise is cumbersome, limiting our ability to fully 
characterize the extent of exercise diastolic function. Therefore we cannot 
eliminate the possibility that diastolic abnormalities during exercise may have 





 Due to the small sample size and cross-sectional nature of our study, we 
cannot infer causality between MetS and CV abnormalities. Although pressure 
and flow were not directly measured, but rather estimated from non-invasive 
surrogates, these have been previously validated against invasive hemodynamic 
measurements performed at rest [20, 21]. However, the non-invasive 
measurement of end-systolic elastance and pre-load recruitable stroke work 
have been validated during exercise. Further, our peak cardiac data may be 
underestimated due to the challenge of acquiring echocardiograhic images 
during exercise, but this technique has been successfully used by others [56, 57], 
to which we observe similar values and responses in our subjects, suggesting 
fidelity in our data. Although, it is possible that the lower peak HR and respiratory 
exchange ratio in MetS may have contributed to their blunted CV response to 
exercise, this impaired CV response remained evident in a subcohort of 
individuals matched for peak HR and the respiratory exchange. The overall 
significance and strength of our study is that our MetS patient population did not 
have the disease-related confounders and/or medications seen in most of the 
existing studies, which allows to report a comprehensive examination of resting 
and exercise arterial and LV measures in MetS individuals prior to the 
development of chronic disease. 
 
Conclusion 
 This study demonstrates that individuals with MetS display evidence of 
impaired systolic contractile function, vasodilator, and cardiac pump function 
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reserve capacity during exercise. These deficits contribute to abnormal arterial-
ventricular coupling and exercise intolerance in individuals with MetS without 
diabetes and/or overt CVD. Whether the development of MetS and associated 
CV changes, and the progression to MetS together with diabetes is along the 
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Table 1. Clinical Characteristics 






Age, years 45 ± 2.5 49 ± 1.9   0.24 
Sex, female %       65 63   0.57 
Height, cm 169 ± 2 169 ± 2   0.92 
Weight, kg 71 ± 2 103 ± 4 <0.001 
Waist circumference, cm 85 ± 5 119 ± 5 <0.001 
Body Fat, % 25 ± 2 39 ± 2 <0.001 
BSA, m2 1.80 ± 0.03 2.11 ± 0.04 <0.001 
BMI, kg/m2 25.0 ± 0.8 36.0 ± 1.0 <0.001 
SBP, mmHg* 115 ± 2 134 ± 3 <0.001 
DBP, mmHg* 75 ± 1 83 ± 1 <0.001 
Ejection Fraction, % 61 ± 1 58 ± 1   0.06 
Triglycerides, mg/dL 94 ± 10 170 ± 29   0.036 
HDL, mg/dL 55 ± 3 43 ± 2  <0.001 
Glucose, mg/dL 93 ± 2 99 ± 1   0.018 
HbA1c, % 5.35 ± 0.09 5.60 ± 0.07   0.03 
Insulin, µIU/mL 6.1 ± 1 12.1 ± 1 <0.001 
HOMA-IR 1.32 ± 0.23 2.98 ± 0.37 <0.001 
Hypertensive %  0  56 % <0.01 
Diabetes Mellitus %  0   0   
Medications        
   Hypertension  0  56% <0.05 
   Cholesterol  0  7% <0.05 
Values are mean ± 1 SEM; BSA: body surface area; BMI: body mass index; 
SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-
density lipoprotein; HbA1c: hemoglobin A1c; HOMA-IR: homeostatic model 




Table 2: Measures of Cardiovascular Geometry at Supine Rest 






Arterial Geometry         
  cIMT, mm 0.61 ± 0.02 0.72 ± 0.04 0.02 
  Diastolic diameter, mm 5.78 ± 0.12 6.17 ± 0.13 0.04 
  Carotid CSA, mm2/m2 10.3 ± 0.32 12.7 ± 0.68 <0.01 
Cardiac Geometry        
  LV Mass, g 136 ± 7 186 ± 11 <0.01 
  LV Mass Index, g/m2 75 ± 3 88 ± 5 0.046 
  LV Mass/height2.7, g/m2.7 33 ± 1 46 ± 3 <0.01 
  Relative Wall Thickness 0.39 ± 0.02 0.41 ± 0.02 0.41 
  LV Hypertrophy % 1 19 0.18 
  Concentric Remodeling, %  25 33 0.14 
  Concentric Hypertrophy, % 1 7 0.14 
  Eccentric Hypertrophy, % 0 7 0.14 
Values are mean ± 1 SEM, p-values adjusted for sex; cIMT: carotid intima-medial thickness; 


























































LV Diastolic Function 
E, m/s 0.81 ± 0.04 0.82 ± 0.03 0.65 
A, m/s 0.57 ± 0.03 0.73 ± 0.03 <0.01 
E/A ratio 1.47 ± 0.08 1.19 ± 0.07 <0.01 
IVRT, m/s 71 ± 3 74 ± 3 0.54 
Dec T, m/s 220 ± 7 203 ± 7 0.10 
e’, m/s 0.13 ± 0.01 0.11 ± 0.01 0.03 
τ, ms 28 ± 3 41 ± 3 <0.01 
E/e’ 6.46 ± 0.40 8.19 ± 0.59 0.02 
LV EDP, mmHg 15.9 ± 0.24 16.9 ± 0.36 0.02 
Values are mean ± 1 SEM, p-values adjusted for sex; E: peak 
velocity of the early diastolic mitral flow; A: peak velocity of the late 
diastolic mitral flow; E/A: E divided by A;  IVRT: isovolumetric 
relaxation time; Dec T: mitral flow deceleration time of early filling 
velocity; e’: mitral annular early diastolic velocity; τ: time constant of 




Table 4: Measures of Cardiovascular Function at Seated Rest 







  EDV, ml 87 ± 6 103 ± 5 0.02 
  EDVi, ml/m2 48 ± 3 48 ± 2 0.92 
  ESV, ml 36 ± 3 49 ± 2 <0.01 
  ESVi, ml/m2 20 ± 1 21 ± 1 0.52 
  SV, ml 51 ± 3 59 ± 3 0.09 
  SVi, ml/m2 28 ± 2 28 ± 1 0.76 
LV Contractility 
  Ees, mmHg/ml 3.21 ± 0.33 2.91 ± 0.18 0.45 
  Ees·EDV0.45 85 ± 6 91 ± 25 0.48 
  PRSW, g/cm2 90 ± 4 94 ± 3 0.93 
  PRSWi, g/cm2/m2 52 ± 2 51 ± 2 0.66 
Integrated indexes 
  Heart rate, bpm 68 ± 2 66 ± 2 0.46 
  Ea/Ees ratio 0.91 ± 0.06 0.93 ± 0.07 0.93 
  Cardiac Output 3.43 ± 0.22 3.85 ± 0.20 0.18 
  Cardiac Index, L/m2·min 2.03 ± 0.12 2.16 ± 0.08 0.33 
Arterial Function        
  SBP, mmHg 116 ± 3 127 ± 3 <0.01 
  MAP, mmHg 90 ± 2 99 ± 2 <0.01 
  Ea, mmHg/ml 2.71 ± 0.17 2.58 ± 0.15 0.58 
  SVRi, dyne·m2/s·cm-5 1261 ± 78 1063 ± 75 0.08 
  cf-PWV, m/s 6.6 ± 0.2 8.0 ± 0.2 <0.01≠ 
  Carotid Circum Stress, 
mmHg 
18.8 ± 0.8 23.4 ± 1.4 0.01 
Values are mean ± 1 SEM, p-values adjusted for sex; ≠ adjusted for 
differences in mean arterial pressure; EDV: end-diastolic volume (i=index); SV: 
stroke volume; Ees: end-systolic elastance; PRSWi: preload recruitable stroke 
work index; Ea/Ees: arterial-ventricular coupling ratio; Ea: arterial elastance; 




























Exercise duration, s 869 ± 65 946 ± 49 0.34 
Peak respiratory exchange ratio 1.15 ± 0.02 1.09 ± 0.02 0.01 
Peak work load, W 113 ± 9 123 ± 5 0.29 
Peak Heart rate, bpm 166 ± 4 154 ± 3 0.01 
Peak SBP, mmHg 177 ± 8 191 ± 4 0.01 
Peak DBP, mmHg 68 ± 4 77 ± 4 0.09 
Subjective effort score (6-20) 19 ± 0.3 19 ± 0.3 0.56 
VO2peak, ml/kg/min  24.6 ± 1.4 17.1 ± 0.9 <0.01 
VO2 at ventilatory threshold, ml/kg/min 16.8 ± 1.1 11.8 ± 0.8 <0.01 
Time to ventilatory threshold, s 638 ± 72 628 ± 57 0.91 
Ratio VO2 at ventilatory threshold to VO2peak, % 65 ± 2 67 ± 2 0.58 
Ratio of observed to predicted VO2peak, % 91 ± 5 69 ± 2 <0.01 
VE/VO2 at VT, % 29 ± 1 29 ± 1 0.70 
VE/VO2 at max 41 ± 1 38 ± 1 0.10 
VE/VCO2 at max 35 ± 1 35 ± 1 0.75 




Figure 1. Schematic illustration of the experimental set-up for the graded 
exercise test. Subjects performed maximal upright cycle ergometry with the back 
support angled at approximately 130°.  
 
Figure 2. LV Diastolic function at rest and during exercise. The change from rest 
to max exercise in (A) isovolumetric relaxation time (IVRT), (B) early (E) and late 
(A) mitral inflow velocities, and (C) the deceleration time of early filling velocity 
(Dec T) in MetS and controls. No significant time by group interactions for IVRT 
or Dec T were evident between MetS and controls during max exercise. Further 
at peak exercise no differences were observed between groups for the early (E) 
and late (A) mitral inflow filling velocities, however, at moderate workloads the E- 
and A-waves become superimposed at extreme workloads the A-wave 
dominates over the E-wave. *p<0.05 MetS vs. controls; # p<0.05 time by group 
interaction. Data presented as means ± SEM. 
 
Figure 3. Cardiac pump performance at rest and during upright exercise. The 
change from rest to max exercise in (A) cardiac volumes, (B) ejection fraction 
(EF), (C) cardiac index (Ci), and (D) heart rate (HR) in MetS and controls. During 
exercise the change from rest to max exercise in EDVi and SVi was similar 
between MetS and healthy controls. A significant time by group interaction was 
identified for the reduction of ESVi during exercise with MetS displaying a blunted 
decrease vs. controls. Compared to controls MetS also demonstrated a blunted 
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increase in EF and Ci at max exercise, which was evident at submaximal 
workloads. Peak HR was significantly lower in MetS vs. controls. *p<0.05 MetS 
vs. controls; #p<0.05 time by group interaction. Data presented as means ± 
SEM. 
 
Figure 4. Cardiac contractility and arterial-ventricular coupling response to 
exercise. The change from rest to max exercise in (A) pre-load recruitable stroke 
work index (PRSWi), (B) end-systolic elastance (Ees) and effective arterial-
elastance (Ea), (C) and the arterial-ventricular coupling ratio (Ea/Ees) in MetS 
and controls. Compared to controls, MetS displayed a blunted increase in Ees 
and PRSWi at max exercise. During exercise the combination of a blunted 
increase in Ees and a comparable change in Ea between groups resulted in a 
blunted Ea/Ees ratio in MetS compared to controls. *p<0.05 MetS vs. controls; 
#p<0.05 time by group interaction. Data presented as means ± SEM. 
 
Figure 5. Pressure and vascular resistance response during exercise. The 
change from rest to max exercise in (A) systolic (SBP) and diastolic (DBP) blood 
pressure,  and (B) systemic vascular resistance index (SVRi) in MetS and 
controls. Systolic BP and diastolic BP were higher in MetS vs. controls at 
submaximal and maximal workloads. +p=0.08 vs. controls; *p<0.05 MetS vs. 
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 The metabolic syndrome (MetS) is associated with a 3-fold increase risk of 
cardiovascular disease (CVD) mortality partly due to increased arterial stiffening. 
We compared the effects of aerobic exercise training on arterial 
stiffening/mechanics in MetS without overt CVD or Type 2 Diabetes. MetS and 
healthy controls (Con) underwent 8 weeks of exercise training (ExT; 11 MetS and 
11 Con) or remained inactive (NonT; 11 MetS and 10 Con). The following 
measures were performed pre and post intervention: radial pulse wave analysis 
(applanation tonometry) was used to measure augmentation pressure and index, 
central pressures, and an estimate of myocardial efficiency; arterial stiffness was 
assessed from carotid-femoral pulse wave velocity (cfPWV, applanation 
tonometry); carotid thickness was assessed from B-mode ultrasound; and peak 
aerobic capacity (gas exchange) was performed in the seated position. Plasma 
matrix metalloproteinases (MMP), and CVD risk (Framingham risk score) were 
also assessed. cfPWV was reduced (p<0.05) in MetS-ExT (7.9+0.6 to 7.2+0.4 
m/s) and Con-ExT (6.6+1.8 to 5.6+1.6 m/s). Exercise training reduced (p<0.05) 
central systolic pressure (116+5 to 110+4, mmHg), augmentation pressure (9+1 
to 7+1, mmHg), augmentation index (19+3 to 15+4%), and improved myocardial 
efficiency (155+8 to 168+9) but only in the MetS group. Aerobic capacity 
increased (p<0.05) in MetS-ExT (16.6±1.0 to 19.9±1.0) and Con-ExT (23.8±1.6 
to 26.3±1.6). MMP-1 and 7 were correlated with cfPWV and both MMP-1 and 7 
were reduced post-exercise training in MetS. These findings suggest that some 
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of the pathophysiological changes associated with MetS can be improved after 
aerobic exercise training thereby lowering their CV risk. 
 























 The metabolic syndrome (MetS) is associated with a 3-fold increase risk of 
cardiovascular disease (CVD) mortality than individuals without MetS [1]. Current 
predictions are that by the year 2020, as much as 40% of the population will have 
MetS. Part of this increased CVD risk in MetS is attributed to the 
pathophysiological changes to the arterial system, namely increased arterial 
stiffness, carotid thickening, and higher central arterial pressures [2, 3]. A 1 m/s 
increase in central pulse wave velocity (PWV: a measure of arterial stiffness) 
corresponds to an age-, sex-, and risk factor–adjusted risk increase of 15% in 
cardiovascular and all-cause mortality [4]. Further, a 0.1 mm increase in carotid 
artery intima media thickness (cIMT) is associated with a 18% and 15% 
increased risk for a stroke and myocardial infarction, respectively [5]. Therefore, 
it is critically important that effective interventions aimed at improving arterial 
health are identified.  
Aerobic exercise training has been shown to be an effective intervention to 
improve arterial compliance/stiffness in healthy young and middle/older persons 
[6, 7]. However, with metabolic disease, previous studies have examined 
exercise interventions in populations with a single metabolic risk factor (obesity, 
hypertension, hypercholesterolemia) [8-10], or in MetS with type 2 diabetes 
(T2DM) [11, 12]. Because the development of MetS occurs prior to the 
development of T2DM and overt CVD, it is important to know if exercise training 
can reverse the arterial stiffening and produce improvements in the CVD risk 
profile of MetS individuals prior to overt T2DM or CVD. Understanding the 
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mechanisms mediating favorable changes in arterial function prior to the 
progression to T2DM are important. It is possible that the changes in the arterial 
expression, architecture, and/or bioactivity of structural proteins that play a major 
role with CVD, are either reversed or ameliorated through exercise. Favorable 
effects of exercise on improving the balance with pro-and anti-inflammatory and 
oxidative stress markers could improve nitric oxide bioavailability, and alter 
matrix metalloproteinases (MMPs), and/or tissue inhibitors of MMP (TIMPs) 
activity. MMP are regulators of tissue remodelling and its activity is greatly 
affected by mechanical stretch. Chronic exercise training, which acts as a 
mechanical stressor to the arteries, could exert its effects by altering MMP/TIMP 
activity directly and/or indirectly via the anti-inflammatory and oxidative stress 
responses of exercise.  
We examined whether aerobic exercise training can reverse arterial 
stiffness and improve arterial mechanics including central pressures in 
individuals with MetS without overt CVD or T2DM. Further, we examined the 
potential mechanisms (inflammation, and MMP/TIMP activity) through which 
aerobic exercise may improve arterial health. We hypothesized that exercise 
training in MetS would reduce central arterial stiffness compared to the non-








Study Population  
 21 healthy controls (41+ 2 years; 71% female) and 22 MetS (45 + 2 years; 
60% female) subjects participated in the study. The healthy controls were free 
from CVD, as determined by a detailed history, physical examination, and a 
normal resting and exercise electrocardiogram. MetS subjects were free from 
overt CVD and diabetes. Further, none of the participants were current or former 
smokers or were being treated for peripheral artery disease. MetS was defined 
according to the updated National Cholesterol Education Program: Adult 
Treatment Panel III [13] comprised of 3 out of the following 5 components: 1) 
obesity (waist men >102 cm, women >88 cm); 2) low HDL cholesterol (men<40 
mg/dL; women<50 mg/dL); 3) hypertriglyceridemia (≥150 mg/dL); 4) elevated 
glucose (≥100 mg/dL & <126 mg/dL), and; 5) elevated BP (130/85 mmHg or use 
of hypertensive medications).  
Exclusion criteria included T2DM (HbA1c ≥6.5 % or use of diabetic 
medications), pulmonary disease, angina, atrial fibrillation, aortic stenosis, 
anemia, myocardial infarction, stroke, or coronary revascularization as assessed 
by a detailed medical history physical examination, and a resting and exercise 
electrocardiogram. Subjects who participated in regular exercise, defined as >30 
minutes, 3 times/week were excluded. All subjects provided written informed 
consent to participate that was submitted to and approved by WVU Institutional 




Study Design.   
 Assessments were performed between 7:00-10:00 AM, in a quiet, 
temperature-controlled room, after a 12 hour fast, and abstinence from alcohol, 
caffeine, and vitamins. Cardiovascular medications were withheld 24 hours prior 
to assessments. Upon completion of the anthropometric assessments and after a 
minimum 15 minutes of quiet supine rest, subjects underwent supine measures 
of arterial structure/function followed by a blood draw. 
 
Body Anthropometry 
 Height, and weight, along with waist and hips circumference were 
measured using standard laboratory procedures. Fat distribution was assessed 
by measuring the waist circumference at the site of the smallest circumference 
between the rib cage and the ileac crest with the subjects in standing position. 
Hip circumference was measured at the site of the largest circumference 
between waist and thighs. Body composition was calculated from body volume of 
the BodPod® (Life measurement, Concord, CA, USA). Subjects wore tightly 
fitting bathing suits and a swim cap during the volume-measurements in the 
BodPod®. Body mass index (BMI) was calculated as weight (kg)/height (m)2. 
 
Arterial Geometry 
 Ultrasound (GE Vivid i) 2-D images of the right common carotid artery 
were obtained 1-2 cm proximal to the carotid bifurcation to measure maximal 
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lumen diameter, and intima-medial thickness (cIMT). Cross-sectional area of the 
carotid artery was calculated as [(maximal lumen diameter/2)2 x π]-(maximal 
lumen diameter/2-cIMT)2 x π). The wall to lumen ratio of the right common 




 Brachial systolic (SBP) and diastolic (DBP) blood pressure was measured 
with an automated, oscillometric, sphygmomanometer (Critikon Dinamap 
Compact BP monitor, GE Medical, Tampa, Fla , USA) and pulse pressure (PP) 
was calculated from SBP-DBP. Pulse wave analysis was performed 
noninvasively on the radial artery (SphygmoCor system, AtCor Medical, Sydney, 
Australia). All measurements were made in triplicate, and the mean values used 
for subsequent analysis. The SphygmoCor system synthesizes a central 
(ascending aortic) pressure waveform from the radial pressure waveform that 
does not differ from that of an intra-arterially recorded wave [14] using a validated 
generalized transfer function [15] that has good reproducibility under major 
hemodynamic changes [16]. These waveforms were calibrated against brachial 
mean arterial and diastolic pressure to estimate aortic pressures. 
 The characteristics of the aortic pulse wave (Figure 1) were determined as 
follows using established guidelines [17]. Forward wave pressure was defined as 
the difference between pressure at the waveform foot and the pressure at the 
inflection point and used as an index of peak left ventricular ejection velocity (P1, 
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Figure 1). Left ventricular (LV) systolic ejection duration was taken as the time 
from the foot of the pressure wave upstroke to the incisura of the dicrotic notch. 
Augmented pressure (AP), a measure of the contribution of wave reflections to 
SBP, was defined as the difference between aortic SBP and the pressure at the 
forward wave peak. Augmentation index (AGI) provides a measure of the 
contribution of wave reflection pressure (i.e. AP) to SBP relative to total PP. AGI 
was calculated as the ratio of amplitude of the pressure wave above its systolic 
shoulder (i.e. the difference between the early and late systolic peaks of the 
arterial waveform), to the total PP expressed as a percentage (P2−P1/PP*100) 
[14]. Since AGI varies with heart rate, AGI is commonly adjusted to a ‘standard 
heart rate’ of 75 beats per minute (AGI@75). Travel time of the forward pressure 
wave from the aorta to the peripheral reflection site and back (Tr) was 
determined from the time from the initial upstroke of the pressure wave to the 
foot of the reflection wave and used as a proxy of aortic pulse wave velocity. 
Systolic-to-diastolic pressure shifts were assessed by the systolic (red shaded 
area, Figure 1) and diastolic (blue shaded area, Figure 1) pressure-time 
integrals. The Buckberg sub-endocardial viability ratio (SEVR) index, which 
correlates with LV sub-endocardial:sub-epicardial flow ratio (an apparent marker 
of sub-endocardial ischemia) [18], was calculated as the percentage ratio of the 
diastolic (diastolic time index, DTI):systolic (tension time index, TTI) pressure-
time integral.  
 Carotid to femoral pulse wave velocity (cfPWV; central arterial stiffness) 
and carotid to radial pulse wave velocity (crPWV: peripheral arterial stiffness) 
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were measured by applanation tonometry (AtCor Medical, Sydney, Australia). 
ECG-gated waveforms were sequentially recorded. Aortic distance (D) was 
calculated as the difference in the distances from the carotid to the suprasternal 
notch and from the suprasternal notch to the femoral artery or radial artery. Time 
delay was calculated using a foot-of-the-wave method.  
 Using B-mode ultrasound (GE Vivid i) the right CCA strain was calculated 
as (ΔDc)/D x 100, where ΔDc is the difference between systolic and diastolic 
carotid diameter, D is the diastolic diameter. CCA circumferential wall stress = 
Mean BP x CCA W/L. Peak CCA circumferential wall tension was calculated as 
aortic SBP x (Dc in systole/2) 
 
Blood Analysis 
 Venous blood sampling was obtained in the morning after a 12-hour 
overnight fast. Post training blood samples were collected at least 48 hours after 
the last exercise session. Serum and plasma was obtained from blood samples 
collected in either serum separation tubes with polymer gel/silica activator (BD 
Vacutainers®) or plasma separation tubes (BD Vacutainers®). Using standard 
procedures total cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, glucose and insulin were processed at West Virginia University 
Hospital’s central laboratory in Morgantown, West Virginia. Homeostasis model 
assessment of insulin resistance (HOMA-IR) was estimated with the following 
formula: insulin resistance = fasting plasma insulin (in microunits per ml μU/mL) × 
fasting plasma glucose (FPG, in millimoles per litre)/22.5. HOMA β-cell function 
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was also assessed from 360* fasting insulin/(fasting glucose-63). Plasma MMP 
(1, 2, 7, 9, and 10) and TIMP (1 and 2) activity, serum adhesion molecules 
(Serum Endothelial Leukocyte Adhesion Molecule-1, soluble cell adhesion 
molecules-1, vascular cell adhesion molecule-1, and tissue plasminogen 
activator inhibitor-1), and serum inflammatory markers (IL-6, IL-8, and TNFα) 
were run on a Luminex® 100™ Bioanalyzer (Luminex Corp., Austin, TX, USA) 
according to the kit manufacturer's (Milliplex ELISA kits, Millipore Corporation, 
MA, USA) instructions.  The reader is referred to the online supplement for 
further details on blood processing. 
 
CVD Risk 
 The Framingham Risk Score (FRS) was calculated based on sex, age, 
brachial SBP, treatment for hypertension, smoking and diabetes status, HDL, 
and total cholesterol to establish an individual’s general 10 year CVD risk, along 
with their estimated Framingham vascular age [19]. Further, we also estimated 




 Individuals were assigned into either an 8-week aerobic exercise 
intervention group (ExT) or an 8 week non-exercise control (Non-ExT) group. 
Initially, 11 controls were assigned to the Non-ExT group however, one dropped 
out for personal reasons. Data were only analyzed on subjects who completed 
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the study. The Non-ExT exercise training groups (Controls: n=10, 80% female; 
MetS: n=11; 55% female) were instructured to maintain their normal lifestyle 
activities. The ExT groups (Controls: n=11, 64% female; MetS: n=11; 73% 
female) performed 8 weeks of supervised aerobic exercise, 3 days/week for 60 
min/day at a fixed exercise intensity performed in the Human Performance Lab at 
West Virginia University. The intensity of prescribed exercise was based on 
individual results of maximal upright bicycle cardiopulmonary exercise tests with 
the resistance to peddling increasing by 25 watts every 3 minutes until subjects 
reached exhaustion. Subjects were required to pedal at 50 revolutions/minute. 
We deployed a ramp exercise protocol, whereby the exercise intensity started at 
60% of heart rate reserve (heart rate range determined during exercise stress 
test) and increased every 2 weeks by 10%; from weeks 6-8 heart rate reserve 
was set at 85%. Adherence to the exercise prescription was documented through 
the use of Portable heart rate monitors (E600, Polar Electro OY, Oulu, Finland) 
and physical activity logs. Approved modalities included treadmills, elliptical 
machines, and cycle ergometers. The participants were instructed to maintain 
current eating behaviors for the duration of the 8-week intervention. All post-
training measurements were performed at least 48 hours after the last exercise 
session to avoid the immediate effects of a single bout of exercise. In addition, 
measurements before and after intervention periods were obtained at the same 






 Our sample size calculation for our primary outcome measures (cfPWV) 
assumed a power of 90% and an alpha error probability of 0.05. We found that 
we required a sample size of at least 11 subjects to detect a clinically significant 
effect of exercise training on arterial stiffness such as a difference in cfPWV of 
1±1 (SD) m/s. Normality was evaluated by the Kolmogorov-Smirnov test. 
Categorical variables were compared by the chi-square test. Continuous 
variables were log transformed as necessary and pre-exercise variables were 
compared between groups with a One-way ANOVA with a Tukey’s post hoc test. 
To evaluate the effects of exercise training paired t-tests and two-way repeated-
measures ANOVA were used. All analyses were performed with the statistical 
package SPSS version 21 (SPSS, Chicago, IL). Values shown in the tables 













Results   
 Age, anthropometric and metabolic characteristics of the healthy controls 
and MetS groups are shown in Table 1. MetS and controls groups did not differ 
by age or sex; however, by study design the MetS groups had significantly higher 
anthropometric and metabolic characteristics.  Additionally, pre-exercise peak 
VO2 was lower (p<0.05) in MetS NonT (18 ± 2 ml/min/kg) and MetS ExT (16 + 1 
ml/min/kg) groups vs. healthy NonT (25 + 2 ml/min/kg) and healthy ExT (24 ± 2 
ml/min/kg) controls. However, within each group (i.e., MetS Non-ExT vs. ExT, 
and controls Non-ExT vs. ExT) individuals were well matched with no significant 
differences in age, baseline metabolic and arterial parameters. 
 
Arterial Parameters 
 It is well known that MetS patients have higher central and brachial 
pressures, an increased arterial stiffness, and arterial remodeling compared to 
healthy controls. Similar differences were evident in our population (Table 2). In 
healthy controls, 8 weeks of exercise training significantly reduced cfPWV and 
AGI, and there was a significant time (Pre vs. Post) by group (Non-ExT vs. ExT) 
group interaction for cfPWV. However, no other significant differences in arterial 
structure/function were found pre-and post-exercise training in healthy controls. 
Importantly, 8 weeks of exercise training in MetS patients reduced brachial and 
central SBP, although only a significant reduction was identified in the central 
SBP (p<0.05). Further, AP was significantly reduced (20%, p<0.05) in the MetS-
ExT group. Although AGI was not affected by exercise training, a reduction (21%, 
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p=0.06) in AGI@75HR was identified. Indeed, resting HR was reduced (6%, 
p<0.05) in MetS-ExT group. Due to the reduction in central SBP the systolic 
region of the pressure wave was reduced (9%, p<0.05) along with an 
improvement in SEVR (8%, p<0.05) in the MetS-ExT group, and there was a 
significant time (Pre vs. Post) by group (Non-ExT vs. ExT) interaction for SEVR. 
Importantly, aerobic training lowered cfPWV in MetS individuals by 9% (p<0.05), 
which remained significant after adjusting for differences in MAP. Further, there 
was a significant time (Pre vs. Post) by group (Non-ExT vs. ExT) group 
interaction for cfPWV. In contrast, 8 weeks of exercise training had no effect on 
improving crPWV, cIMT, carotid cross-sectional area, carotid lumen to wall ratio, 
carotid wall stress or tension in MetS-ExT. 
In the Non-ExT controls and MetS, no differences in arterial structure and 
function were found 8 weeks post-intervention compared to baseline values 
(Table 2).  
 
Blood Biomarkers 
 We also examined the effects of exercise training on improving metabolic 
markers, inflammation, and vascular proteins circulating in the blood. No 
differences in metabolic markers, adhesion or the inflammation markers were 
evident in either the healthy controls or MetS group after the intervention (Table 
3). However, a reduction in MMP-1 (p<0.05), and to a lesser extent MMP-7 
(p=0.06), was evident after exercise training in the MetS group, but not in the 
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healthy control group. A significant time (pre and post intervention) by group 
(MetS NonT vs. MetS ExT) interaction was identified for MMP-7.   
 
Aerobic Capacity and CVD risk 
 Aerobic capacity was increased (p<0.05) in MetS (16.6±1.0 to 19.9±1.0) 
and healthy controls (23.8±1.6 to 26.3±1.6) after exercise training, whereas no 
changes were found in MetS (18.5±1.6 vs. 18.2±1.2) and healthy controls 
(25.6±2.8 vs. 25.8±2.5) who remained inactive. As expected the FRS and the 
vascular age calculated from the Framingham Risk algorithm were higher 
(p<0.05) in both MetS groups compared to healthy controls (Table 1). Exercise 
training did not affect the FRS in MetS (8±4% vs. 6±3) or healthy controls (2±1% 
vs. 2±1). However, in MetS exercise training significantly reduced vascular age 
calculated from the Framingham Risk algorithm (from 47±8 to 44±7 years, 
p=0.02), and from cfPWV (from 55±5 to 50±4 years, p=0.04). Adding PWVage to 
the FRS tended to reduce the calculated CVD risk (10±5 vs, 6±3%), but 
statistical significance was not reached (p=0.15). In contrast, neither vascular 
age calculated from the FRS (34±4 vs. 33±4 years, p=0.6) or from cfPWV (40±3 
vs. 37±4 years, p=0.1) was altered in the healthy controls ExT group. Similarly, 
adding PWV to the FRS did not alter their calculated CVD risk (3±1% vs. 2±1%).  
 
Relationship between Aerobic Capacity, and Arterial Health. 
 An inverse relationship (p<0.05) was identified between VO2peak, and 
cfPWV (Figure 2A), cIMT (Figure 2B), AP (Figure 2C), and both central and 
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brachial SBP (Figure 2D). We also calculated the change (post-pre values) in 
cfPWV, cIMT, AP, AGI, AGI@HR75, and both brachial and central SBP, and 
compared that to the change in VO2peak. A significant and inverse relationship 























 Our laboratory [2] and others [3] have shown that the MetS is associated 
with arterial dysfunction, reflected by an increase in arterial stiffness, cIMT, 
carotid cross-sectional area, carotid wall stress and tension. Part of this arterial 
dysfunction reflects the sedentary lifestyle of individuals with MetS, and physical 
inactivity is independently associated with cardiovascular and all-cause mortality 
[21]. The present study is novel in that we examined whether aerobic exercise 
training would be an effective non-pharmacological therapy to lower arterial 
stiffness and improve other markers of arterial health in MetS patients who had 
yet to transition to more adverse stages of the cardiometabolic disease such as 
the co-occurrence of T2DM, or the presence of overt CVD (angina, heart attack, 
stroke etc). Of particular importance, cfPWV, which is increased in MetS (even 
without overt CVD) compared to age-matched healthy controls, is significantly 
reduced after 8 weeks of aerobic exercise in MetS by almost 1 m/s. Given the 
clinical significance of increased arterial stiffness, this reduction in cfPWV after a 
short period of exercise training likely reflects a reduction in CV risk. 
In the present study, the reduced cfPWV in MetS after exercise training 
occurred in the absence of significant improvements in weight, BMI, and 
metabolic profile, suggests the effects of aerobic training on the arterial stiffness 
may be independent of these other well-established benefits of exercise. The 
reduction in cfPWV coincided with a reduction in central SBP, AP, AGI, and an 
improvement in sub-endocardial variability. The average reduction in SBP with 
aerobic exercise training is 3.9 mmHg and is independent of body weight and 
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race [22]. We found that 8 weeks of exercise training reduced brachial and 
central SBP between 5-6 mmHg in MetS. As central SBP predicts cardiovascular 
outcomes more closely than brachial BP [23], the reduction in cSBP is clinically 
relevant. Given that arterial stiffness and augmentation pressure play key roles in 
determining central SBP, the reduction in central SBP can be attributed in part to 
a reduction in arterial stiffness, and a reduction AP. Central AP represents the 
amount of pressure added to the systolic pressure peak based on the reflected 
wave. A decrease in arterial stiffness can result in a corresponding decrease in 
the transmission velocity of the forward and reflected waves causing the reflected 
wave to arrive later in the central aorta and augment pressure in late systole or 
early diastole. Thus, once AGI (an indirect measure of systemic arterial stiffness), 
was adjusted to a standard HR (AGI@HR75) a reduction in the reflected 
pressure wave was evident. Adjusting for HR in our study was important given 
that exercise training in MetS was associated with a 4 bpm reduction in HR. 
Effectively, a decrease in HR will extend the duration of the cardiac cycle, shifting 
the reflected wave into systole and increasing AP. In addition to the effects of 
HR, wave reflection is also dependent on arterial stiffness [24], which decreased 
to a greater extent than HR in exercised trained MetS. The improvements in 
central pressure dynamics corresponded to an increase in SEVR, an indirect 
marker of subendocardial perfusion [18], which may suggest an improvements in 
cardiac function.   
Aerobic exercise training did not alter cIMT, carotid cross-sectional area, 
or wall to lumen ratios, or carotid dynamics (CCS strain, wall stress or wall 
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tension) in MetS. This lack of change in cIMT is similar to that reported 
elsewhere in middle-aged and older healthy men [25, 26] suggesting that regular 
exercise training typically does not alter the large conduit vessels. 
Our data might suggest that exercise training exerted greater benefits to 
MetS than healthy controls as evident by the larger exercise-induced decreases 
in cSBP, AP, TTI and increase in SEVR in MetS compared to healthy controls. 
Likewise, MetS patients also exhibited a tendency to have greater reduction in 
cfPWV (0.7 vs. 0.3 m/s) and VO2peak (3.3 vs. 2.5 ml/min/kg) than controls. 
However it must be emphasized no significant ANOVA interaction effects were 
observed between MetS and healthy controls with these pre-post training 
responses, and that our study was also not originally powered to test this 
question. Nevertheless, it is tempting to speculate that potential for greater 
improvement in these parameters for MetS patients may be due to their elevated 
baseline compared to controls and therefore could provide a greater range for 
the exercise stimulus to act on. This is an important question that will require 
additional research/subjects before a clear understanding is gained. 
Recent evidence suggests that any initial benefit with exercise training on 
arterial stiffness in persons with established MetS and T2DM is attenuated over 
the long term [11, 27]. Whereby, at 3 months of aerobic exercise training a 14-
23% reduction in cfPWV has been reported [11, 28], yet after 6 months of 
exercise training the reduction in cfPWV was not maintained [11]. These data 
suggest that the prescription of aerobic exercise on improving arterial stiffness 
may be more beneficial prior to the occurrence of T2DM in those with MetS, than 
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starting once the patient is already at a high cardiometabolic risk. To what extent 
this initial reduction in arterial stiffness through short-term exercise training in 
MetS without T2DM is maintained for an extended period of time, and whether 
exercise training helps to delay or prevent the transition from MetS to T2DM 
warrants further investigation.  
 
Potential mechanism behind improved arterial stiffness 
 The stiffness of the arterial system is dependent on the dynamic 
(autonomic tone, smooth muscle cell contractility, endothelial function) and 
material properties (elastin content and integrity, collagen content, fibrosis, 
elastin and collagen cross-linking, calcification) of the artery [29]. Sympathetic 
activation of the vascular smooth muscle cells causes vasoconstriction, 
decreasing lumen diameter, and increasing arterial stiffness. Although we did not 
measure sympathetic activity, exercise training has been shown to improve 
sympathetic -and parasympathetic nervous activities in obese individuals [30, 
31]. Thus, it is possible that the improvement in arterial stiffness in the current 
study may be in part due to improved autonomic function.   
Arterial stiffness is also in part modulated by endothelial dysfunction. 
Exercise training in both obese/MetS patients has been shown to improve 
endothelial function [32, 33], which may improve arterial function via intermittent 
increases in shear stress, which stimulates nitric oxide bioavailability, and up-
regulating endothelial NO synthase protein expression and phosphorylation [34]. 
Changes in distending pressure affect arterial stiffness, where at higher 
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pressures the force on the arterial wall is transferred to the stiffer collagen limiting 
distention. In our study, MAP did not change, and the decrease in cfPWV in the 
training groups remained significant after adjusting for MAP. Thus, it is unlikely 
that a reduction in distending pressure contributed to the improved arterial 
compliance. 
 In terms of the material properties that effect arterial stiffness, the main 
contributors to increased arterial stiffness are increased collagen concentration, 
non-enzymatic glycation resulting in the formation of collagen crosslink, and 
vascular smooth muscle hypertrophy [29]. Hyperglycemic conditions, and 
oxidative stress, accelerate the generation of advanced glycation end-products 
precursors contributing to variable pathologies such as T2DM, MetS and obesity. 
In our study, we did not measure the amount of advanced glycation end-product 
deposition; however we did measure plasma markers of tissue remodelling 
(MMP and TIMP) and found that exercise training lowered circulating MMP-1 and 
7. Interestingly, both MMP-1 and 7 were positively associated with cfPWV. More 
evidence is required to identify to what extent MMPs play a role in arterial 
remodeling through exercise training. 
Chronic low grade inflammation, specifically IL-6, IL-8, and TNFα have 
been postulated to be involved in the pathogenesis of MetS [35] and arterial 
stiffness [36], and in the present these markers tended to be elevated in MetS vs. 
controls. However, we found that exercise training did not alter inflammatory 
markers in MetS. In contrast, improvements in TNFα, and IL-18 have been found 
after 12 weeks and 1 year of exercise training in MetS with or without T2DM [37, 
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38]. Thus, the lack of change in inflammatory state in our MetS group after 
exercise training maybe due to the shorter duration of exercise we used. 
Clinical implications 
 A strong relationship exists between arterial stiffness and CVD mortality 
[4] and in our study the decrease in cfPWV by almost 1 m/s may reflect a 
lowering of CVD events and mortality by approximately 14% [4]. The reduction in 
cfPWV coincided with a reduction in central SBP, which is important given that a 
reduction SBP by 2 mmHg is associated with a 10% and 7% decrease in 
mortality from cerebral vascular and CVD events [39]. Arterial stiffness 
contributes substantially to cardiac workload and energetics, and is inversely 
correlated with VO2peak [40, 41]. We have confirmed this relationship and shown 
that the change in VO2peak and cfPWV with exercise training are inversely related. 
These data suggest that individuals with more compliant arteries may have more 
optimal coupling between the heart and arterial system allowing for greater peak 
CV performance. Indeed, arterial-ventricular coupling is a critical determinant of 
net CV performance [42]. It has been reported that MetS with a high aerobic 
fitness have a lower risk of mortality than unfit MetS [43], which may in part be 
explained by the lower degree of arterial stiffening [41]. 
Increasing arterial stiffness is regarded as a measure of premature 
vascular aging [44]. According to normative reference values of arterial stiffness 
[45], the baseline biologic vascular age of our MetS group may be estimated to 
be 6 years older than it would be in healthy individuals of a similar age. The 
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reduction in cfPWV observed in the MetS ExT group may translate into a reversal 
of age-related arterial stiffening of 5 years [46]. Adding vascular age calculated 
from cfPWV to the FRS lowered the calculated CVD risk by 4%. 
 
Future directions 
 The mechanisms responsible for improving arterial function and aerobic 
capacity in MetS patients after exercise training likely reflect multiple CV 
adaptations some of which we have pointed out. However, the specific roles of 
the sympathetic nervous system, the structure and function of resistance vessels, 
and oxidative stress require further examination in both human and animal 
models. Given the lack of change in metabolic profile of our MetS population it 
would be important to identify whether exercise training of longer durations (6 
months plus), or exercise training plus diet control would exert greater benefits 
on both arterial function and metabolic profile of MetS patients. It would also be 
important to identify whether the beneficial effects of short term exercise training 
on lowering arterial stiffness is maintained over a longer period of time or indeed 
is it lost as evident in T2DM patients. Further, it will also be important to conduct 
longitudinal studies to identify whether persistent exercise training in MetS can 
delay or prevent the transition to MetS with overt CVD/diabetes.” 
 
Limitations  
 There are several limitations. There may be sex differences in the effects 
of exercise training on arterial stiffness that could not be detected given the small 
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number of male vs. female subjects. Second, more direct measures of autonomic 
function should be used to assess whether changes in sympathetic activity 
contributed to a reduction in cfPWV. Another limitation is the circulating levels of 
MMP’s do not necessary reflect what is going on at the arterial sites. However, 
because the changes on the cellular level are reflected in body fluids, 
determination of MMPs in blood have been recommended as noninvasive tools 
in the diagnosis and monitoring of several diseases [47]. Although we reviewed 
each participant medical history and performed a physical examination we 
cannot completely rule out that participants may have had some degree of 
peripheral artery disease. Despite this exercise training in MetS (with or without 
peripheral artery disease) significantly improved arterial health. Four of our MetS 
patients had a BMI >40 kg/m2 indicating they were severely obese. However, 
being severely obese did not limit their ability to improve arterial function, as we 
repeated the statistical analyses excluding these individuals and found that the 
main story of the paper did not change. Lastly, a potential limitation is the 
measurement of plasma lipids obtained from lithium heparin coated collection 
tubes, given that heparin precipitates some lipoproteins. This may explain, in 
part, the lack of change in blood lipids post-exercise training the short duration of 
exercise training. 
In conclusion, the present study indicates that aerobic exercise training is 
an effective approach to reduce arterial stiffening and improve CVD risk profiles 
in individuals with the MetS (without T2DM and overt CVD). Whether long-term 
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aerobic exercise training maintains the beneficial effects on arterial stiffness in 
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Table 1: Clinical Characteristics of the subject cohorts 
 Controls NonT  Controls ExT  MetS NonT  MetS ExT 
Age, years 40 ± 4 41 ± 4 44 ± 3 46 ± 4 
Sex, female % 80% 64% 64% 73% 
Height, cm 165 ± 3 168 ± 2 171 ± 3 168 ± 3 
Weight, kg 68 ± 4 69 ± 4 102 ± 7*^ 106 ± 5* 
Body Fat, % 25 ± 4 24 ± 2 36 ± 2*^ 45 ± 2* 
BSA, m2 1.75 ± 0.06 1.78 ± 0.06 2.13 ± 0.08*^ 2.13 ± 0.06* 
BMI, kg/m2 25 ± 1 24 ± 1 34 ± 2*^ 38 ± 2* 
Waist circumference, cm 83 ± 3 86 ± 6 107 ± 3*^ 124 ± 9* 
Total Cholesterol, mg/dL 191 ± 11 177 ± 12 189 ± 12 191 ± 12 
Triglycerides, mg/dL 93 ± 14 81 ± 14 161 ± 23*^ 115 ± 16 
HDL, mg/dL 56 ± 5 57 ± 4 40 ± 4*^ 50 ± 5 
Glucose, mg/dL 93 ± 3 92 ± 3 97 ± 1 98 ± 2 
HbA1c, % 4.9 ± 0.3 5.4 ± 0.1 5.7 ± 0.1* 5.6 ± 0.1* 
Insulin, µIU/mL 5 ± 1 5 ± 1 11 ± 2*^ 10 ± 1*^ 
Beta Cell function 62 ± 10 79 ± 37 111 ± 20*^ 105 ± 16*^ 
HOMA IR 1.3 ± 0.2 1.0 ± 0.3 2.7 ± 0.5*^ 2.4 ± 0.3*^ 
Framingham Risk Score, % 2 ± 1 2 ± 1 8 ± 2*^ 8 ± 4*^ 
Framingham Vascular Age, years 36 ± 3 34 ± 4 54 ± 4*^ 47 ± 7*^ 
Hypertensive %  0   0   73   82  
Hypertension category             
   Normal, %  40 64 18 18 
   Pre-hypertension, % 10 18 0 0 
   Stage 1, % 0 0 82 73 
   Stage 2, % 0 0 0 1 
Diabetes Mellitus % 0 0 0 0 
Smokers, % 0 0 0 0 
Medications             
   Diuretics, %   0 0 10 18 
   Β-blockers, %   0 0 0 18 
   ACEI/ARB, % 0 0 36 18 
   CA2+ blockers, %   0 0 0 0 
   Statins, % 0 0 0 18 
Values are mean ± 1 SEM; BSA: body surface area; BMI: body mass index; HDL: high density lipoprotein; HbA1c: hemoglobin A1c; HOMA-IR: homeostatic model 
assessment of insulin resistance. 
*p<0.05 compared to healthy control NonT group; ^ p<0.05 compared to healthy control ExT group; 
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Table 2: Differences in arterial parameters pre and post intervention in MetS and controls 
 
 
Controls NonT (n=10) Controls ExT  
(n=11) 




 Pre Post 
Pre Post  Pre Post 
Pre Post 
bSBP (mmHg) 117±3 115±4 111±3 110±3  128±4^ 126±4 125±5^ 120±4 
bDBP (mmHg) 74±2 75±3 73±2 71±2  84±3* 81±2 80±2* 78±2 
bPP (mmHg) 42±3 41±2 38±2 39±2  43±3 45±3 46±5 42±3 
bMAP (mmHg) 91±3 88±3 87±2 85±2  100±3* 97±2 96±2*^ 93±3 
cSBP (mmHg) 107±3 104±4 103±3 101±2  117±4^ 114±3 116±5^ 110±4† 
cPP (mmHg) 31±2 30±2 29±2 28±2  32±2*^ 33±2 36±5 32±3 
P1 H (mmHg) 24±2 23±1 22±2 23±1  25±2 26±2 27±3 25±2 
AP (mmHg) 7.2±1.7 6.5±1.8 6.6±1.8 5.6±1.6  6.9±1.4 6.7±1.3 8.9±1.4 7.1±1.4† 
AGI (%) 22±5 20±5 21±5 18±5†  21±4 20±3 24±2 23±4 
AGI@75HR (%) 18±4 16±5 14±5 11±4  17±4 16±3 19±3 15±4† 
HR (bpm) 67±3 67±4 61±2 61±2  68±2 66±2 65±2 61±3† 
SEVR (%) 153±7 156±8 170±6 169±6  149±6 150±7 155±8 168±8†# 
TTI (mmHg.sec/min) 2137±91 2090±87 1945±71 1904±78  2430±84^ 2345±93 2297±112^ 2098±93† 
DTI (mmHg.sec/min) 3278±114 3179±136 3267±84 3183±103  3581±122 3457±97 3460±88 3465±116 
AoTr  (msec) 141±4 146±5 151±6 152±4  143±4 148±3 148±3 155±5 
cfPWV (m/s)  6.59±0.35 6.86±0.45 6.34±0.25 6.06±0.27†#  7.45±0.44*^ 7.44±0.36 7.93±0.58*^ 7.24±0.44†# 
crPWV (m/s) 8.29±0.32 7.97±0.37 8.33±0.32 7.65±0.39  7.76±0.22 7.64±0.24 7.93±0.40 7.98±0.36 
cIMT (mm) 0.61±0.03 0.63±0.03 0.58±0.02 0.58±0.02  0.69±0.06^ 0.67±0.04 0.70±0.04^*                               0.67±0.04 




















CCA W/L ratio 0.21±0.02 0.21±0.02 0.20±0.01 0.20±0.01  0.23±0.02 0.23±0.02 0.22±0.01 0.22±0.01 


















CCA WS (mmHg) 20±1 19±1 17±1 17±1  24±3^ 23±2 22±2^ 21±2 
CCA WT (kPa) 33±1 33±1 32±1 32±1  37±1^ 37±1 39±2^ 37±2 
b=brachial; c = central; SBP, systolic pressure; DBP, diastolic pressure; PP, pulse pressure; P1 H, aortic incident pressure wave; AP, aortic augmentation pressure; AGI, aortic augmentation index; 
AGI@75HR, aortic augmentation adjusted for heart rate; HR, heart rate; SEVR Subendocardial viability ratio;  TTI, Tension time index; DTI, Diastolic time index. AoTr, return of aortic reflective wave; 
cfPWV, carotid-femoral pulse wave velocity; crPWV, carotid-redial pulse wave velocity; Dc, carotid diameter in diastole; CCA W/L, common carotid artery wall to lumen ratio; CCA Strain, common carotid 
artery strain; CCA WS, common carotid artery circumferential wall stress, CCA WT, common carotid artery circumferential wall tension. FRS; Framingham Risk Score. Data presented as Mean ± SEM 
*p<0.05 compared to healthy control NonT group; ^ p<0.05 compared to healthy control ExT group; 
†p<0.05 compared to Pre-values within a group (Controls NonT, Controls ExT, MetS NonT, MetS-ExT) 
≠significant (p<0.05) group (e.g., MetS-NonT vs. MetS-ExT) by time (pre to post) interaction 
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Table 3: Differences in blood biomarkers pre and post intervention in MetS and controls 
 
 Controls NonT  Controls ExT  MetS NonT  MetS ExT 
 Pre Post Pre Post Pre Post Pre Post 
Total cholesterol, mg/dL  191±11 178±13 177±12 173±11 189±12 194±15 191±12 183±9 
Triglycerides, mg/dL 93±14 86±10 81±17 90±17 161±23*^ 173±18 115±16 130±17 
HDL, mg/dL 56±5 52±5 57±4 53±4 40±4*^ 38±3 50±5 47±4 
Glucose, mg/dL 94±3 89±3 92±3 94±2 97±1 96±2 98±2 96±3 
Insulin, µIU/mL 5.2±1.0 5.3±1.0 4.5±1.4 4.4±1.1 11.1±2.3* 11.8±2.3 9.8±1.4^ 11.5±2.5 
HOMA_IR 1.25±0.27 1.21±0.24 1.02±0.33 1.00±0.24 2.71±0.61*^ 2.83±0.58 2.37±0.34^ 2.68±0.57 
sE-Selectin, ng/ml 0.78±0.09 0.75±0.07 0.57±0.06 0.56±0.02 0.91±0.10 0.87±0.09 0.95±0.01 0.83±0.01 
sVCAM-1, ng/ml 7.7±1.8 8.6±1.9 6.4±1.4 5.5±1.2 7.3±1.4 7.2±1.3 6.0±1.5 5.5±1.3 
sICAM-1, ng/ml 3.5±0.9 3.4±0.8 4.4±0.7 4.2±0.7 4.0±0.6 3.8±0.6 5.0±0.7 5.1±0.9 
tPAI-1, ng/ml 1.2±0.1 1.1±0.1 1.2±0.3 1.0±0.2 1.4±0.2 1.4±0.2 1.2±0.2 1.3±0.2 
IL-6, pg/ml 1.3±0.4 1.4±0.4 1.3±0.4 1.0±0.3 4.3±1.9 2.3±0.3 3.1±1.1 3.0±0.8 
IL-8, pg/ml 3.2±1.0 3.7±1.0 2.8±0.6 2.4±0.5 5.1±0.8 4.8±1.2 4.1±0.9 4.0±0.6 
TNFα, pg/ml 5.3±1.1 5.5±1.5 3.2±0.4 2.8±0.3 5.3±0.9 5.0±0.9 5.5±0.6 6.0±0.8 
MMP-1, pg/ml 21±3 32±10 23±3 24±5 24±3 24±4 27±5 22±5† 
MMP-2, pg/ml 3452±429 3484±508 3962±202 3962±442 4263±427 4260±326 4383±405 3793±143 
MMP-7, pg/ml 648±61 629±60 705±139 674±138 543±48 571±64 893±215 789±202# 
MMP-9, pg/ml 849±145 656±111 751±77 635±100 853±121 741±55 858±95 879±141 
MMP-10, pg/ml 20±2 30±8 25±3 24±1 25±3 24±2 27±4 27±5 
TIMP-1, pg/ml 1459±711 1173±456 1533±544 1569±555 1245±205 1323±222 2273±581 2302±664 
TIMP-2, pg/ml 1585±836 1314±607 1794±655 1781±694 1290±233 1305±239 1824±470 1888±575 
*p<0.05 compared to healthy control NonT group; ^ p<0.05 compared to healthy control ExT group; 
†p<0.05 compared to Pre-values within a group (Controls NonT, Controls ExT, MetS NonT, MetS-ExT) 
≠significant (p<0.05) group (e.g., MetS-NonT vs. MetS-ExT) by time (pre to post) interaction 
Sample size for examining the effects of exercise training on blood biomarkers is noted below: 
    Adhesion molecules: Con NonT n=6; Con ExT, n=9; MetS NonT n=9; MetS ExT, n=9 
    Inflammatory markers: Con NonT n=6; Con ExT, n=10; MetS NonT n=9; MetS ExT, n=9 




Figure 1. Example of central pressure waveform. The systolic and diastolic 
pressures are the peak and trough of the pressure waveform. Augmentation 
pressure (AP) is the pressure added to the forward wave by the reflected wave 
(P1-P2), whereas augmentation index is the ratio between AP and central pulse 
pressure (PP = systolic - diastolic pressure). The dicrotic notch represents 
closure of the aortic valve and is used to calculate ejection duration (ED). Time to 
wave reflection is calculated at the point of rise in the initial ejection wave to the 
onset of the reflected wave. Travel time (Tr) represents the time taken for the 
forward pressure wave from the aorta to the reflection site and back. Systolic-to-
diastolic pressure shifts were assessed by the systolic (red shaded area) and 
diastolic (blue shaded area) pressure-time integrals. 
 
Figure 2. Relationship between peak aerobic capacity (VO2 peak) and arterial 
markers, namely carotid femoral pulse wave velocity (A), carotid intima medial 
thickness (B), augmentation pressure (C), and brachial (bSBP) and central 
(cSBP) systolic pressure (D).   
 
Figure 3. Relationship between the change (post- pre values) in peak aerobic 
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 Purpose: The metabolic syndrome (MetS) is associated with a three-fold 
increase risk of cardiovascular (CV) morbidity and mortality, which is in part, due to a 
blunted CV reserve capacity, reflected by a reduced peak exercise left ventricular 
contractility and aerobic capacity, and a blunted peak arterial-ventricular coupling. To 
date, no study has examined whether aerobic exercise training in MetS can reverse the 
peak exercise CV dysfunction. Further, examining how exercise training alters CV 
function in a group of individuals with Mets prior to the development of diabetes and/or 
overt CVD, can provide insights into whether some of the pathophysiological changes to 
the CV can be delayed/reversed, lowering their CV risk. The objective of this study was 
to examine the effects of 8 weeks of aerobic exercise training in individuals with MetS 
on resting and peak exercise CV function.  
 Methods: Twenty MetS underwent either 8 weeks of aerobic exercise training 
(MetS-ExT; n=10) or remained sedentary (MetS-NonT; n=10) during this time period. 
Resting and peak exercise CV function was characterized using Doppler 
echocardiography and gas exchange.  
 Results: Exercise training did not alter resting left ventricular diastolic or systolic 
function and arterial-ventricular coupling in MetS. In contrast, at peak exercise an 
increase in LV contractility (40%, p<0.01), cardiac output (28%, p<0.05) and aerobic 
capacity (20%, p<0.01), while a reduction in vascular resistance (30%, p<0.05) and 
arterial-ventricular coupling (27%, p<0.01), were noted in the MetS-ExT but not the 
MetS-NonT group. Further, an improvement in Lifetime Risk Score was also noted in 
the MetS-ExT group.  
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 Conclusions: These findings have clinical importance as they provide insight that 
some of the pathophysiological changes associated with MetS can be improved and 
lower the risk of CVD. 
 






















 The metabolic syndrome (MetS) is a cluster of metabolic risk factors 
(abdominal obesity, elevated blood pressure and glucose, and dyslipidemia) that exerts 
a three-fold increased risk of cardiovascular disease (CVD) mortality compared to non-
MetS individuals [1]. Alarmingly, the prevalence of MetS in US adults is 34% and is on 
the rise due, in part, to rising rates of obesity [2]. MetS has become a leading health 
concern because of its strong association with future myocardial/cerebral vascular 
events and CVD mortality [1].  
 The MetS-associated pathophysiological changes to the CV system contribute to 
the increased CVD risk. Such changes include an increase in arterial dysfunction 
(increased arterial stiffness, and endothelial dysfunction), left ventricular (LV) 
hypertrophy, and impaired CV reserve capacity [3-5]. In particular, individuals with MetS 
demonstrate an impaired coupling between the heart and arterial system [5]. This 
interaction, termed arterial-ventricular coupling (Ea/Ees), is an important determinant of 
net CV performance [6] and cardiac energetics [7]. Ea/Ees is indexed by the ratio of 
effective arterial elastance (Ea; a measure of the net arterial load imposed on the left 
ventricle) to left ventricular end-systolic elastance (Ees; measure of LV chamber 
performance) [6]. Impaired Ea/Ees is most readily evident when the CV system is under 
stress and/or with increasing age [8]. For example, in MetS, the ability to reduce the 
Ea/Ees ratio is blunted during aerobic exercise [5]. Further, this impaired coupling 
response coincides with a reduced peak aerobic capacity in MetS [5], which has been 
proposed to be an independent predictor of mortality relative to other risk factors [9]. 
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 In healthy older individuals, exercise training has been shown to increase aerobic 
capacity, improve peak LV performance (smaller end-systolic volume and increased 
stroke volume), and increase LV contractility [10, 11]. In patients with coronary artery 
disease, Ea/Ees during handgrip isometric exercise was improved after exercise 
training. It is unknown whether exercise training in people with MetS (prior to the 
development of diabetes or overt CVD) can improve peak exercise LV-arterial coupling 
and CV function. An improvement in Ea/Ees and CV function in MetS would likely reflect 
a lower CVD risk. Thus, the objective of this study was to examine the effects of 8 
weeks of exercise training on peak exercise arterial-ventricular coupling in clinically 
defined MetS patients without diabetes or clinical indications of CVD. We hypothesized 
that aerobic exercise training would improve peak Ea/Ees in MetS due to an 


















Study Population  
 Twenty MetS subjects free from overt CVD and diabetes as determined by a 
detailed medical history, physical examination, and a normal resting and exercise 
electrocardiogram participated in this study. MetS was defined according to the updated 
National Cholesterol Education Program: Adult Treatment Panel III  comprised of three 
out of the following five components: 1) obesity (waist men >102 cm, women >88 cm); 
2) low HDL cholesterol (men<40 mg/dL; women<50 mg/dL); 3) hypertriglyceridemia 
(≥150 mg/dL); 4) elevated glucose (≥100 mg/dL & <126 mg/dL), and; 5) elevated BP 
(130/85 mmHg or use of hypertensive medications).  
Exclusion criteria included diabetes mellitus (HbA1c ≥6.5 % or use of diabetic 
medications), pulmonary disease, angina, atrial fibrillation, aortic stenosis, anemia, 
myocardial infarction, stroke, or coronary revascularization as assessed by a detailed 
medical history physical examination and a resting and exercise electrocardiogram. 
Subjects who participated in regular exercise, defined as >30 minutes, 3 times/week 
were excluded. All subjects provided written informed consent to participate that was 
approved by WVU Institutional Review Board.  
 
Study Design 
 Physiological assessments were performed between 7:00-10:00 AM, in a quiet, 
temperature-controlled room, after a 12 hour fast and abstinence from alcohol, caffeine, 
and vitamins. CV medications were withheld 24 hours prior to assessments. After a 
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minimum 15 minutes of quiet rest subjects underwent resting non-invasive assessments 
of arterial and cardiac structure and function.  
 
Exercise Performance 
 Following assessment of resting CV measurement, subjects exercised to 
exhaustion on a modified cycle ergometer (Monarch 827, Sweden) equipped with a car 
seat to allow semi-recumbent exercise in seated upright position at approximately 130 
degrees. This upright position is necessary and important to allow acquisition of optimal 
echocardiographic images during exercise. Throughout exercise the echo images were 
acquired approximately 60-90 seconds into each 3-minute exercise workload. If all 
images were not acquired within the time frame the duration of the exercise stage was 
extended to acquire those images. Pedal speed was maintained at 50 rpm, and 
workloads increased by 25 W every 3 minutes until exhaustion. Oxygen consumed 
(VO2), carbon dioxide produced (VCO2), respiratory exchange ratio (RER=VCO2/VO2), 
ventilation (Ve), ventilatory threshold (VT), and the ventilatory equivalent for CO2 
(Ve/VCO2) were measured throughout exercise using a metabolic cart (TureOne 2400, 
ParvoMedics, Sandy, UT). Subjective symptoms of fatigue (BORG score 6 to 20), and 
blood pressure (sphygomomanometry) were recorded at the end of each workload.  
 
Rest and Exercise Echocardiography 
 Echocardiograms were obtained using a GE Vivid i (GE Healthcare, Chalfont St. 
Giles, United Kingdom), portable ultrasound imaging system with a 5S-RS (2.0-5.0 
MHz) Wideband Phased Array transducer. All echocardiograms were performed by 
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experienced registered diagnostic cardiac sonographers. At rest, standard 2-
dimensional images were obtained in the following acoustic views; parasternal long 
axis, and apical 4 chamber view. Pulsed wave Doppler tracings of the mitral valve inflow 
velocity (recorded at the leaflet’s tips) were recorded in the apical 4 chamber view. 
Continuous/pulse wave Doppler tracings of the LV outflow track velocity were obtained 
in the apical 5 chamber view positioned 5 mm proximal to the aortic valve. Spectral 
tissue Doppler imaging was performed in the apical 4 chamber view with the gate 
sample positioned in the lateral corner and septal side of the mitral annulus. During 
exercise, the sonographer quickly acquired a 2-dimensional image of the parasternal 
long axis view to obtain the size of the LV outflow tract diameter (base of the aortic 
leaflets). The sonographer then focused on capturing: 4-chamber views to obtain 
cardiac volumes and mitral flow velocities; and 5-chamber views to obtain pulse-and 
continuous-wave Doppler-flow from the LV outflow track.  
 
Left Ventricular Geometry and Remodeling 
 In the supine position, LV dimensions, wall thickness, and chamber volumes 
were determined in triplicate from 2-dimensional, M-mode, and Doppler spectra 
echocardiography using standard methods [12]. Sex-specific LV hypertrophy (LVH) and 
geometry patterns, based on LV mass index and relative wall thickness were defined as 
LV mass index >95 g/m2 for women or >115 g/m2 for men, and LV geometry was 
classified as normal, concentric remodeling, concentric LVH, or eccentric LVH [12]. 
 
Arterial-Ventricular Measurements  
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 In the upright, seated rest position and during exercise, LV end diastolic (EDV) 
and end-systolic (ESV) volumes, along with ejection fraction (EF) were determined from 
Simpson’s biplane method [12]. Cardiac volumes were normalized to body surface area 
(BSA). Cardiac index (Ci) was determined from the product of heart rate (HR) and 
stroke volume index. Peak arteriovenous oxygen extraction was calculated from the 
Fick equation (VO2peak/cardiac output). Systemic vascular resistance index (SVRi) was 
calculated as mean arterial pressure (MAP) × 80/Ci. The indexes of arterial and 
ventricular elastance were calculated as; 1) arterial elastance (Ea) a measure of the net 
arterial load, was calculated as end-systolic pressure (ESP)/stroke volume (SV), where 
ESP is approximated as 0.9 × systolic blood pressure (SBP)[6]. Of note, ESP calculated 
as 0.9 × SBP has previously been shown to closely approximate central ESP [13]; 2) LV 
end-systolic elastance (Ees [calculated from BP, stroke volume, EF, and pre-ejection 
and systolic ejection time intervals from LV outflow Doppler]), was determined by the 
validated single-beat technique [14]; and 3) Arterial ventricular coupling ratio was 
determined from Ea/Ees [6]. Of note, Ea/Ees is mathematically related to EF via the 
formula Ea/Ees = (1/EF)-1. Reserve was defined as the difference in these variables 
between seated rest and peak exercise.  
 
Diastolic Function 
 In the supine position, the medial mitral annular early diastolic velocity (e’) was 
determined by spectral tissue Doppler imaging (GE Vivid i) using standard methods. 
Early (E-wave) and late (A-wave) transmitral flow velocities, the isovolumetric relaxation 
time (IVRT), and the deceleration time of early filling velocity (Dec T) were measured by 
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pulsed-wave Doppler (GE Vivid i). End-diastolic pressure was estimated as EDP = 
11.96 + 0.596 × E/e’ [15]. Because of the high incidence of fusion of the E- and A-wave 
during moderate/high intensity exercise, with the A-wave dominating, we are not able to 
measure Dec T- or E-wave. Therefore we were limited to measuring peak exercise 
IVRT and A-wave.  
 
Body Anthropometry 
 Height, weight, and waist and hip circumference were measured using standard 
laboratory procedures. Fat distribution was assessed by measuring the waist 
circumference at the site of the smallest circumference between the rib cage and the 
iliac crest with subjects in a standing position. Hip circumference was measured at the 
site of the largest circumference between waist and thighs. Lean body mass and fat 
mass were measured using air displacement plethysmography (BodPod, COSMED Inc., 
USA). During assessment of body composition subjects wore close-fitting bathing suits 




 Venous blood sampling was obtained in the morning after a 12-hour overnight 
fast. Post training venous samples were collected at least 48 hours after the last 
exercise session. Plasma obtained from blood sampling was analyzed at West Virginia 
University Hospital’s central laboratory in Morgantown, West Virginia. Total cholesterol, 
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high-density lipoprotein (HDL) cholesterol, triglycerides, and glucose were determined in 
plasma (lithium heparin, Becton Dickenson Plasma Separator Tubes) using Beckman-
Coulter (CA, USA) DxC automated chemistry analyzers. Total cholesterol was 
measured using a cholesterol esterase/cholesterol oxidase/peroxidase-driven, timed-
endpoint method (Coefficients of Variation <7%). HDL cholesterol was measured using 
a cholesterol esterase/cholesterol oxidase/peroxidase-driven, timed endpoint assay with 
automated initial homogeneous solubilization step (Coefficients of Variation <7%). 
Triglycerides were measured using a lipase/glycerol kinase/glycerophosphate 
oxidase/horseradish peroxidase-driven, timed-endpoint method (Coefficients of 
Variation 5-7%). Glucose was measured electrochemically using a glucose 
oxidase/catalase/molybdate-driven oxygen rate method (Coefficients of Variation <5%). 
Glycated hemoglobin (A1c fraction) was measured in whole blood (K2-EDTA, Becton 
Dickenson) using a BioRad (Hercules, CA, USA) Variant II Turbo High Performance 
Liquid Chromatography (HPLC) system (Coefficients of Variation <2%). Insulin was 
measured in serum (untreated/red-top tube, Becton Dickenson) on an Immulite 2000 
immunochemistry system (Siemens, USA; Coefficients of Variation <10%). 
Homeostasis model assessment of insulin resistance (HOMA-IR) was estimated with 
the following formula: insulin resistance = fasting plasma insulin (in microunits per 
millileter, μU/mL) × fasting plasma glucose (FPG, in millimoles per liter, mmol/L) / 22.5.  
 
Training Intervention  
 MetS were assigned into either an 8 week aerobic exercise intervention group 
(MetS-ExT) or an 8 week non-exercise control (MetS-NonT) group. Group assignments 
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were made using a pseudo-random balance approach to ensure equal numbers 
enrolled in each group. The MetS-NonT exercise group (n=10; 50% female) were asked 
to maintain their normal sedentary lifestyle.  The MetS-ExT group (n=10; 70% female) 
performed 8 weeks of supervised aerobic exercise in the Human Performance Lab at 
West Virginia University School of Medicine, 3 times per week for 60 minutes at a fixed 
exercise intensity. The intensity of prescribed exercise was based on individual results 
of maximal cardiopulmonary exercise tests. We used a ramp exercise protocol, whereby 
exercise training intensity started at 60% of heart rate reserve (heart rate range 
determined during exercise stress test) and increased every 2 weeks by 10%; from 
weeks 6-8 heart rate reserve was set at 85%. Adherence to the exercise prescription 
was documented through the use of wrist watch-style heart rate monitors (E600, Polar 
Electro OY, Oulu, Finland) and physical activity logs. Approved modalities included 
treadmills, elliptical machines, and cycle ergometers. All participants were instructed to 
maintain current eating behaviors for the duration of the 8-week intervention. All post-
training measurements were performed 24-48 hours after the last exercise training 
session to avoid the immediate effects of a single bout of exercise. Measurements 
made before and after exercise training were obtained at the same time of day for each 
subject.   
 
Lifetime Risk Score for CVD 
 The Lifetime Risk Score is a strong predictive capacity for future CV mortality and 
is based on an algorithm that incorporates sex (male/female), age (years), SBP 
(mmHg), diabetes mellitus (yes/no), total cholesterol (mg/dL), smoking (yes/no), BMI 
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(kg/m2), and physical fitness (Metabolic equivalent; 1 MET = 3.5 ml/kg/min) [16, 17]. 
Calculation of the score is available using a web-based interface (www.lifetimerisk.org).  
 
Statistical Analysis 
 Measurements of CV function were performed offline by a single investigator who 
was blinded to group allocation. The intra-class correlation coefficient (ICC) and 
coefficient of variations for all echocardiographic variables were derived in a subset of 
subjects (n=8). At rest, the ICC and the coefficient of variation for all variables, collected 
on two separate days, was >0.80 or between 7-12%, respectively. Similar results were 
obtained for echocardographic variables evaluated during peak exercise with all 
variables having an ICC>0.80 and coefficient of variation between 7-12% with the 
exception of the arterial-ventricular coupling ratio (ICC=0.63).  
 Normality was evaluated by the Kolmogorov-Smirnov test. Continuous variables 
were log transformed as necessary. To evaluate the effects of exercise training, paired 
t-tests and two-way repeated-measures ANOVA were used. We also ran a mixed 
effects models with a time-varying covariate to examine whether the change (pre vs 
post training intervention) in CV parameters where due to changes other CV 
parameters. All analyses were performed with the statistical package SPSS version 21 
(SPSS, Chicago, IL). Values shown in the tables represent means ± SEM unless 












 Age, anthropometric, and metabolic characteristics of MetS individuals are 
shown in Table 1. The breakdown of metabolic components were: 100% had a waist 
circumference >102 cm (men) or >88 cm (women); 75% had elevated BP 
(130/85 mmHg or use of hypertensive medications); 70% had a low HDL cholesterol 
(men<40 mg/dL; women<50 mg/dL); 30% had hyper-triglyceridemia (≥150 mg/dL); and 
50% had elevated glucose (≥100 mg/dL). In terms of LV remodeling, 15% had normal 
LV geometry and concentric remodeling, 50% had eccentric LV hypertrophy, and 20% 
had concentric LV hypertrophy. 
 
Effects of Exercise Training on Metabolic Profile, Body Composition, and LV Geometry  
 Eight weeks of exercise training did not alter basal fasting HbA1C, glucose, 
insulin, HDL, triglycerides, or HOMA-IR (Table 1). Further, exercise training was 
insufficient to significantly alter body composition (weight, lean mass or percent body 
fat), LV mass (in absolute terms and relative to BSA), the internal LV dimensions 
(internal diameter, septal and posterior wall thickness), and relative wall thickness in 
MetS (Table 2).  
 
Effects of Exercise Training on LV Diastolic Function 
 Resting LV diastolic function (i.e., E-wave, A-wave, E/A ratio, IVRT, Dec T, E/e' 
and EDP) was not affected by 8 weeks of exercise training in MetS (Table 2). During 
exercise we were limited to examining changes in components of LV diastolic function 
namely IVRT, and A-wave. No significant differences in peak IVRT (MetS-ExT; 16±1 vs. 
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16±2; Non-T; 15±1 vs. 15±2), and A-wave (MetS-ExT; 1.38±0.06 vs. 1.28±0.11; Non-T; 
1.48±0.08 vs. 1.53±0.06) were found in either MetS-ExT or Non-T pre and post 
intervention. 
 
Effects of Exercise Training on Arterial Ventricular Coupling 
 Exercise training in MetS did not alter resting Ea/Ees, Ea, or Ees (Figure 1). 
Further, with the exception of resting SVRi which was lower in the MetS-NonT, no 
differences in resting CV function were evident in either MetS group (Table 3). There 
were no significant time (pre and post) by group (MetS-ExT vs. NonT) interactions at 
rest for any CV parameter. 
 At peak exercise, aerobic training in MetS lowered peak Ea/Ees (-27%, p<0.01) 
by increasing peak Ees (+40%, p<0.01) and no change in peak Ea in MetS-ExT (Figure 
1). In contrast, peak Ea/Ees, Ea, and Ees did not significantly differ between pre and 
post visits in MetS-NonT. Similarly, peak EF, and Ci were significantly (p<0.05) 
increased, and peak ESVi and SVRi were reduced (p<0.05) after exercise training in 
MetS-ExT, whereas no differences were found in MetS-NonT (Table 4). Furthermore, 
significant time (pre and post) by group (MetS-ExT vs. NonT) interactions for peak 
Ea/Ees, Ees, EF, and SVRi were evident.  
 Exercise capacity, in both absolute (L/min) and relative (ml/min/kg of body mass 
or lean mass) terms was improved in MetS after 8 weeks of exercise training as 
reflected by a 19-20% increase (p<0.01) in VO2peak and a 4% increase (p<0.05) in 
Ve/VCO2 (Table 4). Of note, a time (pre and post) by group (MetS-ExT vs. NonT) 
interaction for VO2peak was identified despite no differences in the respiratory exchange 
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ratio, or perceived rate of exertion, in either MetS group. Further, no differences in peak 
arteriovenous oxygen difference were evident pre or post intervention in MetS (Table 4). 
Taking all individuals into consideration, an initial relationship between pre-intervention 
values for Ea/Ees delta (max-rest) and VO2peak (r=-0.58, p<0.01) was found. We then 
examined whether the difference in Ea/Ees delta from visit 1 and visit 2 was correlated 
with the change from visit 1 and 2 in VO2peak, however this relationship did not reach 
statistical significance (r=-0.40, p=0.09). In a stepwise mixed model approach with 
repeated measures and a time-varying covariate, we found that Ea/Ees delta 
contributed towards 16% of the variance on the effects of exercise training on peak 
VO2. 
 
Lifetime Risk Score 
 In the MetS-ExT group, the Lifetime Risk Score was significantly reduced 
(20±7% to 16±6%, p=0.01) after training, whereas in the MetS-NonT group no 
difference was found (13±2% vs. 13±2%, p=0.8). Further, we identified a significant 











 This is the first study to examine the effects of aerobic exercise training on peak 
arterial-ventricular coupling in patients with the MetS. We report that following 8 weeks 
of aerobic exercise training, peak arterial-ventricular coupling, peak LV contractility and 
aerobic capacity were significantly improved and similar to levels noted in healthy 
untrained controls [5]. Our unique patient population afforded the opportunity to assess 
whether exercise training can reverse impaired CV function reported in MetS patients 
prior to a diagnosis of CVD and/or diabetes. Since MetS is believed to be a harbinger in 
the pathogenesis of diabetes and CVD, these data provide evidence that exercise 
based interventions at this critical (preclinical disease) time point may help to reverse 
the pathophysiological progress of CVD, and/or delay the progression to overt CVD 
and/or diabetes. 
 The MetS is associated with pathophysiological changes to the CV system 
associated with an increased CVD mortality risk. Recently we reported that resting LV 
systolic function was well preserved in MetS patients who clearly manifested the 
symptoms of the metabolic disorder (including hypertension, insulin resistance, and 
hyperlipidemia) but who are free from overt CVD and/or diabetes [5]. Conversely, in this 
same population we observed LV remodeling, LV hypertrophy and reduced LV diastolic 
function at rest [5]. The progression from MetS to T2DM is characterized by additional 
LV enlargement and LV diastolic dysfunction, with evidence of LV systolic dysfunction 
and related sympathetic alterations [18]. In our MetS population, exercise training was 
unable to reverse the LV structural changes or impairments in LV diastolic function. The 
lack of an observed effect of exercise training on LV mass is likely due to the duration of 
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the exercise stimulus (8 weeks). Indeed, an intervention consisting of several months of 
aerobic training was found to be sufficient to exert physiological LV remodeling [19], 
reduce LV wall thickness, and reduced LV wall thickness-to-radius ratio [20]. To what 
extent exercise training can improve LV diastolic function by improving the compliance 
of the heart remains controversial. Two recent studies examining a full year of exercise 
training, in MetS patients without T2DM or CVD [21] and healthy senior individuals [19], 
found no significant improvements in resting LV diastolic function. Advancing age and 
the development of CVD induce structural and functional alterations to the heart that is 
reflected by a reduction in the number of cardiomyocytes, an increase in connective 
tissue volume, and an increase in the formation of advanced glycation end products, 
which collectively result in impairment of LV diastolic function [22]. Data would suggest 
that once these cross-linked collagen proteins are formed they are pathologically 
irreversible. Thus, any potential improvements in LV diastolic function to be gained from 
exercise training may be limited by cross-linked collagen [19]. 
 The coupling between the heart and arterial system is an important and largely 
underappreciated determinant of cardiac performance and energetics [6]. At rest, the 
coupling ratio is well maintained around 0.7-1.0 to optimize CV efficiency. This ratio is 
preserved with advancing age and in patients with heart failure [8, 23]. Indeed, we have 
also recently shown that resting Ea/Ees is around 0.9 in MetS patients [5]. In this study, 
exercise training in MetS did not alter resting Ea/Ees, or its components. While resting 
Ea/Ees is fairly well conserved, the ability of the CV system to respond to stress, in 
particular exercise, is blunted with age, and in heart failure patients [8, 24]. We have 
previously shown that the Ea/Ees response to exercise is significantly impaired in MetS 
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patients [5], which is, in part, due to impaired LV contractility and a blunted peripheral 
vasodilatory response to exercise [5]. Importantly, this study indicates that 8 weeks of 
exercise training is sufficient to increase the peak LV contractile response and improve 
peak exercise Ea/Ees in MetS patients, as direct result of improved peak Ees.  
 Although we have shown that arterial-ventricular coupling is improved after 
exercise training in middle-aged individuals with MetS, it is also important to identify 
whether older individuals with MetS would have the same beneficial effects of exercise 
training. In older (age >60 years) healthy individuals, peak exercise cardiac function is 
typically improved, at least up to the 7th decade, after exercise training depicted by 
increases in Ci, SV, EF, LV contractility, and VO2peak [25-28]. Future research should 
establish to what extent older individuals with MetS demonstrate improvements in 
arterial and cardiac function after exercise training. This is especially important given 
that the presence of MetS with older age is often accompanied by CVD (i.e., T2DM, 
coronary artery disease, etc.), and with increased formation of cross-linked advanced 
glycation end products in the LV and arterial walls, which may limit the physiological 
responses to exercise training [29]. 
 A blunted Ea/Ees response during exercise has been shown to correspond with 
a decrease in VO2peak in MetS [5] and heart failure [24] patients. An inverse relationship 
has also been reported between VO2peak and Ea/Ees during exercise [30], which was 
confirmed in our study. In addition, acute infusion of verapamil improved arterial-
ventricular coupling and resulted in a corresponding improvement in exercise capacity 
[31]. These data suggest a direct link between Ea/Ees and aerobic capacity, in that an 
improvement in the coupling likely results in a more effective transfer of blood from the 
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heart to periphery thereby increasing functional reserve capacity. Indeed, in the 
presence of a stiffer heart there is a greater change in BP for a given change in volume, 
which in a closed-system, can amplify the BP response and impair net cardiac ejection 
[31]. In the current study, we found an increase in peak SV without a significant change 
in BP suggesting a more compliant cardiac response after exercise training. Further, the 
improvement in peak Ea/Ees was accompanied by a 20% increase in VO2peak, and that 
the change in Ea/Ees seemed to contribute (≈16%) towards the improved VO2peak. 
Given that aerobic capacity is determined by both central (HR and SV) and peripheral 
factors (skeletal muscle mass, calcium cycling, mitochondria capacity, capillary density, 
etc.), it is likely that the improved coupling, along with other physiological adaptations 
that were not examined in our study, contributed towards the improved VO2peak in MetS 
after exercise training. Indeed, Tjonna et al. [32] observed a 16% and 36% increase in 
VO2peak after 16 weeks of either continuous aerobic exercise or high intensity aerobic 
interval training in MetS, respectively. It was suggested that enhanced skeletal muscle 
capacity (improved calcium cycling and mitochondria capacity) contributed to the 
exercise-induced improvement in VO2peak [32]. Although, we did not directly measure 
skeletal muscle oxidative capacity or oxygen extraction, these responses to exercise 
training have been reported elsewhere [32, 33]. In contrast to these findings, we did not 
observe an improvement in peak arteriovenous oxygen difference (estimated from the 
Fick equation) after 8 weeks of exercise training in MetS, suggesting that muscle 
adaptation played a minor role in the reported improvements in aerobic exercise 
capacity in our patients. The effects of exercise training on improving peak 
arteriovenous oxygen difference in other populations are mixed with some reporting no 
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changes [19, 28] and others showing an increase [26, 34]. This lack of change may be 
related to the intensity of exercise training, whereby an increase arteriovenous oxygen 
difference was reported after high-intensity exercise training, but not after low-intensity 
training [26]. An increase in exercise intensity and duration may be required to increase 
peripheral oxygen extraction in individuals with MetS. Further, research is needed to 
clarify the relationship between Ea/Ees, and VO2peak. 
 The improvement in LV contractility during exercise may have been due, in part, 
to an increased stroke volume, a decreased afterload, and improved arterial-ventricular 
coupling. Indeed, improvements in peak exercise SVi and ESVi were reported in MetS 
after exercise training. Similar improvements in cardiac volumes have been reported 
after exercise training in older sedentary individuals [10, 19]. Improved peak LV 
performance post exercise training is unlikely to be due to enhanced myocardial β-
adrenergic responses, as chronic exercise training has not been reported to alter β-
adrenergic function [35]. However, exercise training has been shown to improve calcium 
handling in experimental animal models, thereby improving cardiomyocyte function [36]. 
Accordingly, improvements in calcium handling may have contributed to the 
improvement in LV contractility noted in MetS. The enhanced ability of the LV to empty 
as fitness increases may relate to a reduction in arterial stiffness/afterload in the 
conditioned state [37]. However, following 8 weeks of exercise training, no 
improvements in Ea during exercise were reported in MetS. In contrast, a significant 
reduction in peak vascular resistance was established in the exercise trained MetS 
patients. Ea is an integrative index that incorporates the principal elements of arterial 
load, including systemic vascular resistance, total arterial compliance, characteristic 
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impedance, and systolic and diastolic time intervals. Ea is therefore regarded a 
measure of the net arterial load that is imposed on the LV [6]. Thus, the lack of change 
in Ea does not necessarily indicate that specific components of arterial load where not 
improved at peak exercise after training. This was clearly evident with the improvement 
in peak SVRi. Further, the improvement in SVRi or the lack of change in Ea, were not 
attributed to the slight changes in peak HR noted in the control group, as evident by 
similar findings after adjusting for HR as a time-vary covariate in a mixed effects model. 
Whether the improvement in SVRi at peak exercise is due to release of vasodilators 
causing vascular relaxation remains to be elucidated. Improvements have also been 
noted in resting endothelium-dependent vasodilatation in obese and MetS patients after 
exercise training [32]. Accordingly, despite the lack of change in Ea, peak arterial 
function may have been improved in MetS, thus contributing to an improved aerobic 
capacity. 
The beneficial CV effects at peak exercise attributed to exercise training were not 
a reflection of a change in body fat or lean mass. However, numerous studies have 
reported that regular moderate intensity exercise can result in reductions in weight and 
fat mass [38, 39]. Thus, the lack of change in body composition in our study is likely due 
to the short duration of exercise training (8 weeks). Further, clinical metabolic 
biomarkers (HDL, triglycerides, glucose, etc.) remained unchanged. Although we did not 
find improvements in body composition or clinical blood biomarkers after training in 
MetS, we believe that improvements in peak CV function and aerobic capacity reflect a 
reduction in CV risk in MetS patients. A strong association exists between aerobic 
capacity and mortality with a positive correlation between improvements in aerobic 
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capacity and an improved prognosis [40]. A relationship that seems to be more robust 
than the relationship between weight loss and mortality [41]. For example, for each MET 
(3.5 ml/kg/min) increase in exercise capacity confers a 12% improvement in survival [9]. 
The average increase in peak VO2 (ml/kg/min) in the MetS-ExT group was 3.2 
ml/kg/min, suggesting an improvement in survival. Further, the Lifetime Risk Score in 
MetS-ExT was significantly reduced by 4%, and the Lifetime Risk Score was inversely 
correlated with peak VO2. However, to fully prevent the progression to overt CVD and/or 
diabetes, and the pathophysiological changes to the CV system that accompanies this 
transition, persistent physical activity in combination with a nutritional dietary regimen 
(that includes optimal vitamin/mineral consumption) is required. 
 
Study Limitations 
 There are several limitations. First, the sample size for our training and non-
training group is modest (n=10 in each). Although we find significant differences in peak 
Ea/Ees, this was due principally to a significant change in peak Ees (p<0.05 with 
statistical power >0.75), but we were underpowered in our statistical power for Ea 
(power=0.10). While it is evident that we have sufficient power in those CV variables 
where significance was observed, we cannot exclude the possibility of a type II 
statistical error (i.e. that we have falsely accepted the null hypothesis) in the CV 
variables that we not-significantly different where power was low. Therefore, these data 
should be regarded as preliminary until we, or others can obtain data on a larger 
population sample. In the current study, we examined the effects of exercise training on 
Ea (net arterial load) as our arterial function parameter. Although it is important to study 
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the interaction between the heart and arterial system in the same domain (i.e., 
elastance), measuring specific aspects of arterial function such as characteristic 
impedance, arterial stiffness (via pulse wave velocity), and intima medial thickness 
would provide additional insights into the beneficial effects of exercise training in MetS. 
Further, sex differences in the effects of exercise training on LV stiffness may have 
gone undetected given the small number of male vs. female subjects. Future research 
should examine whether there are sex-related differences in the coupling response, at 
rest and during exercise, after exercise training. 
Second, pressure and flow were not directly measured, but rather estimated from 
non-invasive surrogates. However, the methods we used have been previously 
validated against invasive hemodynamic measurements [14]. Our peak cardiac data 
may be underestimated due to a systematic underestimation of LV volumes from 2-D 
echocardiography [42, 43] and the challenge of acquiring echocardiograhic images 
during exercise. However, the technique we used has been successfully used by others 
[24, 44], and similar values have been observed suggesting fidelity in our data.  
 Third, we were limited in our ability to comprehensively characterize the extent of 
diastolic function during exercise because the focus of this study was to examine the 
impact of exercise training on peak exercise Ea/Ees and LV systolic function, and 
therefore echocardiographic views were optimized to examine systolic function. Further, 
the acquisition of LV diastolic parameters during exercise is challenging. Thus, we 




Fourth, peak arteriovenous oxygen difference was not measured but rather it was 
estimated using the Fick equation (VO2 divided by cardiac output). The Fick technique 
has been used to calculate arteriovenous oxygen difference in number of recent 
physiologic studies investigating mechanisms of exercise intolerance [45, 46]. Our peak 
arteriovenous oxygen difference values were somewhat higher than reported by others 
[45], possibly due to underestimation of cardiac output. Most importantly, because key 
variables were measured at all testing times using identical methods in both groups, 
and because we assessed changes in reserve capacity (peak values – resting values) 
within individuals, comparisons of cardiac output and estimated arteriovenous oxygen 
difference between groups are valid.  
 Lastly, the short duration of exercise training (8 weeks) may have been 
insufficient to alter cardiac structure, body composition, and metabolic blood 
biomarkers. Thus, longer exercise training programs that incorporate different exercise 
modalities (interval, aerobic, and resistance training) are important to fully understand 




 In conclusion, 8 weeks of aerobic exercise training of moderate-to-high intensity 
significantly improved peak exercise arterial-ventricular coupling, LV contractility, 
peripheral vascular resistance, and aerobic capacity in MetS individuals without overt 
CVD and Type 2 Diabetes. However, no improvements were evident in resting LV 
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Table 1. Effects of exercise training on body composition and metabolic biomarkers in 
MetS 
 MetS non-trained (n=10)  MetS trained (n=10)  
 Pre  Post  Pre  Post  
Age, years  43 ± 3  48 ± 3  
Sex, female % 60  70  
Height, cm  171 ± 3  168 ± 3  
Weight, kg  99  ±  7  99  ±  7  105  ±  6  105  ±  6  
Lean Mass, kg  64  ±  4  64  ±  4  59  ±  5  59  ±  2  
Body fat, %  35  ±  2  35  ±  3  43  ±  3† 43  ±  2†  
BSA, m2  2.10  ±  0.08  2.10  ±  0.09  2.13  ±  0.07  2.12  ±  0.07  
BMI, kg/m2  34  ±  2  34  ±  2  37  ±  2  37  ±  2  
Waist 
circumference, cm  
104  ±  3  103  ±  5  124  ±  10  122  ±  10  
Triglycerides, mg/dL  149  ±  21  169  ±  20  116  ±  17  140  ±  24  
HDL, mg/dL  41  ±  4  40  ±  2  47  ±  5  45  ±  4  
Glucose, mg/dL  98  ±  2  97  ±  3  99  ±  3  97  ±  3  
HbA1c, %  5.7  ±  0.1  5.5  ±  0.1  5.7  ±  0.1  5.6  ±  0.1  
Insulin, µIU/mL 10.4  ±  2.4  10.7  ±  2.2  9.0  ±  1.5  9.0  ±  1.8  
HOMA-IR  1.34  ±  0.30  1.27  ±  0.30  1.23  ±  0.19  1.45  ±  0.34  
Hypertensive 
(>140/90) % 
70  60  
Diabetes Mellitus % 0  0  
Medications, %             
     Hypertension 20  30  
     Cholesterol 0  10  
Values are mean ± sem; BSA: body surface area; BMI: body mass index; HDL: high 
density lipoprotein; HbA1c: hemoglobin A1c; HOMA-IR: homeostatic model assessment 
of insulin resistance.  
†p<0.05 vs, MetS non-trained group at specific visit (i.e., Pre or Post)  








Table 2: Effects of exercise training on supine left ventricular geometry and diastolic 
function in MetS 
 
 MetS non-trained (n=10)  MetS trained (n=10)  
 Pre  Post  Pre  Post  
LV geometry             
  Septal wall 
thickness, cm 
0.95  ± 0.05  0.96  ± 0.06  0.92  ± 0.06  0.92  ± 0.05  
  Posterior wall 
thickness, cm 
0.87  ± 0.06  0.89  ± 0.06  0.86  ± 0.07  0.93  ± 0.06  
  LV internal 
dimension, cm 
4.41  ± 0.13  4.38  ± 0.16  4.73  ± 0.16  4.67  ± 0.12  
  LV Mass, g 161  ± 8  164  ± 11  181  ± 21  187  ± 16  
  LV Mass Index, 
g/m2  
77  ± 3  78  ± 3  84  ± 9  88  ± 6  
  Relative Wall 
Thickness 
0.40  ± 0.03  0.42  ± 0.04  0.36  ± 0.03  0.40  ± 0.02  
LV diastolic function             
  E, m/s 0.75  ± 0.03  0.75  ± 0.04  0.88  ± 0.05  0.92  ± 0.06  
  A, m/s 0.64  ± 0.03  0.60  ± 0.04  0.77  ± 0.07  0.74  ± 0.07  
  E/A ratio 1.21  ± 0.07  1.29  ± 0.07  1.24  ± 0.14  1.32  ± 0.13  
  IVRT, m/s 76  ± 5  71  ± 5  75  ± 8  61  ± 5  
  Dec T, m/s 203  ± 12  204  ± 14  193  ± 9  175  ± 8  
  e’, m/s 0.12  ± 0.01  0.13  ± 0.01  0.11  ± 0.01  0.11  ± 0.01  
  E/e’ 6.20  ± 0.26  6.21  ± 0.46  9.28  ± 1.05  9.13  ± 1.18  
  LV EDP, mmHg 16  ± 1  16  ± 1  18  ± 1  17  ± 1  
Values are mean ± SEM; E: peak velocity of the early diastolic mitral flow; A: peak velocity 
of the late diastolic mitral flow; E/A: E divided by A; IVRT: isovolumetric relaxation time; Dec 
T: mitral flow deceleration time of early filling velocity; e’: mitral annular early diastolic 
velocity; E/e’: E divided by e’; LV EDP: left ventricular end-diastolic pressure. Of note no 








Table 3. Effects of exercise training on cardiovascular function in MetS 
 MetS non-trained (n=10)  MetS trained (n=10)  
 Pre  Post  Pre  Post  
EDVi, ml/m2                     
Seated  
47  ±  2  53  ±  3  47  ±  2  49  ±  2  
                                          
Peak 
49  ±  2  51  ±  2  46  ±  2  52  ±  3  
ESVi, ml/m2                     
Seated  
21  ±  1  23  ±  2  20  ±  1  20  ±  1  
                                          
Peak 
18  ±  1  17  ±  1  17  ±  2  14  ±  2*  
SVi, ml/m2                        
Seated  
26  ±  2  30  ±  2  26  ±  2  29  ±  1  
                                          
Peak 
31  ±  2  35  ±  2  29  ±  2  38  ±  2*  
HR, bpm                            
Seated  
68  ±  4  67  ±  4  65  ±  3  64  ±  3  
                                          
Peak 
164  ±  4  157  ±  4*  154  ±  6  151  ±  6  
CI, L·min/m2                     
Seated  
1.81  ±  0.16  2.05  ±  0.15  1.70  ±  0.11  1.85  ±  0.12  
                                          
Peak 
4.98  ±  0.27  5.39  ±  0.32  4.50  ±  0.42  5.78  ±  0.46*  
EF. %                                
Seated  
56  ±  2  58  ±  2  56  ±  2  60  ±  1  
                                          
Peak≠  
62  ±  2  67  ±  3  63  ±  3  74  ±  2*† 
SBP, mmHg                      
Seated  
127  ±  4  122  ±  3  121  ±  4  122  ±  3  
                                          
Peak 
192  ±  6  190  ±  6  188  ±  5  185  ±  7  
DBP, mmHg                     
Seated  
82  ±  3  80  ±  3  83  ±  2  80  ±  1  
                                          
Peak 
73  ±  8  76  ±  4  76  ±  5  64  ±  7  
ESP, mmHg                      
Seated  
117  ±  4  110  ±  2  109  ±  4  110  ±  3  
                                          
Peak 
173  ±  5  171  ±  5  169  ±  4  167  ±  6  
SVRi, dyne·m2/s·cm-5       
Seated  
4593  ±  381  3848  ±  256*  4729  ±  360  4245  ±  301  
                                          
Peak≠  
1877  ±  141  1755  ±  115  2243  ±  244  1565  ±  167*  
Values are mean ± SEM; EDVi: end-diastolic volume index; SVi: stroke volume index; ESVi: end-systolic 
volume index; Ci: cardiac output index; EF: ejection fraction; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; ESP: end systolic blood pressure; SVRi: systemic vascular resistance index.*p<0.05 
compared to Pre-values within a group (MetS-NonT or MetS-ExT); ≠significant (p<0.05) group (MetS-
NonT vs. MetS-ExT) by time (pre to post) interaction. †p<0.05 vs, MetS non-trained group at specific visit 




Table 4: Effects of exercise training on aerobic capacity in MetS 
 
 MetS non-trained (n=10)  MetS trained (n=10)  
 Pre  Post  Pre  Post  
Ventilatory threshold, l/min  1.13  ±  0.14  1.27  ±  0.12  1.20  ±  0.13  1.56  ±  0.21*  
Ve/VCO2 slope  34.8  ±  1.49  34.4  ±  1.27  34.4  ±  1.4  35.7  ±  1.2*  
Respiratory exchange ratio  1.13  ±  0.03  1.10  ±  0.01  1.10  ±  0.02  1.09  ±  0.02  
BORG scale 19  ±  0.3  19  ±  0.2  19  ±  0.5  19  ±  0.4  
Peak VO2, (L/min) ≠             1.89  ±  0.20  1.84  ±  0.18  1.68  ±  0.16  2.00  ±  0.19*  
Peak VO2, (ml/kg/min) LM ≠            29.4  ±  2.2  28.7  ±  1.5  29.4  ±  1.6  35.0  ±  1.7*† 
Peak VO2, (ml/kg/min) BW ≠            19.1  ±  1.6  18.6  ±  1.2  16.2  ±  1.0  19.4  ±  1.0*† 
Peak A-VO2 Diff, ml/100ml           18.4  ±  2.0  16.4  ±  1.2  18.5  ±  1.5  16.2  ±  1.0  
Values are mean ± SEM; A-VO2 Diff: arteriovenous oxygen difference. *p<0.05 compared to Pre-
values within a group (MetS-NonT or MetS-ExT); ≠significant (p<0.05) group (MetS-NonT vs. 
MetS-ExT) by time (pre to post) interaction. †p<0.05 vs, MetS non-trained group at specific visit 



















Figure 1. Change in arterial-ventricular coupling (Ea/Ees), LV end-systolic elastance 
(Ees), and arterial elastance (Ea) from rest to peak exercise in Mets who underwent 
exercise training (MetS-ExT, diamond) and in MetS who remained inactive (MetS-NonT, 
triangles). Post intervention for both MetS group is depicted by a dashed line. Exercise 
training significantly reduced peak Ea/Ees, and increased peak Ees in MetS, and there 
was a significant time (pre and post intervention) by group (MetS-ExT vs. MetS-NonT) 
for Ea/Ees and Ees. *p<0.05 illustrates significant differences pre and post intervention 
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Background and Aims: Large elastic artery stiffening (AS) is a feature of normative 
aging and reflects a process by which degenerative adaptations in large arteries lead to 
wall stiffening. Metabolic syndrome (MetS) is associated with pathological vascular 
adaptations including AS which may play a role in mediating CVD risk in this population. 
Resveratrol (RSV), a naturally occurring polyphenol, has been shown to indirectly 
increase bioavailability of nitric oxide through changes in vascular oxidative stress and 
inflammation. Thus, RSV may represent an ideal therapy to target AS in MetS. The 
objective of this study was to investigate whether single oral doses of RSV can reduce 
AS and central aortic blood pressure in large elastic arteries of individuals with MetS. 
Methods and Results: 28 subjects (28-70 years): 17 healthy controls and 11 MetS 
consumed two doses of RSV (500 and1000 mg) and a placebo at weekly intervals in a 
double-blind, randomized fashion. AS and BP were measured before and at 45 and 75 
minutes after consumption of the supplement. Plasma samples were obtained at 
baseline and at 60 minutes after consumption of the supplement and subsequently 
analyzed for RSV concentration. Data were analyzed by a two-way repeated-measures 
analysis of variance. No significant effect of RSV was observed, however, detectable 
concentration of RSV and its primary metabolites was shown in a small subset of 
participants (n=20). 
Conclusion: Acute supplementation with 500 or 1000mg of RSV had no observable 
effect on AS or blood pressure at 45 or 75 minutes post-consumption. These results 
warrant further investigation of the use of supplementation with RSV as a strategy to 




Large elastic artery stiffening (AS) occurs as a result of normative biological 
aging, and describes a process by which degenerative adaptations in the conduit 
arteries lead to wall stiffening. In the presence of AS, the heart must fulfill the increased 
force requirements to accommodate the less compliant arteries. Over time, the 
additional load placed on the heart leads to LV hypertrophy (LVH) and heart failure. 
Importantly, AS has notable functional implications on the large elastic arteries, as it 
contributes to a diminishing of the Windkessel effect, or in other words the ability of the 
elastic aorta to maintain a continuous and steady blood flow to peripheral vessels [1]. 
AS is increased in the presence of CVD and results in elevations in pulse pressure at 
the site of central and peripheral arteries, which can extend to the microcirculation 
contributing to target organ damage [2-5].   
 The metabolic syndrome (MetS) is defined by the co-occurrence of clinical 
criteria and is used to identify patients at high risk for CVD, type II diabetes (T2DM), and 
all cause mortality and accordingly, has become an important therapeutic target of 
lifestyle modification. MetS is associated with pathological vascular adaptations 
including, but not limited to, AS [6, 7]. AS is known to be significantly increased in MetS 
compared to age-matched healthy controls [6, 8]. In MetS, AS may have a detrimental 
impact on cardiac function; Increases in central systolic blood pressure that accompany 
AS, promote cardiac hypertrophy leading to decreases in diastolic pressure, and 
impairment of coronary perfusion [9].  Thus, the increased risk of CVD associated with 
MetS may be due, in part, to increased AS. Indeed, data from our laboratory 
demonstrates that MetS patients have increased AS, arterial wall remodeling, abnormal 
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resting cardiac diastolic function, impaired peak exercise cardiac contraction, and 
reduced aerobic capacity compared to non-MetS [6]. The increase in AS observed in 
MetS is of clinical importance as a 1.0 m/second increase in AS is associated with a 15-
18 percent increase risk of CV events [10, 11]. Promising evidence from animal [12-14] 
and initial human research [15, 16] demonstrate the potential of resveratrol (RSV) for 
CV protection. Specifically, the cardioprotective effects of RSV supplementation have 
been attributed to the actions of RSV to acutely reduce inflammation and oxidative 
stress; two phenomena associated with MetS that are known to alter the arterial wall, 
decrease the bioavailability of the vasodilator nitric oxide (NO) and contribute to acute 
changes in AS [17-20]. Furthermore, RSV has been demonstrated to exert a 
vasorelaxing effect in an ex-vivo preparation of abdominal aortic rings of Spraque-
Dawley rats [21]. The vasorelaxing effects of RSV in Sprague-Dawley aortic rings were 
attributed to endothelial-dependent and endothelial-independent mechanisms, opening 
of the K+ channel resulting in hyperpolarization of vascular smooth muscle, and 
inhibition of extracellular calcium influx and intracellular calcium release in smooth 
muscle cells [21].  
While changes in structural components of the arterial wall occur over a longer 
duration to negatively increase AS, acute changes may also occur to mediate stiffness. 
Notably, changes in vascular smooth muscle cell (VSMC) tone and sympathetic 
nervous system activity have been shown to acutely modulate AS [22]. More 
specifically, sympathetic stimulation can alter AS through an indirect change in arterial 
pressure or through a direct increase in vascular tone, causing vasoconstriction and 
decreased arterial diameter [23-25]. Moreover, impaired endothelial dysfunction, as a 
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result of low-grade inflammation [26] enhances vasoconstrictor activity, altering large 
artery smooth muscle tone [27-29] which may contribute to acute changes in AS.   
Accordingly, nutritional supplementation with RSV may represent a promising 
therapy for reducing AS, and subsequently alleviating CVD risk in individuals with MetS. 
Therefore, the objective of the current randomized, double-blind, placebo-controlled 
study was to investigate whether single oral doses of RSV can reduce AS and central 
aortic blood pressure (cSBP) in large elastic arteries of individuals with MetS. We 
hypothesized that treatment with single doses of RSV would result in acute reductions 



















 The study population consisted of 28 subjects (28-70 years): 17 healthy controls 
(44 ± 3; 83% Female) and 11 MetS (51 ± 3; 64% Female). Healthy controls were free 
from clinically manifest CVD as determined by a detailed medical history, physical 
examination, and evidence of normal resting and exercise electrocardiograms. MetS 
subjects were free from clinically manifest CVD and diabetes mellitus. None of the 
participants were current or former smokers or were currently receiving treatment for 
peripheral artery disease. Exclusion criteria included T2DM (HbA1c ≥ 6.5% or use of 
diabetic medications), pulmonary disease, angina, atrial fibrillation, aortic stenosis, 
anemia, myocardial infarction, stroke, or coronary revascularization as assessed by a 
detailed medical history, physical examination, and a resting and exercise 
electrocardiogram. Subjects who participated in regular exercise, defined as >30 min, 3 
times/week were excluded. All participants signed a written informed consent form that 
was approved by the Institutional Review Board of West Virginia University.   
 
Definition of the Metabolic Syndrome 
 MetS was defined according to the Third Report of the National Cholesterol 
Education Program Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (NCEP ATPIII) [30] which requires three or more of the 
following five components: abdominal obesity (waist men >102 cm, women 95 >88 cm), 
low HDL cholesterol (men <40 mg/dl; women <50 mg/dl), hypertriglyceridemia (≥150 
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mg/dl), elevated fasting glucose (≥100 mg/dl and <126 mg/dl) and elevated blood 
pressure (≥130/≥85 mmHg or use of hypertensive medications). 
 
Study Design 
 All assessments were performed between 7:00 and 10:00AM in a quiet, 
temperature-controlled room following a 12-hour fast and abstinence from alcohol, 
caffeine, and vitamins. Participants were asked to withhold all cardiovascular 
medications for at least 24 hours prior to assessments. All participants were asked to 
maintain current dietary habits and to limit excessive polyphenol intake (including 
consumption of peanuts, red wine, green tea, etc.) for the duration of the study. 
 Participants attended the laboratory on 4 separate occasions. The first occasion 
was for the completion of a screening visit to acquire patient consent and to perform 
anthropometric measures. On each of the 3 remaining visits, participants consumed 2 
identical capsules containing the following: inert placebo or 500mg trans-resveratrol. 
The capsules were combined to achieve combinations of placebo, 500mg of trans-
resveratrol, or 1000mg of trans-resveratrol. Each treatment was assigned an A, B, or C 
by an independent staff member. Each treatment was consumed ad libitum with water 
at weekly intervals in a double blind randomized fashion. No member of the 
investigational team was aware of the contents of the capsules until a blind-data review 
was completed. 
On completion of anthropometric measurements and a minimum of 15 minutes of 
quiet supine rest supine measures of baseline arterial structure and function were 
performed followed by a baseline venous blood draw. Based on pharmacokinetic 
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results, peak RSV concentrations occur between 0.8-1.5 hours following  administration  
of  RSV [31].  Thus, measures of arterial structure and function were repeated at 45 and 
75 minutes post-capsule consumption. An additional venous blood draw was collected 
at 60 minutes post-capsule consumption.  
 
Anthropometric Measurements 
 At screening visit, height, weight, and waist and hip circumferences were 
determined using standard laboratory procedures for all participants. Waist 
circumference was assessed at the site of the smallest circumference between the rib 
cage and the iliac crest with subjects in a standing position. Hip circumference was 
assessed at the site of the largest circumference between the waist and thighs. Lean 
body mass and fat mass were measured using air displacement plethysmography 
(BodPod®; Life measurement, Concord, CA, USA). During the assessment of body 
composition subjects were dressed in close-fitting bathing suits and a swim cap. Body 
mass index (BMI) was calculated as weight (kg) / height (m)2. 
 
Arterial Function 
 Brachial systolic (SBP) and diastolic (DBP) blood pressures were measured 
using an automated, oscillometric sphygmomanometer (Critikon Dinamap Compact BP 
monitor, GE Medical, Tampa, Fla, USA) and pulse pressure (PP) was calculated from 
SBP-DBP. Pulse wave analysis was performed noninvasively on the radial artery 
(SphygmoCor system, AtCor Medical, Sydney, Australia). All measurements were made 
in triplicate, and the mean values used for subsequent analysis. The SphygmoCor 
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system synthesizes a central (ascending aortic) pressure waveform from the radial 
pressure waveform that does not differ from that of an intra-arterially recorded wave [32] 
using a validated generalized transfer function [33]. These waveforms were calibrated 
against brachial mean arterial and diastolic pressure to estimate aortic pressures. The 
characteristics of the aortic pulse wave (Figure 1) were determined as previously 
described [34] using established guidelines [35].  
 Carotid to femoral pulse wave velocity (cfPWV; central arterial stiffness) and 
carotid to radial pulse wave velocity (crPWV: peripheral arterial stiffness) were 
measured by applanation tonometry (AtCor Medical, Sydney, Australia). ECG-gated 
waveforms were sequentially recorded. Aortic distance (D) was calculated as the 
difference in the distances from the carotid to the suprasternal notch and from the 
suprasternal notch to the femoral artery or radial artery. Time delay was calculated 
using a foot-of-the-wave method.  
 
Blood Collection and Analysis 
 Venous blood sampling was performed between 7:00 and 10:00AM following an 
overnight 12-hour fast at baseline and again at 60 minutes following capsule 
consumption. Patient plasma acquired from venous blood samples was sent to West 
Virginia University Hospital’s central laboratory in Morgantown, WV for lipid profile 
analysis. Total cholesterol, HDL cholesterol, triglycerides, and fasting blood glucose 
were determined in plasma (lithium heparin, Becton Dickenson plasma separator tubes) 
using Beckman Coulter (Brea, CA) DxC automated chemistry analyzers. Total 
cholesterol was measured using a cholesterol esterase/cholesterol oxidase-or 
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peroxidase-driven, timed endpoint method (coefficient of variation, <7%). Triglycerides 
were measured using a lipase/glycerol kinase/glycerophosphate oxidase/horseradish 
peroxidase-driven, timed endpoint method (coefficient of variation, 5%-7%). Glucose 
was measured electrochemically using a glucose oxidase-/catalase-/molybdate-driven 
oxygen rate method (coefficient of variation, <5%). Glycated hemoglobin (A1c fraction) 
was measured in whole blood (K2-EDTA; Becton Dickenson) using a Bio-Rad (Hercules, 
CA) Variant II Turbo high-performance liquid chromatography system (coefficient of 
variation, <2%). Insulin was measured in serum (untreated/red top tube; Becton 
Dickenson) on an Immulite 2000 immunochemistry system (Siemens) (coefficient of 
variation, <10%).  
 
Plasma Concentration of Resveratrol and its Metabolites 
 Select plasma samples (n=20) were delivered to Protea Biosciences, Inc. 
(protea®, Morgantown, WV) for determination of resveratrol and its primary metabolites. 
Plasma concentrations of resveratrol (3,5,4'-trihydroxy-trans- stilbene) and its primary 
metabolites, including trans-resveratrol-3-O-sulfate, trans-resveratrol-3-O-glucuronide, 
and trans-resveratrol-4-O-glucuronide were determined using liquid chromatography 
tandem mass spectrometry (HPLC: Shimadzu LC-20AD HPLC, Tokyo, Japan); MS: 
Triple-Quad 4000, ABSciex Toronto, Canada). Briefly, fasting venous blood samples 
(15-20ml) were drawn at baseline and at 60 minutes post-capsule ingestion of 500mg of 
trans-resveratrol, 1000mg of trans-resveratrol or placebo in a small sample of 
participants (n=20) in EDTA coated tubes. Blood samples were processed into plasma 
and stored at -80°C before extraction. Plasma samples were delivered to Protea 
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Biosciences, Inc. (protea®, Morgantown, WV) for the determination of concentrations of 
resveratrol and its metabolites.  
 Calibration and quality control solutions were prepared by spiking human plasma 
with solutions of varying concentrations of resveratrol and metabolites in 50:50 
methanol:water. Blank solutions were prepared by spiking human plasma with 50:50 
methanol:water. All standards, controls, and blanks were then aliquotted into 1.5μl 
microcentrifuge tubes using a 50μl sample volume.  
 All plasma samples were thawed on the bench top at room temperature, 
vortexed for 1 minute and aliquoted into 1.5μl microcentrifuge tubes using a 50μl 
sample volume. Acetonitrile was added to all internal standards. Next, 200μl of Working 
Internal Standard Solution (50ng/ml resveratrol- 13C6 in acetonitrile) was added to all 
other samples using a repeater pipet to precipitate the proteins. All tubes were capped 
and vortexed for 1 minute. The samples were then centrifuged for 5 minutes at 10,000 
RMP. 100μl of water was added to each sample well of a Nunc (U96 PP 2ml) 96-well 
plate. The plate was then sealed with a pre-slit capmat, vortexed for 1 minute, and 
stored at 4°C. 
 
Statistical Analysis 
Normality was evaluated by the Kolmogorov-Smirnov test. Categorical variables 
were compared by the chi-square test, whereas baseline comparisons between groups 
were analyzed by an independent t-test or Mann–Whitney test. The changes from 
baseline to 45 and 75 minutes post capsule consumption in arterial parameters were 
examined by a time (baseline to 45 or 75 minutes post capsule consumption) by group 
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(MetS vs. Controls) by treatment (placebo, 500mg RSV, or 1000mg RSV) interaction 
evaluated using a two-way repeated-measures analysis of variance with Tukey’s post 
hoc test. Additionally, the changes from baseline to 45 and 75 minutes post capsule 
consumption in arterial parameters were examined by a time (baseline to 45 or 75 
minutes post capsule consumption) by treatment (placebo, 500mg RSV, or 1000mg 
RSV) interaction evaluated using a two-way repeated-measures analysis of variance 
with Tukey’s post hoc test. Multiple linear regression analysis was used to determine 
whether age, risk score, and baseline measurements could predict changes in arterial 
and central blood pressure parameters following supplementation with RSV. Data are 
presented as means ± s.e.m. and P<0.05 was required for significance. All analyses 


















Baseline characteristics of the study cohort are presented in Table 1. Twenty-
eight participants were recruited from the surrounding Morgantown area and were 
separated into two groups, healthy controls and MetS, based on the NCEP ATPIII 
guidelines for the definition of MetS. Age and sex were similar between groups despite 
an overall majority of female participants. As expected, Mets participants had 
significantly elevated baseline CVD risk factors.  
 
Baseline Arterial Measurements 
Baseline arterial measurements for MetS and controls are represented in Table 
2. Mets and controls exhibited similar baseline values in arterial parameters with the 
exception of brachial and central systolic blood pressure, SEVR, and AS as measured 
using cfPWV. In aggreement with previous findings from our laboratory [6, 34, 36] MetS 
were characterized by general increases in bSBP and cSBP and increased AS 
compared to healthy controls. 
 
Resveratrol Plasma Concentrations 
Mean plasma concentrations of trans-resveratrol and its conjugates at baseline 
and 60 minutes post-capsule consumption in a small sub sample of participants (n=20) 
are shown in Figure 2. Due to rapid and extensive metabolism and formation of 
metabolites including resveratrol glucuronides and resveratrol sulfates. Unmetabolized 
trans-resveratrol reached small but detectable concentrations in plasma following oral 
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doses of 500 mg and 1000 mg. These results demonstrate that, irrespective of the 
presence or absence of MetS, plasma RSV and three of its primary metabolites were 
detectable at 60 minutes post-oral supplementation of 500mg or 1000mg of RSV. Our 
resolution to examine RSV at doses of 500mg/day and 1000mg/day was primarily 
based on the understanding that RSV when administered orally is well absorbed but 
exhibits a very low bioavailability, and has been shown to be well tolerated in humans 
with no marked toxicity reported at much higher dosages as compared to our selected 
dosage. Evidence indicates that a range of dosages from 30mg to 5000mg produce 
various physiological effects in humans [37-40]. These results demonstrate the 
feasibility of administering RSV at levels detectable in plasma. 
 
Relationship between Resveratrol Supplementation on AS and Blood Pressure 
Graphical representation of the change in arterial stiffness and central blood 
pressure parameters at 45 and 75 minutes post oral supplementation with placebo, 
500mg RSV, and 1000 mg RSV is shown in Figures 3-5. Using a two-way we evaluated 
the effect of RSV to elicit changes in Arterial and central blood pressure parameters at 
45 and 75 minutes post capsule consumption by a time (baseline to 45 or 75 minutes 
post capsule consumption) by group (MetS vs. Controls) by treatment (placebo, 500mg 
RSV, or 1000mg RSV) interaction evaluated using a two-way repeated-measures 
analysis of variance. Interestingly, no significant effect of resveratrol on arterial and 
central blood pressure parameters was identified between MetS and healthy controls. 
Next, we repeated this statistical analysis without separation of participants into MetS 
and control groups. Similarly, no time (baseline to 45 or 75 minutes post capsule 
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consumption) by treatment (placebo, 500mg RSV, or 1000mg RSV) effects were 
observed.  
 Moving forward, we wanted to understand whether changes in AS and blood 
pressure following supplementation with RSV can be predicted based on age, 
riskpoints, and baseline values of AS and blood pressure. Using multiple regression 
analysis we report that baseline bPP and cPP significantly predict changes in bPP and 
cPP 75 respectively, 75 minutes following oral ingestion of 500mg of RSV. Additionally, 
basline values of bSBP, bPP, and cPP significantly predict changes in bSBP, bPP, and 
cPP, respectively, 45 minutes following oral ingestion of 1000mg of RSV. Importantly 
the these relationships were inverse, meaning that higher baseline values of select 
brachial and central blood pressure measurements predict decreases in delta values 
(baseline – 45 or 75 minutes) following treatment with RSV. Results from multiple 














AS occurs with advancing age and is further elevated in MetS compared to age-
matched healthy controls [6, 8]. Complications of AS include the development of LVH, 
reductions in coronary perfusion [9].  Thus, the increased risk of CVD associated with 
MetS may be due, in part, to increased AS. Indeed, data from our laboratory 
demonstrates that MetS patients have increased AS, arterial wall remodeling, abnormal 
resting cardiac diastolic function, impaired peak exercise cardiac contraction, and 
reduced aerobic capacity compared to non-MetS [6]. Importantly, changes in vascular 
smooth muscle cell (VSMC) tone and sympathetic nervous system activity have been 
shown to acutely modulate AS [22] and may represent effective therapeutic targets for 
affecting improvements in AS and likely CVD in MetS. 
 Resveratrol, is a polyphenolic compound found in dietary sources including, but 
not limited to, grape skins, peanuts, and red wine.  In the last decade RSV has 
generated substantial interest among the scientific community and within popular culture 
for its CV protective potential. Namely, RSV has been shown to reduce inflammation and 
oxidative stress, as well as to promote smooth muscle vasorelaxation through both 
chronic and acute mechanisms that remain unclear. For these reasons, we sought to 
investigate the effects of two single doses of RSV on arterial and blood pressure 
parameters in MetS and healthy controls.  
 A comparison between MetS and controls to determine the whether RSV was 
able to improve AS and blood pressure showed no significant interactions. These 
findings precluded our original hypothesis that 500mg or 1000mg of RSV would affect 
acute improvements in AS and blood pressure, and further, that we would be able to 
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capture these acute improvements at 45 and 75 minutes following capsule ingestion in 
MetS.  Further investigation revealed the ability of some baseline blood pressure 
parameters to predict how they would change in response to treatment with RSV. While 
the literature regarding RSV treatment in clinical research is still in its infancy and is 
largely controversial, the results from this study are in contrast to recent evidence that 
RSV at higher doses (≥150 mg/day) significantly decreases SBP [41]. Further, single 
doses of RSV have recently been demonstrated to acutely improve flow-mediated 
dilation (FMD) in a dose-dependent manner [39].  
Although the data presented here do not find a significant short-term effect of 500 
and 1000mg of RSV on AS and central blood pressure, it must be emphasized that our 
results should neither discourage nor slight the actions of RSV as a therapeutic 
approach to human disease. It is true that we are unable to draw a significant positive 
conclusion for our investigation of whether 500mg and 1000mg can acutely alter AS and 
blood pressure in MetS; however, by the same token we are unable to demonstrate that 
RSV exerts any negative effects that may exacerbate AS, or contribute to elevated blood 
pressure in MetS. Moreover, addressing the many limitations and caveats of this study 




First, due to the small sample size of our MetS and control groups our study is 
underpowered for the comparisons required to determine a time by treatment by group 
effect on AS. For this reason these data should be regarded as preliminary until we can 
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obtain data on a larger population sample.  While we reported non-significant results 
from multivariate modeling, we can speculate that in MetS significant elevations in 
baseline parameters of AS and blood pressure, may indicate a greater potential for 
improvement in these parameters and warrants further investigation. Second, although 
age and sex were similar between groups in our study, we included a wide range of aged 
individuals, a majority of which were women, begging the question as to whether there 
may be divergent mechanisms by which RSV can exert its effects in men and women 
and whether or not these differences have the potential to mask improvements in AS 
conferred by RSV require further investigation in a cohort with more equal numbers of 
both men and women. Third, we did not provide a measure of autonomic function in this 
study. The potential affects of RSV on autonomic function [42], which has been shown 
to modulate acute changes in AS [22], was not assessed, but future studies should 
consider this mechanism which can be easily accomplished in the short-term by 
recording beat-to-beat changes in BP and HR.  Additional concerns that may limit the 
interpretation of this study include patient selection. While comparisons of group 
demographics and baseline parameters of AS and blood pressure were indicative of our 
ability to successfully screen for MetS, the elevations in this small group were only 
moderate, especially with respect to age and elevations in blood lipid profile, blood 
pressure, and AS. As MetS can be considered to exist as a spectrum in terms of 
disease severity, the pariticpants recruited in this study may represent less severe 
MetS. It is possible that the determination of the therapeutic potential of RSV to reduce 
AS may require the use of participants with more severe disease. Of equal importance 
is our resolution to examine two single doses of RSV.  Future studies to evaluate the 
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therapeutic potential of RSV may be more clinically relevant if they are designed with 
the goal of demonstrating long-term disease prevention and maintenance of CV health 
via chronic supplementation with RSV. With that in mind, the acute nature of our study 
may be too short to show the benefits of RSV for lowering CVD risk in MetS. Finally, our 
resolution to examine two time points based on pharmacokinetic data in the existing 
literature may have inherently limited our resolution for detecting improvements in AS 
and blood pressure. Data from plasma concentrations of RSV and its primary 
metabolites suggest that delivery of RSV is not a limiting factor in this study, however, it 
is possible that changes elicited by RSV to alter AS or BP may occur before or after our 
selected time points and future studies would be better to perform a dose-response 
study in a separate cohort to more accurately select the best time points for 
investigation into the short-term affects of RSV.  
 
Conclusion 
In conclusion, this study demonstrates that acute supplementation with 500 mg 
and 1000 mg of RSV failed to modulate improvements in AS and blood pressure at 45 
and 75 minutes post-supplementation. Taken together, these findings suggest future 
investigation of the short-term and chronic benefits of RSV for improving AS and blood 
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Age, years 44 ± 3 51 ± 3 
Sex, % Female 83 64  
Height, cm 163.12 ± 2.71 166.75 ± 2.16 
Weight, lbs *147.45 ± 6.4 219.69 ± 8.25 
BSA, m
2 *2.40 ± 0.05 2.90 ± 0.06 
BMI, kg/m
2 *25.49 ± 1.45 35.83 ± 1.14 
Waist Circumference, cm *82.33 ± 2.90 110.32 ± 3.84 
Triglycerides, mg/dL *79.33 ± 7.67 151.29 ± 21.63 
HDL Cholesterol, mg/dL *57.00 ± 2.75 42.21 ± 1.34 
Glucose, mg/dL *91.50 ± 2.03 118.71 ± 8.16 
HbA1c, % *5.15 ± 0.07 5.88 ± 0.28 
Insulin, μIU/mL *5.76 ± 0.69 17.36 ± 1.81 
Riskpoints *14.89 ± 1.89 39.07 ± 2.45  
Avg HR, bpm 69.40 ± 1.93 73.00 ± 2.48 
Avg. bSBP, mmHg *114.38± 2.81 124.33 ± 2.87 
Avg. bDBP, mmHg 77.15 ± 1.92 82.01 ± 2.21 
Avg. bPP, mmHg 37.23 ± 2.39 42.32 ± 3.81 
  Avg. cSBP, mmHg *105.52 ± 3.07 113.40 ± 2.23 
  Avg. cDBP, mmHg 75.02 ± 2.28 78.52 ± 2.62 
  Avg. cPP, mmHg 30.51 ± 2.05 34.88 ± 3.60 
Values expressed as mean ± SEM. Abbreviations: MetS, metabolic syndrome; 
BSA, body surface area; BMI, body mass index; HDL, high-density lipoprotein; 
HR, heart rate; bSBP, brachial systolic blood pressure; bDBP, brachial diastolic 
blood pressure; bPP, brachial pulse pressure; cSBP, central systolic blood 
pressure; cDBP, central diastolic blood pressure. 
 












HR, bpm 66.21 ± 2.06 71.11 ± 2.59 
bSBP, mmHg *110.29 ± 2.60 123.08 ± 3.43 
bpDBP, mmHg 73.29 ± 2.03 76.69 ± 2.24 
bPP, mmHg 37.00 ± 1.82 46.38 ± 4.67 
cSBP, mmHg *102.01 ± 2.95 111.26 ± 2.37 
cDBP, mmHg 74.13 ± 2.05 77.73 ± 2.25 
cPP, mmHg 27.82 ± 1.82 34.41 ± 3.63 
AP, mmHg 7.11 ± 1.19 6.94 ± 1.05 
AGI 23.42 ± 3.23 19.86 ± 2.41 
AGI@HR75, % 19.25 ± 13.53 18.11 ± 2.41 
SEVR, % *158.69 ± 5.20 136.97 ± 8.58 
cfPWV, m/s *6.54 ± 0.24 7.73 ± 0.41 
Values expressed as mean ± SEM. Abbreviations: MetS, metabolic syndrome; 
HR, heart rate; pSBP, brachial systolic blood pressure; bDBP, brachial diastolic 
blood pressure; bPP, brachial pulse pressure; cSBP, central systolic blood 
pressure; cDBP, central diastolic blood pressure; cPP, central pulse pressure; 
AP, augmentation pressure; AGI, augmentation index; AGI@HR75, 
augmentation index corrected for a HR of 75; SEVR, sub-endocardial viability 
ratio; cfPWV, carotid to femoral pulse wave velocity 
 







Table 3. Multiple linear regression models  
 
 B SE B β p 
Delta bSBP at 45 min post 500mg RSV     
Riskpoints 0.072 0.107 0.129 0.512 
Age 0.207 0.100 0.433 0.050 
bSBP -0.269 0.114 -0.470 0.027 
Delta bPP at 45 min post 500mg RSV     
Riskpoints -0.071 0.107 -0.127 0.511 
Age 0.190 0.091 0.393 0.048 
bPP -0.305 0.108 -0.519 0.009 
Delta cPP at 45 min post 500mg RSV     
Riskpoints 0.064 0.093 0.149 0.496 
Age 0.120 0.071 0.323 0.104 
cPP -0.285 0.108 -0.542 0.015 
Delta cPP at 75 min post 1000mg RSV     
Riskpoints 0.150 0.089 0.378 0.107 
Age -0.057 0.064 -0.173 0.382 
cPP -.0199 0.097 -0.442 0.051 
Delta bPP at 75 min post 1000mg RSV     
Riskpoints 0.072 0.097 0.147 0.465 
Age -0.051 0.079 -0.124 0.529 
bPP -0.211 0.094 -0.431 0.033 
B denotes the variable estimate; SE B denotes the standard error of the variable estimate; β 










Figure 1. Example of central pressure waveform. The systolic and diastolic pressures 
are the peak and trough of the pressure waveform. Augmentation pressure (AP) is the 
pressure added to the forward wave by the reflected wave (P1-P2), whereas 
augmentation index is the ratio between AP and central pulse pressure (PP = systolic - 
diastolic pressure).  
 
Figure 2. Mean (±SEM) plasma concentrations of trans-resveratrol (A) and its 
glucuronidated and sulfated conjugates (B) at baseline and 60 minutes-post ingestion of 
500mg or 1000mg of RSV in a small sub cohort of participants (n=20) as determined by 
HPLC. 
 
Figure 3. Mean (±SEM) changes (45 or 75 minutes – baseline) in cSBP (A) and cPP 
(B) at 45 and 75 minutes post-supplementation with placebo, 500mg RSV, and 1000mg 
RSV in MetS and healthy controls. Positive bars represent increases relative to baseline 
values and negative bars represent reductions relative to baseline values. 
 
Figure 4. Mean (±SEM) changes (45 or 75 minutes – baseline) in AP (A) and SEVR (B) 
at 45 and 75 minutes post-supplementation with placebo, 500mg RSV, and 1000mg 
RSV in MetS and healthy controls. Positive bars represent increases relative to baseline 




Figure 5. Mean (±SEM) changes (45 or 75 minutes – baseline) in AGI (A) and 
AGI@HR75 (B) at 45 and 75 minutes post-supplementation with placebo, 500mg RSV, 
and 1000mg RSV in MetS and healthy controls. Positive bars represent increases 

































































































































































The overall purpose of the investigations presented within this dissertation was to 
define CV dysfunction in the metabolic syndrome and to identify practical therapeutic 
strategies to improve CV function. Specifically, our goals were to (1) comprehensively 
evaluate CV function at rest and during maximal exercise and to validate the presence 
of CV dysfunction in a cohort of human subjects with MetS; (2) to evaluate the 
therapeutic value of aerobic exercise training for improving large elastic artery stiffening 
and arterial-ventricular coupling; and (3) to determine the effect of single-dose 
supplementation with RSV on AS and central systolic blood pressure in MetS and 
healthy controls. The central hypothesis of this collective work was that subclinical CV 
dysfunction develops as a result of co-occurring risk factors associated with MetS, and 
can be improved by the implementation of therapeutic lifestyle interventions including 
aerobic exercise training and nutritional supplementation with RSV. The rationale for the 
work presented within this document is based on the importance of reversing CV 
dysfunction associated with MetS for CVD risk reduction as well as to advance our 
understanding of the link between CVD and MetS. 
MetS is defined by the co-occurrence of clinical risk factors and has become a 
principal health concern in the U.S. due to its association with CVD [1]. A systematic 
review of data from existing observational studies has determined that MetS is 
associated with a 2-fold increased risk in CV outcomes and a 1.5-fold increase in all-
cause mortality [2]. Numerous studies have demonstrated LV dysfunction at rest in 
MetS [3-6], but not all [7, 8], suggesting that LV dysfunction may mediate, in part, the 
link between CV risk and MetS. Accordingly, the purpose of our initial efforts was to 
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complete a comprehensive assessment of LV and arterial structure and function at rest 
and during exercise in MetS vs. age- and sex-matched healthy controls. This study, 
presented in Chapter 2, was the first to provide a comparison of LV and arterial function 
responses at rest and during dynamic exercise in individuals with MetS but without 
T2DM and/or overt CVD and healthy controls. Exclusion of subjects with T2DM and 
symptomatic or clinical CVD was an important strength of this study and permitted the 
interpretation of our results to be a reflection of MetS rather than a consequence of 
conditions that may exacerbate LV dysfunction. Use of load-independent measures to 
assess LV contractility at rest eliminated a general shortcoming of many existing 
studies. Indeed, altered loading conditions, including abnormal resting HR and 
pathological LV chamber remodeling are key features of MetS and may influence load-
dependent measures of systolic function. Under resting conditions we observed 
elevations in arterial parameters including cIMT and cfPWV (arterial stiffness; AS), and 
LVmass, which have been previously described in earlier investigations of MetS [8-10].   
Literature suggests that changes in the mechanical and elastic properties of the 
large elastic arteries play a role in the underlying mechanism contributing to AS 
associated with MetS [11]. Stability and compliance of the large elastic arteries are 
dependent on the relative content of two important scaffolding proteins: collagen and 
elastin. An imbalance in the production and degradation of these two proteins 
contributes to large artery stiffness and may occur in response to inflammation and 
endothelial dysfunction [11].  
 Furthermore, load-independent assessments of LV contractility described in 
Chapter 2 revealed no evidence of contractile dysfunction in MetS. Exercise testing is a 
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well-established method to generate physiological stress in order to reveal pathological 
alterations not present at rest. During maximal exercise MetS demonstrated impaired 
LV systolic function, blunted systemic vasodilation, and reduced cardiac pump 
performance [12]. Collectively, LV contractile deficits contributed to a blunted arterial-
ventricular coupling reserve and impaired peak aerobic capacity in MetS [12]. Taken 
together, these data demonstrate the capacity for the development of 
pathophysiological adaptations to CV structure and function in the presence of co-
occurring CV risk factors prior to the development of chronic disease. Notably, these 
findings underscore the value of MetS as a prognostic tool for the identification of 
individuals at high risk for CVD but without evidence of clinical disease including T2DM 
and/or overt CVD. Importantly, these data formed the foundational work for 
investigations into the use of exercise training for the treatment of arterial stiffness in 
MetS without T2DM and/or overt CVD.  
As detailed by assessment of arterial structure and function in Chapter 2, this 
work and others [12, 13], have demonstrated arterial dysfunction in MetS that is 
characterized by elevations in cfPWV, cIMT, carotid cross-sectional area, and carotid 
wall stress and tension. Notably, large elastic artery stiffening has been shown to 
modulate LV loading conditions through elevations in central systolic pressure [14].  Left 
ventricular hypertrophy (LVH) occurs as a maladaptive response to chronic elevations in 
central arterial pressure. Complications of LVH include diastolic heart failure, systolic 
heart failure, and impaired coronary flow reserve [4]. In Chapter 2 we describe evidence 
of early diastolic dysfunction during supine rest in MetS. Consequently, early recognition 
and identification of effective strategies for reducing AS may have important clinical 
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implications for individuals with MetS.  
Aerobic exercise training has been shown by others to be an effective 
intervention to reduce AS in young and healthy and middle-aged and older individuals 
[15, 16]. Building on our previous findings detailed in Chapter 2, we investigated 
whether 8 weeks of aerobic exercise training is an effective strategy to reduce AS in 
MetS without T2DM and/or overt CVD. These investigations are detailed in Chapter 3 
wherein we demonstrate a reduction in cfPWV in MetS after 8 weeks of aerobic 
exercise training. Importantly, improvements in AS occurred in the absence of 
significant reductions in weight, BMI, and metabolic profile (Table 3.3) suggesting that 
improvements in AS associated with aerobic exercise training are independent of other 
established benefits of exercise training. A lack of training effect on established 
outcomes of aerobic exercise training begs the question of whether or not a longer 
duration or combination diet and exercise is required to elicit improvements in these 
parameters; However, an investigation of the effects of altering the intensity or number 
of treatment strategies to target AS in MetS warrants consideration.  
Central systolic blood pressure, rather than traditional brachial blood pressure, is 
known to provide a more accurate index of afterload; reflecting the pressure that the LV 
must generate in order to eject blood from the heart to the periphery. Using PWA for the 
non-invasive estimation of central pressure we demonstrated significant reductions in 
cSBP in MetS. This finding is of clinical importance, as it is known that cSBP is superior 
to brachial BP for the prediction of CV outcomes [17]. Furthermore, PWA revealed an 
increase in the sub-endocardial viability ratio (SEVR), an index of myocardial oxygen 
supply and demand. In the absence of a direct measurement of CV function by Doppler 
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echocardiography, changes in the SEVR indicate potential improvements in cardiac 
function after 8 weeks of aerobic exercise training in MetS. Whether or not these 
improvements in AS elicited by short-term exercise training in MetS will be maintained 
over a longer duration of time remains unknown. Recent evidence from existing 
literature suggests that in persons with MetS and T2DM, aerobic exercise training elicits 
initial improvements in AS, and these benefits are subsequently lost when training is 
continued for a longer duration [18]. Consequently, the capacity of aerobic exercise 
training to reduce AS may have a more lasting benefit for MetS without chronic disease; 
however, this proposal is merely speculative and cannot be supported by data 
presented within this document.  
Understanding the mechanisms underlying the changes in arterial function 
associated with MetS is essential in the prevention or treatment of individuals with co-
occurring risk factors for CVD. AS is determined by the composition of the extracellular 
matrix (elastin-collagen network) and vascular smooth muscle cell function [11, 19, 20]. 
Changes that occur in the expression and/or bioactivity of structural proteins in the 
arterial wall (and heart) lead to AS. Vascular remodeling of the large elastic arteries, 
including fibrosis and elastic fiber degradation results in decreased arterial compliance 
[21-23]. It is possible that changes in large artery structure may play a role in the 
pathophysiology of AS in MetS. Structural changes to the extracellular matrix of large 
arteries in MetS have been attributed to the activation of matrix metalloproteinases 
(MMPs), key regulators of arterial and cardiac remodeling [20, 24]. Activation of various 
MMPs in the carotid intima-media is associated with characteristics of large artery 
stiffening including increased fragmentation of elastin [25], overproduction of abnormal 
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collagen [20], increased vascular smooth muscle cell migration and proliferation in the 
carotid intima-media layer [26, 27]. In animal models, increased MMP9 activity, 
responsible for the degradation of elastin and collagen [25], was directly linked with AS 
[28] and cardiac stiffness [29]. MMP activation in MetS may be further exacerbated by 
decreased activity of endogenous tissue inhibitor of metalloproteinases (TIMPs). In 
hypertensive patients, plasma concentrations of MMP9 and TIMP1 were elevated vs. 
controls and are implicated in AS and associated with an increased risk of CV events 
[30-32]. Notably, TIMP1 inhibits MMP1 activity that increases type 1 collagen (high 
tensile strength and rigidity) formation. MMP/TIMP activity is altered in MetS, with higher 
concentrations of MMP2, 8, 9 and TIMP1 vs. controls [33-35]. The ratio of MMP/TIMP 
activity plays a central role in remodeling of the extracellular matrix and thus, may 
mediate structural changes of the large arteries in the presence of a chronic pro-
inflammatory environment as observed in MetS. As detailed in Chapter 3 we measured 
plasma markers of tissue remodeling (MMPs and TIMPs) and found that exercise 
training was able to produce favorable reductions in circulating MMP1 and MMP7, both 
of which were found to have positive associations with cfPWV [36]. 
Expanding on structural changes that occur to the extracellular matrix in MetS 
that may contribute to AS, additional material properties of the vasculature can play a 
role in arterial stiffening, as well. Among these properties the most important 
contributors to large artery stiffness include increased synthesis of collagen, non-
enzymatic glycation of collagen to form crosslinks, and vascular smooth muscle cell 
hypertrophy [20]. Under hyperglycemic conditions, proteins and lipids in the vasculature 
may undergo non-enzymatic glycation and oxidation steps that trigger molecular 
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transformations resulting in the formation of advanced glycation end products (AGEs). 
Elevated levels of oxidative stress and the hyperglycemic environment associated with 
MetS promotes the formation and accumulation of advanced glycation end products 
(AGEs) which may play a causative role in large artery stiffening [37]. Indeed, animal 
models of T2DM and MetS have demonstrated significant associations between arterial 
stiffness and enhanced AGE accumulation in conduit arteries [38]. AGE accumulation in 
the vasculature contributes to alterations in extracellular and intracellular structure and 
function through a variety of mechanisms, including crosslink formation between 
proteins in the basement membrane of the extracellular matrix, and through the 
modification of cellular function through the activation of AGEs with the cell surface 
receptor for AGEs [39]. Crosslink formation of proteins in the extracellular matrix can 
alter properties of large structural matrix proteins including type I collagen and elastin 
which fosters reduced arterial elasticity and vascular stiffening. In the endothelium, 
AGEs reduce the bioavailability and activity of endothelium-derived NO and prostacyclin 
and may enhance expression of the vasoconstrictor, endothelin-1 [40]. The fundamental 
determinants of AGE formation include the rate of turnover of proteins for glycoxidation, 
the degree of hyperglycemia, and the level of oxidant stress [41] and thus, AGE 
formation and accumulation is accelerated in MetS and T2DM and likely contributes to 
the pathophysiology of arterial stiffening observed in MetS.  While we did not quantify 
AGE deposition in the studies presented within this dissertation, this measurement 
would provide an enhanced understanding of the underlying mechanisms contributing to 
AS associated with MetS. Taken together, the results detailed in Chapter 3 suggest that 
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aerobic exercise training holds promise as an effective treatment approach for targeting 
AS in MetS without chronic disease.  
Next, we built upon our previous work by broadening our investigation of the 
therapeutic potential of aerobic exercise training for reducing CVD risk in MetS. 
Evidence from Chapter 2 demonstrated that individuals afflicted with MetS display not 
only deleterious adaptations to arterial structure and function at rest, but also 
demonstrate deficiencies during exercise. Specifically, MetS exhibited impaired coupling 
between the heart and the arterial system, an interaction termed arterial ventricular 
coupling (Ea/Ees). Additionally, a blunted decrease in Ea/Ees during exercise in MetS 
was shown to coincide with a significantly reduced exercise capacity. Collectively, these 
results suggest an impaired CV response to physiological stress produced during 
aerobic exercise in MetS.  In Chapter 4 we determine the effects of 8 weeks of aerobic 
exercise training on Ea/Ees during peak exercise in MetS without T2DM or clinical 
indications of CVD. In this investigation we demonstrate that 8 weeks of aerobic 
exercise training was not only able to improve, but to restore peak arterial-ventricular 
coupling, peak LV contractility, and aerobic capacity in MetS to levels observed in 
healthy untrained controls. The key finding of this study was that improvements in peak 
exercise arterial-ventricular coupling in MetS, which was due directly to improvements in 
peak LV end-systolic elastance (Ees), a load-independent index of the contractility and 
systolic stiffness of the LV. Not surprisingly, 8 weeks of aerobic exercise training failed 
to improve resting LV structure, diastolic dysfunction, metabolic profile, or body 
composition. The lack of an observed effect is most likely due to the short exercise 
training duration.  Indeed, others have shown that several months of aerobic training 
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alter deleterious LV remodeling [42, 43]. Improvements in arterial-ventricular coupling 
were accompanied also by a modest increase in exercise capacity as measured by 
VO2peak. It was determined that improvements in Ea/Ees during exercise contributed, to 
a small degree, to improvements in exercise capacity, however, it is likely that this 
improvement can also be explained by other exercise-induced adaptations not 
considered by this study. Nevertheless, improvements in aerobic capacity likely reflect a 
reduced CVD risk in MetS. Our initial investigations in Chapter 2 determined that the 
blunted decrease of arterial-ventricular coupling in MetS is due not only to impaired LV 
contractility but also to a blunted peripheral vasodilation in response to exercise. In 
Chapter 4, we proposed that improvements in LV contractility were mediated, in part, by 
improvements in SV, afterload, and Ea/Ees. In support of this hypothesis, we 
demonstrated improvements in SV but observed no change in the Ea component of 
arterial-ventricular coupling, which was in contrast to observed reductions in peak 
vascular resistance after exercise training in MetS. Importantly, Ea represents an index 
of the net arterial load imposed on the LV that integrates individual elements of arterial 
load including, but not limited to, peripheral vascular resistance. For this reason, a lack 
of change in Ea does not rule out the potential for improvements in other principal 
components of arterial load. As a final point, we reported a lack of effect of exercise 
training on body composition or clinical blood biomarkers, which was in agreement with 
our findings described in Chapter 3. Taken together, this study demonstrated that 8 
weeks of aerobic exercise training of moderate-to-high intensity was sufficient to 
improve peak exercise arterial-ventricular coupling, LV contractility, reduce peripheral 




In Chapters 3 and 4, aerobic exercise training was reported to have beneficial 
effects on AS and the interaction between the arteries and the heart in individuals with 
MetS [36, 44]. Favorable effects of exercise training on modulating CV function in MetS 
may be a result of underlying improvements in inflammation and autonomic nervous 
system activity. MetS is characterized by elevated glucose levels and chronic, low-
grade inflammation [45]. Hyperglycemia and excess cytokine secretion increase 
oxidative stress [46], which reduces NO bioavailability [47]  and may exert an acute 
and chronic influence on AS [48]. Increased large artery stiffness is associated with 
normative aging and is an independent predictor for an increased risk for stroke, 
coronary artery disease, and heart failure [10]. In individuals with metabolic disease, 
such as MetS, the interaction of AS with other CV risk factors (i.e. hypertension, obesity, 
and dyslipidemia) accelerates the vascular aging process [49] that results in large artery 
stiffening. Recent literature has shed light on the importance of inflammation in the 
pathogenesis of AS. 
The activation of MMPs and TIMPs, regulators of tissue remodeling, is mediated, 
in part, by the renin-angiotensin system, oxidative stress, endothelial dysfunction, and 
increased expression of pro-inflammatory cytokines and cellular adhesion molecules 
[50, 51]. MetS is associated with a pro-inflammatory state, which favors endothelial 
dysfunction and impaired vasodilation [21-23]. Impaired relaxation of the smooth muscle 
is associated with diminished production or availability of vasodilator substances, 
particularly NO, due to a decline in the production of NO by the endothelium, 
inactivation of NO by reactive oxygen species (ROS), or a decline in the availability of 
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co-factors required for the synthesis of NO. In the presence of cardiovascular risk 
factors (e.g. hypertension, T2DM, hyperglycemia, etc.) the normal production of NO by 
eNOS is altered such that eNOS favors the generation of ROS including superoxide, 
and hydrogen peroxide. Generation of ROS stimulates the continued production of ROS 
creating a positive feedback loop leading to chronic elevations in oxidative stress and a 
reduction in NO bioavailability [39]. Moreover, inflammation may directly diminish NO 
bioavailability through the production of ROS, which effectively augments oxidative 
stress and promotes the upregulation of inflammation [39].  
In addition, the local production of hormones that play a role in the structural 
modification of the arteries has been implicated in the development of AS. Specifically, 
AS has been linked to increased activity of ANG II, which is responsible for vascular 
smooth muscle cell hypertrophy, increased production of collagen, activation of MMPs 
and increased production of ROS and other inflammatory cytokines [39]. The release of 
inflammatory cytokines stimulates the production of C-reactive protein (CRP) by 
vascular smooth muscle cells. CRP plays an indirect role in the pathology of arterial 
stiffness through its direct promotion of endothelial dysfunction [52]. Taken together, 
these findings suggest an association between the role of inflammation, oxidative 
stress, and endothelial dysfunction in the pathology of impaired arterial elasticity in 
MetS. 
Structural changes that may play a role in arterial dysfunction associated with 
MetS may take several months to develop, however AS may also be altered acutely 
through changes in VSMC tone, which is regulated by sympathetic nervous system 
(SNS) activity and endothelial cell function [53]. The SNS is known to play a key role in 
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the short-term regulation of vasomotor tone and blood pressure in order to maintain 
cardiovascular homeostasis [54]. Recent evidence suggests that sympathetic activity 
and vascular function may be linked and more specifically demonstrate that the activity 
of the SNS may modulate functional properties of large arteries [54]. In terms of large 
artery stiffness, sympathetic activity may alter AS through an indirect change in arterial 
pressure or through an active increase in vascular tone, peripheral vasoconstriction and 
decreased arterial diameter [54]. Data from human-based research has demonstrated 
associations between increased sympathetic discharge and large artery stiffness[54]. It 
is notable that the association between sympathetic activity and large artery stiffness 
may be bidirectional. Large artery stiffness may impair carotid baroreflex sensitivity 
while conversely, increased sympathetic discharge may play a role in the modulation of 
arterial stiffness. Although we did not use a direct measure of SNS activity in the studies 
included in this document, exercise training has previously been reported to improve 
autonomic control in obese women [55] which may represent a potential mechanism by 
which aerobic exercise training can illicit improvements in AS in MetS. 
 Current guidelines for the treatment of MetS suggest therapeutic lifestyle 
changes including both diet and physical activity. Chapters 2-4 demonstrate the 
capacity for improvements in CV function in MetS following short-term exercise training. 
This would suggest that preservation of CV improvements over time requires 
maintenance of lifestyle changes specifically, regular physical activity. Other strategies 
for the treatment of MetS include pharmacological or dietary interventions that focus on 
improving NO bioavailability, oxidant stress, inhibit the renin-angiotensin system, and 
target AGE cross-links. Nutritional supplementation represents an attractive therapeutic 
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intervention for alleviating CV dysfunction in MetS as it is effortless to integrate and 
maintain. Chapter 5 demonstrates a divergence from the use of exercise-training to 
induce improvements in MetS and describes the initial efforts by our laboratory to 
investigate the therapeutic potential for RSV, a naturally occurring nutritional 
supplement, to induce acute changes in AS and BP in MetS. In addition to changes in 
the structural components of the arterial wall that manifest over a period of time, short-
term changes may occur to mediate vascular stiffness. Specifically, changes in VSMC 
tone and SNS activity have been demonstrated to modulate AS in an acute fashion [56-
59]. Evidence from human [60, 61] and animal [62-64] research demonstrate the 
potential of RSV for CV protection based on the ability of RSV to acutely reduce 
inflammation and oxidative stress, two mechanisms mediating large artery stiffness 
associated with MetS [56-59].  
Building on evidence from studies examining the effects of dietary supplements 
on arterial compliance we hypothesized that a single dose of RSV would elicit acute 
improvements in AS and central blood pressure in MetS. For example, high dietary 
intake of isoflavones is associated with a reduced PWV in healthy individuals [20]. 
Further, supplementation with curcumin, the active ingredient in turmeric, a spice that is 
used frequently in Indian cuisine has been shown to improved AS in young rodent 
models [11]. Similarly, in aged animals, 4 weeks of supplementation with curcumin was 
associated with reduced superoxide bioavailability and whole artery AGE expression. 
Taken together, these findings provide support for the use of dietary supplementation as 
an effective intervention for improving AS in individuals in MetS.  
Results from Chapter 5 led us to fail to reject the null hypothesis that an acute 
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dose of 500mg or 1000mg of RSV does not alter AS or central BP at 45 or 75 minutes 
post-supplementation in MetS and we are unable to accept the alternative hypothesis 
that single-dose RSV supplementation can improve AS and central BP at 45 and 75 
minutes post-supplementation in MetS. In an effort to reconcile these findings we 
suggest several limitations that may have contributed to our results. These limitations 
are reviewed in detail in Chapter 5. While we were unable to provide evidence in 
support of the therapeutic potential of RSV to improve CVD risk through AS and BP, 
improvements in study design and recruitment are encouraged for building upon this 
preliminary data and are reviewed in Chapter 7.  
In conclusion, our data provides a comprehensive examination of the 
consequences to CV function in MetS prior to evidence of T2DM and/or chronic CVD. 
Further, we perform initial evaluations of both physical and nutritional changes in 
lifestyle as strategies for improving CV dysfunction and subsequent risk for CVD in 
MetS. The findings of this dissertation are in agreement with the central hypothesis that 
subclinical CV dysfunction at rest and during exercise occurs in the presence of MetS 
without T2DM and/or over CVD, and that this dysfunction can be improved by 
implementation of therapeutic lifestyle interventions, including aerobic exercise training. 
While we cannot apply this conclusion to evidence presented within this document for 
the therapeutic potential of chronic nutritional supplementation with RSV, we believe 
future studies may provide the evidence-based support necessary to extend these 
conclusions to supplementation with RSV in MetS. The results of the studies contained 
within this dissertation underscore the importance of establishing targeted strategies for 
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Metabolic syndrome is a multifaceted disease state characterized by multiple co-
occurring risk factors. Clinical manifestation of MetS carries a profound risk for CVD that 
surpasses the sum of the individual CVD risk carried by each component [1]. Mets can 
lead to deleterious alterations to CV structure and function even in the absence of 
T2DM and overt CVD [2-4]. Current recommendations from the NIH for the treatment of 
MetS include adoption of healthy lifestyle changes including, but not limited to, regular 
physical activity and a heart healthy diet [5]. Preventing or slowing the progression and 
onset of T2DM is one of the primary goals of treating MetS, second only to CVD risk 
reduction [5], however, the ideal treatment or treatment combination for long-term 
improvements in CVD risk and prevention of T2DM in MetS without chronic CVD is 
largely unknown. Future studies in animals and humans examining the long-term effects 
of lifestyle changes in MetS would provide a greater understanding of the underlying 
pathological mechanisms of MetS.  
 Investigations outlined in Chapter 3-4 of this dissertation provide initial evidence 
for the promise of short-term aerobic exercise training for improving AS, LV contractility, 
and coupling of the heart and arteries in MetS without T2DM and/or CVD. Future 
studies should focus on addressing the important limitations reported in these chapters 
as well as build upon the foundation that this work provides. In particular, future studies 
to address the effects of exercise training on AS in MetS should focus on uncovering 
the mechanisms responsible for reported improvements. Specifically, a non-invasive 
assessment of autonomic function using Finapres technology could provide a way to 
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determine the role of sympathetic activity in reductions in cfPWV that accompany short-
term aerobic exercise.  Due to the lack of an observed effect on metabolic plasma 
markers, future studies should consider a longer exercise training duration or higher 
intensity training to identify whether longer duration or higher intensity can exert 
additional benefits to individuals afflicted with MetS. Studies of longer duration would 
have the added advantage of determining whether the benefits associated with short-
term aerobic exercise can be maintained over time. Most importantly, future longitudinal 
studies, which have the benefit of being able to establish a sequence of events, should 
be conducted to examine the ability of long term exercise training to prevent or delay 
the progression to T2DM and CVD.  
 Furthermore, due to a lack of observed effect of exercise training on arterial load 
(as indicated by no pre to post change in Ea in Chapter 3) in MetS, the use of other 
assessments of arterial function including characteristic impedance and cIMT may 
provide evidence for a more conclusive effect of exercise training on arterial 
structure/function.  
 One common challenge in human-based subject research is achieving large and 
equal numbers of both male and female participants, as is evidenced by data presented 
within this document.  Unequal representation in gender within current literature should 
be a key consideration for the planning of future studies. Potential investigations into the 
consequence of sex differences on the effects of exercise training and nutritional 
supplementation may have an important impact on the interpretation of conclusions 
from existing literature, and for the development of target treatment strategies for MetS.  
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A further complication of research surrounding MetS is the inherent complexity of 
co-occurring risk factors. For example, by considering MetS to be a single co-morbid 
condition as the studies presented in this document do, one may overlook the 
importance of different combinations of the individual components of MetS, and how 
these combinations respond to treatment strategies. Future studies using MetS should 
attempt to examine how different clusters of MetS components impact CV function and 
progression to T2DM and overt CVD in MetS. Additionally, the use of a continuous 
scale to classify MetS may allow insight to how metabolic disease severity affects CV 
function and also response to treatment.  
 For a more mechanistic understanding of the CV dysfunction underlying MetS, 
future research may be best conducted in animal models of MetS, such as the obese 
Zucker fatty. Animal models of Mets may allow for a more detailed study of the 
contribution of changes in inflammatory status and oxidant stress to treatment for MetS. 
Furthermore, animal models of disease represent a more controlled and cost-effective 
starting point for determining efficacy of various treatment options for MetS, especially 
future investigations of nutritional supplementation. 
The overall obejective of this dissertation was to define CV dysfunction in the 
metabolic syndrome and to identify practical therapeutic strategies to improve CV 
dysfunction, specifically to target large artery stiffness and coupling between the arteries 
and heart; therefore, future directions should focus on achieving a more thorough 
understanding of the CV risk associated with MetS and whether long-term therapeutic 
lifestyle change (physical and nutritional) can prevent the progression of MetS to T2DM 
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